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Background: The bacterium Pseudomonas aeruginosa is an opportunistic pathogen that can 
cause a wide range of acute and chronic infections. It is a frequent cause of hospital acquired 
infections and chronically infects the lungs of most adults with the genetic disease cystic fibrosis 
(CF). P. aeruginosa has a large genome that allows for many intrinsic antibiotic resistance mechanisms, 
such as, a diverse array efflux pumps, low membrane permeability, and production of enzymes that 
inactivate or modify antibiotics. As well as resisting antibiotic treatment, during chronic infections P. 
aeruginosa rapidly adapts to other challenges, including oxidative stress, the immune system, host 
withholding of micronutrients such as iron and zinc, and competition from other microbiota. 
Results: The overall aim of this research was to use in silico, in vitro, and in vivo approaches to 
understand how antibiotic resistance evolves in P. aeruginosa. Firstly, using a lab based experimental 
evolution approach, the genes that contribute most to resistance to two independent classes of 
antibiotic were identified. Resistance during experimental evolution increased in a stepwise manner, 
associated with the sequential acquisition of mutations, each evolved line obtained 4-8 resistance 
increasing mutations. Experimental evolution experiments also identified large genomic and 
phenotypic changes that can occur during resistance, including large deletions of up to 8% of the 
genome. Combining this experimental evolution with computational analyses showed genes that 
mutate to confer resistance within the lab-based screen are also found commonly mutated in clinical 
isolates of P. aeruginosa. Secondly, a comprehensive phenotypic, genotypic, and transcriptomic 
analysis of a chronic P. aeruginosa isolated from a chronically infected patient was performed. This 
revealed the extent of the transition that occurs within the lung of a patient with cystic fibrosis, 
including antibiotic resistance, changes in growth, increased biofilm production, and decreased 
virulence factor production.     
Conclusions: This study significantly expands the understanding of the genetic basis of 
antibiotic resistance in P. aeruginosa through both lab- and within patient-evolution. Additionally, by 
studying the evolution of P. aeruginosa within a patient with CF we have been able to show the 
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This chapter provides a general introduction to this thesis. Each results chapter contains its 
own introduction that goes into more detail about the work presented within that chapter. 
 
1.1. Pseudomonas aeruginosa as an opportunistic pathogen 
Pseudomonas aeruginosa is a Gram-negative bacterium able to grow in a wide range of 
environments, including soil, water, plants, animals, hospitals, and residential and commercial 
waterways (1-9). P. aeruginosa is also well known as an opportunistic human pathogen. In clinics, it is 
a frequent cause of hospital-acquired infections and pneumonia (10, 11). Chronic respiratory 
infections can occur in patients with predisposing conditions, like cystic fibrosis (CF). The frequency of 
P. aeruginosa infections tends to increase with age in CF patients, by adulthood most have chronic 
infections that contribute to a reduced quality of life for patients (12-16). These infections persist 
despite regular treatment with anti-pseudomonal antibiotics. Treatments can include carbapenems 
(e.g. meropenem), aminoglycosides (e.g. tobramycin), fluoroquinolones (e.g. ciprofloxacin), and 
cephalosporins (e.g. ceftazidime). As treatment continues, P. aeruginosa can adapt and evolve 
becoming antibiotic resistant, leading to multidrug resistant (MDR) P. aeruginosa (17). 
 
1.2. The role of Pseudomonas aeruginosa in human infections 
P. aeruginosa can cause a wide variety of severe chronic and acute infections in patients with 
pre-disposing conditions or with weaken immune systems (18, 19). Infections with P. aeruginosa can 
cause pneumonia and sepsis in patients ventilated, or those in intensive care units. These infections 
lead to drastic increases in morbidity and can lead to death in these patients (20, 21). Additionally, 
chronic infections in patients with CF, non-CF bronchiectasis, and chronic obstructive pulmonary 
disease are quite common (22-24) with P. aeruginosa infection rates as high as 80% in persons with 
CF developing by age 20 (25-27). However, rates of chronic P. aeruginosa infections in persons with 
CF are decreasing (28), likely due to elimination strategies and better treatment options such as 
combinatory antibiotic treatments reducing antibiotic resistance arising as quick as single treatment 
(29-33). In persons with CF the established paradigm is that an environmental strain of P. aeruginosa 
establishes infection (34, 35), often times the infecting strain of P. aeruginosa is naïve to human 




CF, colonisation with a pre-existing, pre-adapted, antibiotic resistant strain can also occur and are 
often associated with worse prognosis than naïve strains (39, 40). This P. aeruginosa infection can 
then adapt to the environment within the lung to continue infection (34, 41). 
 
1.3. Development of antibiotic resistance in Pseudomonas aeruginosa is a global 
health concern 
The emergence of antibiotic resistance in bacteria is a well-publicized global concern. P. 
aeruginosa is no exception as antibiotic resistance is common in chronic infections and rates of 
resistance are increasing globally (42-49). A greater spotlight has been shown to this since 2017 
when the World Health Organisation (WHO) published its first antibiotic-resistant priority 
pathogens (50). This detailed the bacteria that posed the greatest threat to human health. 
Carbapenem-resistant P. aeruginosa was categorised as the highest priority, in critical need of funding 
and research of new antibiotics (50, 51). Studies looking at resistance rates in blood and respiratory 
based P. aeruginosa infections reported that most anti-pseudomonal antibiotics were effective against 
less than 80% of isolates (43, 52, 53). Such high rates of resistance are forcing treatments to “last 
resort” antibiotics like colistin, which also has decreasing efficacy (54-58). The high prevalence of 
antibiotic resistance observed in P. aeruginosa is due to several factors. 
 
1.4. Pseudomonas aeruginosa are diverse allowing adaptation to different 
environments 
P. aeruginosa has a large genome of approximately 6 Mb (> 5000 genes), compared to other 
common human pathogens such as E. coli with a genome size approximately 4.5 mb (< 4500 genes), 
and S. aureus a genome less than 3 mb (< 3000 genes). The larger genome of P. aeruginosa allows for 
many intrinsic resistance mechanisms, such as, a diverse array of efflux pumps, low membrane 
permeability, and production of enzymes that inactivate or modify antibiotics. Additionally, 
resistance genes can also be acquired from other organisms, via plasmids, transposons, and 
bacteriophages (59).  
Studies looking at the diversity of genes present within P. aeruginosa strains have suggested that 





(60) genes and ~4800 genes (61-63), with total genes predicted across P. aeruginosa ranging from 
~14000-55000. These numbers of core genes include those essential to P. aeruginosa survival 
(essential genes or core-genome), and genes present across all lineages analysed in the respective 
research. Changing genomes, increasing sample size, including environmental isolates, and using 
different prediction tools can all change the number of core genes and can explain differences in 
prediction numbers. The number of genes predicted to be in the core-genome of P. aeruginosa is 
varied, experimentally the number of essential core-genes in P. aeruginosa has also been shown to vary 
from strain to strain and growth conditions, ranging from 354-727 genes, although a core essential 
set of genes across all strains was estimated to be ~321 (63). Despite the predictions of a pan-
genome of P. aeruginosa varying, and the number of essential genes varying depending on the strain 
and growth conditions, it is apparent that P. aeruginosa has a high amount of genome plasticity, 
maintaining a diverse array of genes allowing it to adapt to the surrounding environment.    
The basis of antibiotic resistance in P. aeruginosa has been investigated using genetic and 
biochemical approaches. Mechanisms of resistance are typically assigned into one of four groups: 
reduced antibiotic uptake, enhanced antibiotic efflux, reduced affinity of antibiotics to their cellular 
targets, and chemical inactivation of antibiotics (64-66). Although resistance typically occurs through 
mutations in the genome, resistance genes imported into the cell via integrons and horizontal gene 
transfer also confer a resistant phenotype (67-70). These four types of antibiotic resistance 
mechanisms can confer resistance across different antibiotic classes. There is some overlap in genes 
that can confer resistance to multiple antibiotics, however, most resistance associated genes are an 
antibiotic class or molecule specific contributor to resistance. 
 
1.5. Aminoglycoside resistance in Pseudomonas aeruginosa  
Aminoglycosides are a class of antibiotics that are generally active against Gram-negative 
bacteria, such as P. aeruginosa. Aminoglycosides have activity against the bacterial 30S small ribosomal 
subunit, within the 16S rRNA, although precise binding locations vary across different 
aminoglycosides (71-76). Generally, aminoglycoside antibiotic function is thought to occur through 
binding in the 30S subunit and disrupting translation. This disruption can result in anomalous 




peptides that get synthesised while aminoglycosides are bound can be trafficked to the cytoplasmic 
membrane and reduce the integrity of it, leading to further aminoglycoside uptake (71-73, 77, 78). 
Aminoglycosides have been powerful tools in combating P. aeruginosa infections. However, 
resistance to aminoglycosides in P. aeruginosa has been known for over 50 years (79). In P. aeruginosa 
there are currently 4 clinically relevant aminoglycosides used for the treatment of P. aeruginosa 
infections, amikacin, gentamicin, netilmicin, and tobramycin (80). Presently, the most commonly 
used aminoglycosides in the treatment of P. aeruginosa infections in cystic fibrosis patients are 
gentamicin and tobramycin (81-83). However, resistance to these aminoglycosides has been well 
reported. The mechanisms by which P. aeruginosa become resistant to aminoglycosides are diverse 
and encompass all resistance mechanisms mentioned in Section 1.4. 
 
1.5.1. Aminoglycoside chemical inactivation and acquisition of aminoglycoside 
modifying enzymes via mobile genetic elements 
P. aeruginosa typically lacks a diverse array of chromosomally encoded aminoglycoside 
modifying enzymes (AME). The commonly studied strain P. aeruginosa PAO1 has one characterised 
aminoglycoside modifying enzyme (APH3ʹIIb, aminoglycoside 3ʹ-phosphotransferase)1. However, 
there are many reported cases of aminoglycoside resistance in P. aeruginosa from acquired genes 
through mobile genetic elements (i.e., plasmids, transposons, or integrons) (86-90). These AMEs can 
chemically inactivate different aminoglycoside molecules through many different modifications; 
phosphorylation (aminoglycoside phosphoryltransferase), acetylation (aminoglycoside 
acetyltransferase), and adenylation (aminoglycoside adenyltransferases) (73, 91). These modifications 
prevent the aminoglycosides from performing their inhibitory function (Figure 1.1, ‘1A’) (73, 92). 
Although AMEs can be important in the development of antibiotic resistance in P. aeruginosa, there 
will be little focus on them in this study. However, comprehensive reviews on AMEs and their role 
in resistance in P. aeruginosa have been carried out previously (73, 88, 90, 93-95). 
 
1 analysis carried out using CARD (Comprehensive Antibiotic Resistance Database) and annotated P. aeruginosa PAO1 






Figure 1.1|Simplified overview of aminoglycoside resistance mechanisms in Pseudomonas 
aeruginosa. Aminoglycoside resistance in P. aeruginosa can occur through multiple means. 
(1A) Aminoglycoside modifying enzymes, whether chromosomally encoded or obtained 
from horizontal gene transfer, can chemically inactivate aminoglycoside molecules (91, 
94, 96). (2A) Decreased aminoglycoside uptake through the outer-membrane can be 
caused by mutations in proteins involved in LPS synthesis, lowering the binding affinity 
to aminoglycosides (97-100). (2B) Decrease aminoglycoside uptake through the 
cytoplasmic-membrane by changing the proton gradient in the periplasm. This can be 
caused by mutations in the protein machinery involved in the respiratory chain (97, 101-
104). (3A) Increased aminoglycoside efflux can be caused by mutations in negative 
regulators of efflux pumps (3B), or via mutations directly in efflux systems which can 
increase expression or promote higher rates of efflux (97). (4A) Aminoglycoside 
resistance arising through mutations in non-ribosomal translation machinery, as seen in 
fusA1 mutations (65, 105, 106). (4B) Aminoglycoside resistance arising through mutations 
in ribosomal proteins and 16S rRNA methylation, as with (4A) the exact means of how 
this confers resistance is unknown, although it is proposed it may impair aminoglycoside 
binding (91, 107). (4C) The canonical mode of action of aminoglycosides, which involved 






1.5.2. Reduced antibiotic uptake through membrane impermeability 
Aminoglycoside uptake into the cell is by diffusion through the outer-membrane into the 
periplasm and then into the cytoplasm. It is thought that aminoglycosides can bind to cell surface 
lipopolysaccharides (LPS), displacing cations which disrupt cross-linking of LPS molecules (Figure 
1.1 ‘2A’) (86, 101, 108). Disrupting LPS cross-linking leads to a reduction in integrity of the outer-
membrane, allowing more antibiotic to pass into the periplasm (109). As such, changes in outer-
membrane permeability via mutations in genes involved in cell surface lipopolysaccharides 
production can lead to aminoglycoside resistance (Table 1.1) (102, 110, 111). These mutations 
typically change the affinity of the negatively charged LPS for the positively charged aminoglycosides 
(76). This initial interaction with LPS and diffusion into the periplasm is an energy independent 
process unlike the subsequent process of aminoglycosides passing from the periplasm into the 
cytoplasm.  
An additional mechanism of aminoglycoside resistance that impairs uptake is through 
disruption of respiratory chain proteins (Figure 1.1 ‘2B’). Once aminoglycosides pass through the 
outer-membrane into the periplasm they require an energy-dependent uptake across the cytoplasmic 
membrane. This uptake relies on a proton gradient and the proton-motive force (102, 112). As this 
process relies on the proton gradient, disruption to this process would lead to resistance. Indeed, 
this is observed with mutations in genes like nuoG (encoding NADH dehydrogenase I) (102, 112), 
and mutations in cytochrome C machinery (103, 104, 106, 113). As such, there are two independent 
ways of P. aeruginosa limiting aminoglycoside entry into the cytoplasm, changing LPS on the outer-
membrane, or reducing the proton-motive force in the periplasm. However, there are other ways of 
preventing aminoglycoside accumulation within the cell. 
 
1.5.3. Decreased aminoglycoside accumulation through increased efflux 
Chromosomally encoded multi-drug efflux systems have long been established as a resistance 
mechanism in P. aeruginosa (114, 115). Although there are 5 major efflux families in P. aeruginosa, the 
most relevant for antibiotic efflux is the Resistance-Nodulation-cell Division (RND) family of efflux 
pumps (116, 117). These RND efflux systems have been shown to interact with a wide range of 
structurally distinct molecules that includes most classes of antibiotics (118, 119). There are 11 





most well-characterised efflux systems in P. aeruginosa that contribute to aminoglycoside resistance is 
the MexXY-OprM and MexAB-OprM efflux pumps (117, 120-122). Resistance to aminoglycosides 
through these efflux systems is typically through loss of function mutations in negative regulators of 
the genes encoding the efflux system (117, 120) (Figure 1.1 ‘3A and 3B’). For mexXY, genes that 
regulate the expression are mexZ, amgR, and amgS, and for mexAB they are mexR, nalC, and nalD (65, 
117, 120-122). Disruption of the negative regulators leads to increased expression of the efflux 
pumps and decreases the accumulation of aminoglycosides within the cell (Table 1.1). Despite 
decreased aminoglycoside accumulation within the cell through increasing efflux, aminoglycosides 




Table 1.1|Chromosomally encoded genes contributing to aminoglycoside resistance in P. aeruginosa. 
Gene Locus ID Description Predicted 
effect 
Citation(s) Proposed mechanism 




(123, 124) Regulation of efflux; MexXY-OprM 
overexpression  
      
parRS PA1798-PA1799 two-component response 




(125-130) Outer membrane permeability; 
amBCADTED-ugd overexpression 
      




(130-132) Regulation of efflux; MexXY-OprM and 
MexAB-OprM overexpression through 
intermediate genes PA5528 and htpX 
      
fusA1 PA4266 elongation factor G Gain of 
function 
(105, 133-136) Target-site modification, regulation of 
efflux; MexXY-OprM overexpression 
      




(102, 136-139) Currently unknown; Potentially involved in 
stringent response 
      




(140, 141) Stringent response; pathway leads to 
overexpression of efflux systems 
      
cco PA1552-PA1557 Cytochrome C oxidase Loss of 
function 
(134, 135) Inner membrane permeability; reduced 
proton-motive force 
      
PA1767 PA1767 hypothetical protein Loss of 
function 
(113, 134, 135, 142) Currently unknown 
      




(113, 135, 142) Outer membrane permeability; changed LPS 
production/structure 
      
nuo PA2638-PA2649 NADH dehydrogenase I Loss of 
function 





1.5.4. Aminoglycoside cellular target mutations lead to compromised 
antimicrobial activity 
As mention in Section 1.5, aminoglycosides target the 16S rRNA and disrupt protein 
synthesis. Mutations can arise that either directly or indirectly alter the binding of aminoglycosides 
within the ribosome (Figure 1.1 ‘4B and 4C’). Examples of this include recently discovered 
mutations in fusA1 (encoding Elongation Factor-G, EF-G), that confers resistance to 
aminoglycosides (105, 133, 138). Although mutations in EF-G increase aminoglycoside resistance, 
there is no conclusive evidence as to how this resistance occurs. Some research has suggested that 
mutations in fusA1 confer resistance to aminoglycosides through increasing expression of the 
MexXY-OprM efflux pump (105, 145). However, it is striking the prevalence of fusA1 mutations in 
aminoglycoside resistance given that EF-G directly interacts with the P- and A-sites within the 
ribosome (146). Therefore, it would not be unreasonable to posit that mutations in fusA1 conferring 
resistance to aminoglycoside could be, in part, due to changes in aminoglycoside binding affinity in 
the 16S rRNA via structural modifications of EF-G, although, no research has confirmed this. 
Additionally, mutations can arise that are located within the ribosome that confers resistance 
to aminoglycosides. This can include genes like rplY (ribosomal protein L25) (97, 147). Mutations 
within rplY has been found as a stress response that can cause an increase in expression of the 
mexXY efflux system (Section 1.5.3) (97, 112). Separately from direct mutations on ribosomal 
proteins, methlyation of 16S rRNA can also lead to aminoglycoside resistance (148, 149). This 
methlyation is caused by 16S rRNA methlyases. This methlyation of the 16S rRNA is thought to 
disrupt aminoglycoside binding leading to resistance (148, 150). Although this is not an intrinsic 
resistance mechanism in P. aeruginosa it still provides an interesting example of how resistance could 
arise without any apparent mutations. 
Although P. aeruginosa has many intrinsic and accquired means of developing aminoglycoside 
resistance, typically clinical treatment of chronic infections are combated with combinatory 
treatments to reduce the prevalance of antibiotic resistance development. Treatment is often with a 





1.6. Carbapenem resistance in Pseudomonas aeruginosa 
Carbapenems are a sub-class of antibiotics that belong to the β-lactam class of molecules. 
Typically for P. aeruginosa infections, the most commonly used carbapenems are meropenem and 
imipenem (151-154). Carbapenems act by binding to Penicillin-Binding Proteins (PBPs) and restrict 
their ability to cross-link peptidoglycan weakening the cell structure and leading to cell damage and 
death (155, 156). As detailed in Section 1.3 carbapenem-resistant P. aeruginosa is currently classified as 
the most in need of further research by the WHO (50). Carbapenems have previously been used as 
‘last resort’ antibiotics, however, resistance is consistently rising globally (157-164). This alarming 
trend can be attributed to many societal factors (e.g. overuse of antibiotics), but also molecular 
mechanisms, as P. aeruginosa has many innate and acquired resistance mechanisms that confer 
resistance to carbapenems (Table 1.2). 
 
1.6.1. Carbapenem chemical inactivation can arise through β-lactamase 
acquisition and overexpression 
As with aminoglycosides, P. aeruginosa can chemically inactivate carbapenem molecules. This 
chemical inactivation is done by carbapenemases. These carbapenemases are acquired via horizontal 
gene transfer, similarly to aminoglycoside modifying enzymes mentioned in Section 1.5.1 (165-169). 
There are many different types of carbapenemases that have been well-characterised and well-
reviewed (170-172). In short, all the carbapenemases act via hydrolysis of the β-lactam ring of 
carbapenems, the different classifications reflect different substrate specificities and different ligands 
and cofactors (170, 171, 173). However, as carbapenemases are not typically chromosomally 
encoded by P. aeruginosa the specifics of each type are not discussed in depth here. P. aeruginosa does 
contain a β-lactamase that has not been characterised as a carbapenemase that does seem to confer 
some resistance to carbapenems. The β-lactamase AmpC, encoded by the ampC gene, has been 
shown to induce increased carbapenem susceptibility in ampC mutants (64, 174-176). It has also 








Figure 1.2|Simplified overview of carbapenem resistance mechanisms in Pseudomonas 
aeruginosa. Carbapenem resistance in P. aeruginosa is diverse with many ways to become 
resistant. (1A) β-lactamases, specifically carbapenemases, chromosomally encoded or 
acquired can pass into the periplasm and chemically inactivate carbapenem molecules 
through hydrolysis of the β-lactam ring. Carbapenemases are prevalent in clinical isolates 
of P. aeruginosa (between 2-30%, dependent on geographic location) (64, 170, 171, 173-
176, 178-180). (2A) OprD porin mutations and deletions lead to decreased uptake and 
increased resistance to carbapenems, OprD mutations are the most common form of 
carbapenem associated resistance mechanism (152, 154, 174, 181, 182). Other porins can 
be used for carbapenem uptake, but OprD is the most utilised. (2B) A newly emerging 
resistance mechanism is through large genome deletions, this involves alterations to LPS 
and has been shown to cause carbapenem resistance, although the exact mechanism of 
resistance is unknown (144, 183-185). (3A) The decrease in carbapenem accumulation 
through increased efflux is predominantly caused by overexpression of MexAB-OprM. 
This overexpression is typically through deleterious mutations in the negative regulators 
of MexAB-OprM - nalD, nalC, and mexR (42, 65, 186-190). (4A) The canonical mode of 
carbapenem activity involves uptake through the outer-membrane into the periplasm 
where it can bind to Penicillin-Binding Proteins (PBP), this leads to impaired 
peptidoglycan synthesis leading to loss of cell integrity and death. However, mutations 
within PBPs has also been shown to confer carbapenem resistance, likely through 





1.6.2. Reduced uptake of carbapenems arises through mutations in porins 
The most reported and best characterised carbapenem resistance mechanism in P. aeruginosa is 
through disruption in uptake. This is typically through loss of the porin OprD encoded by the oprD 
gene (152, 154, 174, 181, 182) (Table 1.2). Loss of this porin leads to less carbapenem accumulation 
in the periplasm (Figure 1.2 ‘2A’). As OprD is the most commonly utilised porin for carbapenem 
uptake (although not the only porin used (193, 194)) mutations leading to truncation of, or binding 
affinity changes in the protein cause decreased carbapenem susceptibility. 
Although uptake of carbapenems at first seems straightforward, via uptake through porins, 
more research is emerging detailing another resistance mechanism that may be due to changes in 
uptake. Recently it has been discovered that P. aeruginosa can undergo large genomic deletions that 
confer carbapenem resistance, these deletions are larger than 200kb (144, 183-185). Surprisingly all 
these reported deletions overlap with the galU gene, which has been implicated in antibiotic 
resistance through the removal of LPS a- and b- type bands, this changes the electronegativity of the 
cell (195) (Figure 1.2 ‘2B’). However, it is unknown exactly how this pertains to carbapenem 
resistance, and it is likely that multiple genes are playing a role in this resistance due to the size of 
deletion. Disrupting uptake mechanism can provide decreased susceptibility to carbapenems, but as 
with aminoglycosides, efflux also plays a crucial role in development of carbapenem resistance.  
 
1.6.3. Reduced carbapenem accumulation is controlled by increased efflux 
One of the most highly implicated efflux systems in carbapenem resistance is the MexAB-
OprM efflux system (Figure 1.2 ‘3A’). As discussed in 1.5.3 the negative regulators of the MexAB-
OprM efflux pump are mexR, nalC, and nalD (Table 1.2). Loss of function mutations in these genes 
can lead to overexpression of MexAB-OprM and lead to decreased carbapenem accumulation and 
decreased susceptibility (42, 65, 186-190). Although deleterious mutations in the negative regulators 
of the MexAB-OprM efflux pump occur frequently in clinical isolates, increased efflux only prevents 







Table 1.2|Chromosomally encoded genes that contribute to carbapenem resistance in P. aeruginosa. 
Gene Locus ID Description Predicted loss or 
gain of function 
Citation(s) Proposed mechanism 
nalC PA3721 negative regulator, NalC Loss (65, 196) Regulation of efflux; MexAB-
OprM overexpression 
      
nalD PA3574 negative regulator, NalD Loss (65, 197) Regulation of efflux; MexAB-
OprM overexpression 
      
mexR PA0424 multidrug resistance operon repressor Loss (64, 185, 
198) 
Regulation of efflux; MexAB-
OprM overexpression 
      
mexT PA2492 transcriptional regulator MexT Loss (65, 199, 
200) 
Impaired uptake; OprD 
downregulation 
      
oprD PA0958 Basic amino acid, basic peptide and 
imipenem outer membrane porin 
Loss (185, 188, 
201) 
Impaired uptake 
      
ftsI PA4418 penicillin-biniding protein 3 Gain (65, 156, 
185) 
Target site modification 
      
parRS PA1798-
PA1799 
two-component response regulator 
ParR, two-component sensor ParS 
Gain (125-130) Regulation of efflux; MexXY-




1.6.4. Mutations in penicillin-binding proteins can reduce the effectiveness of 
carbapenems 
Although not all the cellular targets of carbapenems are established, it is known that they can 
bind to PBP2 and PBP3 (156, 202, 203) (Figure 1.2 ‘4A’). It has also been discovered that mutations 
in PBP3 encoded by the ftsI gene in P. aeruginosa lead to carbapenem resistance both in vitro and in 
vivo (42, 65, 106, 133, 185, 191, 192). PBP3 is essential for growth (156), thus, it is likely these PBP3 
mutations conferring carbapenem resistance are increasing resistance through gain of function 
mutations and not deleterious loss of function mutations. Although many of the reported variants in 
PBP have a plausible mode of action, with these mutations being located within protein domains 
asscociated with carbapenem binding, there are many variants that have been found in clinical 
isolates in multiple different PBPs that have unknown contributions to carbapenem resistance and 
may be explain as natural genetic variability. 
 
1.7. Studying how Pseudomonas aeruginosa develops antibiotic resistance can 
lead to the discovery of key genes in resistance 
Examining how antibiotic resistance arises in P. aeruginosa is important as it can potentially lead 
to the discovery of new drug targets or inform treatment options if collateral-sensitivities or 
resistances exist across drugs. Collateral sensitivity is when an organism gains resistance to an 
antibiotic at the cost of increased sensitivity to another antibiotic (204). However, looking only at 
clinical P. aeruginosa isolates can confound the view of antibiotic resistance. This is due to clinical P. 
aeruginosa isolates potentially harbouring variants that not only involve antibiotic resistance, but 
involve disease progression, adaptation to host, and virulence (41). Additionally, hypermutator 
phenotypes in clinical isolates contribute genetic noise, making antibiotic resistance associated genes 
harder to identify (205). Hypermutator strains are isolates typically with impaired DNA repair 
machinery (mismatch repair system) that can have up to 1000-fold increased rate of spontaneous 
mutations compared to strains with functional mismatch repair systems (206-208). Although, 
understanding the pathways by which P. aeruginosa adapts within a clinical setting is important 
(discussed in Section 1.9), examining only clinical isolates will dilute the understanding specific 
antibiotic resistance associated genes. A way of adjusting to this is by evolving P. aeruginosa to 
become antibiotic resistant in vitro, this allows for a ‘clean’ genetic background to be used as a 





resistance. However, in vitro evolution can have drawbacks as it is done in the laboratory, typically 
the P. aeruginosa are evolved while growing in nutrient rich media. Growing in such a nutrient rich 
media may allow for mutations in genes that confer antibiotic resistance that might not be viable 
when growing during an infection in a patient. Despite this drawback, many studies have 
successfully looked at adaptation/evolution of antibiotic resistance in vitro (65, 134, 144, 209-216). 
These studies have found mutations in resistance associated genes that are also mutated in clinical 
isolates of P. aeruginosa and have well-understood roles in antibiotic resistance. Mutations in genes 
such as those outlined in Tables 1.1 and 1.2; oprD (carbapenem resistance) (65), nalC/D 
(carbapenem and aminoglycoside resistance) (65, 144, 211), and ftsI (carbapenem resistance) (65, 
185), have consistently been shown to be mutated in in vitro evolution experiments, suggesting a 
strong role in antibiotic resistance. In vitro evolution experiments can also identify resistance 
mechanism that play a larger role in antibiotic resistance than previously thought, such examples 
include respiratory chain proteins (nuoG, nuoD, cco, aminoglycoside resistance) (65, 134, 144), which 
have been identified to confer high amounts of aminoglycoside resistance in vitro. Many of these in 
vitro studies reaffirm the importance of various antibiotic resistance mechanisms, additionally, in vitro 
analysis can also identify previously uncharacterised resistance genes. A recent example of this is 
with mutations in EF-G, encoded by the fusA1 gene which has been implicated in aminoglycoside 
resistance, and subsequently different fusA1 alleles identified in clinical isolates of P. aeruginosa have 
been shown to confer aminoglycoside resistance too (65, 105, 133, 134, 138). Discoveries like this 
aid in our understanding of antibiotic resistance development in P. aeruginosa, informing new 
therapies and new antibiotic targets that may help combat emerging antibiotic resistance. 
 
1.8. The role computational and bioinformatic approaches can play towards a 
greater understanding of antibiotic resistance in Pseudomonas aeruginosa 
A major contributor to furthering the understanding of how antibiotic resistance progresses in 
P. aeruginosa is due to advances in sequencing technologies. Routine whole-genome sequencing of 
experimentally evolved resistant bacterial genomes is commonplace (65, 134, 144, 209-216). As 
mentioned above this is important in reaffirming resistance mechanisms previously established, but 
also play a role in the discovery of new resistance mechanisms. These include the discovery of EF-
Gs role in aminoglycoside resistance (65, 105, 133, 134, 138), and large genomic deletions >200kb in 




experimentally evolved strains is quite routine, typically whole-genome sequencing reads are mapped 
onto a reference genome sequence belonging to the wild-type starting isolate used for evolution. 
Once the sequencing reads have been mapped to a reference genome, different programs can be 
used to identify the locations where the reads differ from the reference, providing mapping statistics 
and probability of the variant being true and not a sequencing artifact (217-220). From prediction of 
variants, a list of genes with variants can be produced identifying the effects the mutations cause at a 
protein level. Furthermore, many different technologies and programs can be applied to clinical 
isolates to provide a rapid identification of resistance associated genes (85), and acquired resistance 
genes (221), or for key mutations in well characterised chromosomally encoded genes (106, 133, 134, 
192, 222, 223). 
 
1.9. The evolutionary progression of Pseudomonas aeruginosa during chronic 
infections indicates the changes that occur to promote infectivity 
Understanding antibiotic resistance development in P. aeruginosa can provide a better 
understanding of adaptation, and potentially identify new resistance mechanisms. As well as resisting 
antibiotic treatment, during chronic infection in CF patients P. aeruginosa adapts to other challenges 
of the lung environment, including oxidative stress, the immune system, host withholding of 
micronutrients such as iron and zinc, and competition from other microbiota  (224, 225). Many of 
these need to be overcome to transition P. aeruginosa infections from acute to chronic (outlined in 
Figure 1.3). In short, it has been established P. aeruginosa can undergo multiple phenotypic changes 
including loss of motility, increased production of the extracellular polysaccharide alginate, reduced 
virulence factor and siderophore production, emergence of auxotrophy, and occurrence of small 
colony variants and hypermutator strains to adapt during infection (41, 226-232). In chronic P. 
aeruginosa infections, like those that occur in patients with CF, an environmental strain of P. aeruginosa 
can infect and undergo changes in pathoadaptive genes to adapt to the host, this can result in an 
infection which is difficult to treat (Figure 1.3) (41). How P. aeruginosa adapts to maintain infection 
within the lung of persons with CF is expanded further in Section 5.4. 
Of late, it has become routine to measure the phenotypic changes that occur in P. aeruginosa during 
infection, but combining these studies with next-generation sequencing data (whole-genome 





progression. The first such study identified multiple mutations associated with antibiotic resistance 
and immune evasion over the course of eight years of infection (233). Strikingly the research 
discovered that multiple distinct but evolutionarily linked lineages coexisted within the lung that 
seemingly worked together to cause disease progression. It also reaffirmed the mechanisms of 
antibiotic resistance and immune evasion within the host, with changes in multidrug efflux pumps 
and a selection pressure against virulence factors that may promote a host immune response (233). 
Subsequent analysis of the same isolates has also implicated hypermutable strains in allowing for 
rapid adaptation to the changing environment they may face within the lung (234). Subsequent 
studies have also followed the progression of genomic changes undergone by P. aeruginosa during 
chronic infection in CF (106, 226, 228, 229, 235-238) and non-CF patients (239) and have identified 
many other genes that undergo mutation during the course of infection. However, it remains to be 
seen if the greater understanding we have of P. aeruginosa infection progression can lead to 
manipulatable novel drug targets or if evolutionary trajectories can be altered to delay infection 
progression. Despite this, it is evident that furthering the understanding of how P. aeruginosa 
develops antibiotic resistance, and how P. aeruginosa adapts to cause chronic infections, specifically at 















Figure 1.3|Overview of mechanisms of Pseudomonas aeruginosa evolution during chronic infections in the lung of persons 
with cystic fibrosis. P. aeruginosa adapts to challenges of the lung environment that include oxidative stress, the host immune 
system, competition from other microbiota, and antimicrobial agents. Typically these are achieved through changes in regulation 
of genes, mutations, and phenotypic adaptation. (1A) Naïve to the lung environment P. aeruginosa colonise the lung, active 
flagella and pili allow for the bacteria to be somewhat motile within the lung. (1B) Bacterial invasion into the thick mucuous 
present in CF lungs allowing for bacteria to begin replication and developing communities. (1C) During the early stage of 
infection P. aeruginosa can produce virulence factors (blue stars) like pyoverdine that can sequester iron from the surrounding 
environment. At this stage many antimicrobials (red circles) are able to permeate the thick mucous and can target the early 
infection. (2A) Bacterial communities with different phenotypes, genotypes, and regulatory restraints have developed 
(represented by different colour bacteria). Additionally the disease co-morbidities associated with CF have worsened, with 
additional mucous buildup and damage to epithelial lining within the lung. (2B) Further adaptation to the environment and 
more diversification of bacteria within the infection. Additionally, increased biofilm and alginate production (red shading) 
gives an additional level of protection to the bacteria. Hypermutator strains can increase the rate of adaptation to the 
environment within the lung. (2C)  Endpoint infection, highly adapted to the conditions within the lung, large amounts of 
biofilm and alginate production, diverse range of bacterial lineages exist, and highly resistant isolates. At this stage small colony 




1.10.  Aims of this thesis 
Experimental evolution studies typically rely on a small number of mutants and so may 
overlook mutations that can contribute to resistance but do not always arise, making it more difficult 
to draw robust conclusions. Additionally, a rigorous comparison of experimentally evolved bacteria 
and those that have evolved naturally during infection is lacking despite the possibility of resistance 
mutations in experimentally evolved bacteria differing from those that arise in bacteria during 
infection. For example, mutations that increase resistance in the laboratory setting may not be 
tolerated in the complex environment of an infection. It is also of clinical importance to determine 
whether experimentally evolved mutants have cross resistance or increased susceptibility to other 
antibiotics. Within host evolution of P. aeruginosa is typically examined through whole-genome 
sequencing, with very few studies linking associated phenotypes to the genetic analyses. Although 
some studies have investigated associated phenotypic changes in attempt to understand the 
relationship between genome-wide genetic changes, consequent changes to the transcriptome, and 
the resulting phenotypic changes that facilitate adaptation to the lung environment is limited. The 
overall aim of this thesis was to address these gaps in our knowledge. Specific aims were to: 
-  Experimentally evolve P. aeruginosa to be resistant to different classes of antibiotics, in order to 
identify the genes that mutate to confer resistance (Chapter 3). 
- Determine the relevance of mutations arising during experimental evolution to the evolution 
of antibiotic resistance during infection (Chapter 3). 
- Determine the progression of genetic and phenotypic changes that occur during experimental 
evolution, examining which genes provide large increases in resistance (Chapter 4). 
- Investigate in detail the evolution of P. aeruginosa during infection over the course of 20 years 
in the lungs of a patient with CF, by comparing multiple isolates and merging phenotypic, 
transcriptional, and genotypic changes (Chapter 5). 
- Develop a computational pipeline to analyse genes and mutations of interest and predict 













2. Materials and Methods 
  




2.1.1. Bacterial strains 
Strains of P. aeruginosa used in this work are outlined with applicable citations in Table 8.1.  
P. aeruginosa PAO1 (240) was used as a laboratory reference strain. However, due to there 
being well-established variability in P. aeruginosa PAO1 isolates from around the world (241), any 
experiments using this strain are using the PAO1 present in the Lamont lab at the University of 
Otago. Variations from this PAO1-Otago and the reference PAO1 sequence have been described 
(135).  
 
2.1.2. Media used for bacterial culturing 
Cetrimide Agar Medium 
For cetrimide agar, 20 g peptone from gelatine, 1.4 g MgCl2, 10 g KCl, 0.3 g cetrimide, 10 mL 
glycerol, 13.6 g agar in 1L of ddH2O (242). Cetrimide agar was sterilised in an autoclave before use.  
King’s B 
For liquid King’s B (KB) media, 20 g Bacto peptone, 1.5 g K2HPO4. 10 mL glycerol in 1 L of 
ddH2O (243). KB was sterilised in an autoclave before use. Before use KB was supplemented with 
6.1 mM MgSO4, added to cooled sterile KB media.  
Lysogeny Broth 
For liquid Lysogeny Broth (LB) media, 10 g of casein hydrolysate, 5 g yeast extract, 10 g of 
NaCl in 1 L of ddH2O. For solid media (L-agar), add 15 g of agar (244, 245). Both LB and L-agar 
were sterilised in an autoclave before use. 
M8 
For liquid 5x M8 minimal media stock, 30 g Na2HPO4, 15 g KH2PO4, 2.5 g of NaCl in 1 L of 
ddH2O (246). 5x M8 stock were sterilised in an autoclave before use. M8 minimal media was used at 






For liquid 5x M63 minimal media stock, 15 g KH2PO4, 25 g K2HPO4, 10 g (NH4)2SO4 in 1 L 
of ddH2O (246). Liquid 5x M63 minimal media stock is pH adjusted to 7.0 and does not need to be 
sterilised in an autoclave. M63 minimal media was used at a 1x concentration by dilution with 
ddH2O and sterilised in an autoclave. Before use, M63 was supplemented with 0.2% glucose, 0.5% 
casamino acids and 1 mM MgSO4, which are all added to cooled sterile 1x M63 minimal media. 
Mueller-Hinton 
For liquid Mueller-Hinton (MH) media, 21 g DifcoTM Mueller-Hinton Broth powder in 1 L of 
ddH2O. For solid media (MH-agar), 38 g of Difco
TM Mueller-Hinton Agar powder in 1 L of ddH2O. 
Both MH and MH-agar were sterilised in an autoclave before use. 
Succinate Salts 
For liquid 10x Succinate Salts media stock 60 g K2HPO4, 30 g KH2PO4, 10 g (NH4)2SO4, 91.8 
g sodium succinic acid in 1 L of ddH2O (247). Liquid 10x Succinate Salts stock is pH adjusted to 7.0 
and sterilised in an autoclave. Succinate salts media is used at a 1x concentration by dilution with 
sterile ddH2O and filter sterilised with a 0.22 µm filter.  Before use, 1x Succinate Salts was 
supplemented with 1 mM MgSO4. 
Synthetic Cystic Fibrosis Media (modified) 
a) 5x SCFM base 
 For liquid 5x Synthetic Cystic Fibrosis Media (SCFM) stock media base 3.75 g Na2HPO4, 
4.435 g NaH2PO4, 0.25 g KNO3, 0.1 g CaCl2 2.9 g MgCl2, 5.57 g KCl, 0.61 g NH4Cl, 15.15 g NaCl in 
800 mL of ddH2O (248, 249). 5x SCFM stock media base is pH adjusted to 7.0 and sterilised in an 
autoclave2.  
b) 1x SCFM supplementation solution (from powder) 
Supplementation of SCFM3, 0.152 g L-serine, 0.128 g L-threonine, 0.159 g L-alanine, 0.008 g 
L-glycine, 0.191 g L-proline, 0.147 g L-isoleucine, 0.211 g L-leucine, 0.131 g L-valine, 0.110 g L-
 
2 Once sterilised the 5x base is stable for up to a month if stored at 4oC and stable for up to 3 months if frozen at -20oC.      
3 All reagents used for SCFM are purchased from Sigma, unless otherwise stated 
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aspartate4,  0.228 g L-glutamate, 0.088 g L-phenylalanine5, 0.145 g L-tyrosine6, 0.003 g L-tryptophan7, 
0.311 g L-lysine, 0.081 g L-histidine, 0.053 g L-arginine, 0.089 g L-ornithine, 0.019 g L-cysteine8, 
0.094 g L-methionine9, 2.7 mL 20% glucose, 10 mL 10% L-lactate, 0.001 g FeSO4.7H2O made to 
200 mL final volume with ddH2O, and filter sterilised using a 0.22 µm filter. This supplement 
solution must be prepared fresh for each batch of SCFM. 
c) 1x SCFM supplementation solution (from solution) 
Supplementation of SCFM, all amino acids were prepared at a 100 mM stock concentration in 
ddH2O (excluding those noted in b to have solubility issues) and must be prepared fresh for each 
batch of SCFM. 14.46 mL L-serine, 10.72 mL L-threonine, 17.8 mL L-alanine, 12.03 mL L-glycine, 
16.61 mL L-proline, 11.2 mL L-isoleucine, 16.09 mL L-leucine, 11.17 mL L-valine, 8.27 mL L-
aspartate, 15.49 mL L-glutamate, 5.3 mL L-phenylalanine, 8.02 mL L-tyrosine, 0.13 mL L-
tryptophan, 21.28 mL L-lysine, 5.19 mL L-histidine, 3.06 mL L-arginine, 6.76 mL L-ornithine, 1.6 
mL L-cysteine, 6.33 mL L-methionine, 2.7 mL 20% glucose, 10 mL 10% L-lactate, 1 mL 3.6 mM 
FeSO4.7H2O.  
d) for 1x SCFM the supplement solution prepared in b) or c), was added to 800 mL of 1x 
SCFM base prepared in a) diluted to 1x with ddH2O. Once combined, the 1x SCFM was filter 
sterilised with a 0.22 µm filter. The SCFM is stable for up to 2 weeks when stored at 4oC in an 
airtight light-proof non-reactive container. 
  
 
4 L-aspartate can have solubility issues in ddH2O, if this happens a 100 mM solution can be prepared in 0.5 M NaOH 
and 8.27 mL can be added (adding less ddH2O to the final 200 mL). 
5 L-phenylalanine can have solubility issues in ddH2O, if this happens a 100 mM solution can be prepared in ddH2O 
adding concentrated HCl dropwise until dissolved, and 5.3 mL can be added (adding less ddH2O to the final 200 mL). 
6 L-tyrosine can have solubility issues in ddH2O, if this happens a 100 mM solution can be prepared in 1 M NaOH and 
8.02 mL can be added (adding less ddH2O to the final 200 mL). 
7 L-tryptophan can have solubility issues in ddH2O, if this happens a 100 mM solution can be prepared in 0.2 M NaOH 
and 0.13 mL can be added (adding less ddH2O to the final 200 mL). 
8 L-cysteine can have solubility issues in ddH2O, if this happens a 100 mM solution can be prepared in ddH2O adding 
concentrated HCl dropwise until dissolved, and 1.6 mL can be added (adding less ddH2O to the final 200 mL). 
9 L-methionine can have solubility issues in ddH2O, if this happens a 100 mM solution can be prepared in ddH2O 






2.1.3. Media supplements 
Casamino acids 
Casamino acids (BD) was prepared in a 20% (w/v) solution and sterilised in an autoclave, 
stored at room temperature (RT). 
Ciprofloxacin 
Ciprofloxacin (Cipflox, Mylan New Zealand Ltd) was at a stock concentration of 2 g.L-1, 
stored at 4oC in a light-proof packaging (used within 2 months). 
Gentamicin 
Gentamicin (Pfizer) was at a stock concentration of 10 g.L-1, stored at -20oC   
Glucose 
Glucose was prepared in a 20% (w/v) solution with ddH2O and sterilised by 0.22 µM filter 
sterilisation, stored at RT. 
Imipenem 
Imipenem (Imipenem + cilastatin RBX, Douglas Pharmaceuticals Ltd) was prepared in a 25 
g.L-1 solution with ddH2O and sterilised by 0.22 µM filter sterilisation, stored at -20
oC (used within 2 
weeks). 
Kanamycin 
Kanamycin (Sigma) was prepared in a 25 g.L-1 solution with ddH2O and sterilised by 0.22 µM 
filter sterilisation, stored at -20oC 
Levofloxacin 
Levofloxacin (Sigma) was prepared in a 10 g.L-1 solution with ddH2O and sterilised by 0.22 
µM filter sterilisation, stored at -20oC (used within 2 weeks). 
Meropenem 
Meropenem (Penembact, Venus Remedies Limited) was prepared in a 50 g.L-1 solution with 
ddH2O and sterilised by 0.22 µM filter sterilisation, stored at -20
oC (used within 1 month). 
Spectinomycin 
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Spectinomycin (Sigma) was prepared in a 20 g.L-1 solution in ddH2O and sterilised by 0.22 µM 
filter sterilisation, stored at -20oC (used within 2 weeks). 
Streptomycin 
Streptomycin (Sigma) was prepared in a 20 g.L-1 solution in ddH2O and sterilised by 0.22 µM 
filter sterilisation, stored at -20oC (used within 2 weeks). 
Tobramycin 
Tobramycin (Mylan New Zealand Ltd) was at a stock concentration of 40 g.L-1, stored at RT 
until opened and then stored at -20oC (used within 3 months). 
2.2.  Laboratory methods 
2.2.1. Growth of bacteria 
Unless otherwise stated, bacterial inoculation of P. aeruginosa overnight cultures were into LB 
at 37oC with shaking (225 rpm) from a single colony taken from an L-agar plate with a sterile 
wooden toothpick. Measurement of bacterial turbidity was performed on overnight cultures diluted 
1-in-10 with fresh LB using a spectrophotometer at OD600. For P. aeruginosa PAO1 an OD600 of 0.1 
indicated a bacterial concentration of 1.5x108 CFU/mL. 
Bacterial inoculation of L-agar plates was done with bacteria streaked onto solid media (1.5% 
agar), grown at 37oC for a minimum of 18 h or until visible single colonies were present. Plates were 
stored at 4oC for up to two weeks for re-plating purposes (if needed). Longer term storage of 
bacterial strains were made using equal parts overnight culture and sterile 80% (v/v) glycerol, 
thoroughly mixed and stored at -80oC in screw cap tubes, indefinitely. 
 
2.2.2. Isolation of Pseudomonas aeruginosa from sputum samples 
Sputum samples from CF patients were inoculated onto cetrimide agar plates (Section 2.1.2) 
to select for P. aeruginosa growth and grown at 37oC for up to 48 hours. Single P. aeruginosa colonies 
were selected and cultured overnight in LB, and glycerol stocks (Section 2.2.1) made and stored at -





2.2.3. Measuring nucleic acid concentration 
To measure the concentration of DNA (plasmids and PCR products), gDNA or RNA 
spectrophotometry was done using a NanoDrop (Thermo Scientific). The NanoDrop also provided 
an approximation of sample purity, giving a absorbance ratio of 260/280 nm and 260/230 nm, for 
DNA a 260/280 nm and 260/230 nm ratio of ≥1.8 suggested a DNA sample free from common 
contaminants (proteins, lipids, chemicals used during extraction and purification). For RNA a 
260/280 nm ratio ≥2.0 and 260/230 nm ratio ≥1.8 suggested a sample free from common 
contaminants. 
 
2.2.4. Minimum Inhibitory Concentration determination 
Minimum Inhibitory Concentration (MIC) testing was carried out in accordance with the 
protocol described by Wiegand and colleagues (250). Overnight culture of the bacterial strains to be 
tested grown in MH-broth (Section 2.1.2) were adjusted to OD600 of 0.01 (estimated 1.5x10
6 
CFU.mL-1) with fresh LB, and 5µL aliquots dispensed onto MH agar plates in duplicate containing 
doubling antibiotic concentrations. Control plates, MH agar without antibiotic supplementation, 
were used as a baseline growth. All MIC plates were incubated at 37°C for 24 hours. The MIC for 
each isolate was determined as the lowest concentration that inhibited visible growth, excluding 
single colonies or faint haze. The EUCAST guidelines (www.eucast.org) were used to interpret 
antimicrobial susceptibility patterns. Each isolate was tested in duplicate and the margin of error for 
MIC was accepted as ± 1 doubling dilution (e.g. an MIC of 4 mg.mL-1 would have a margin of error 
between 2 and 8 mg.mL-1). All reported MIC values within this thesis are the average of biological 
duplicates (each biological replicate contains 4 technical replicates). 
Each antibiotic required a different range depending on which strain was being tested, the 
MIC of P. aeruginosa PAO1 was 0.0625 mg.mL-1 for Ciprofloxacin, 0.5 mg.mL-1 for Levofloxacin, 0.5 
mg.mL-1 for Meropenem, 2 mg.mL-1 for Imipenem, 0.25 mg.mL-1 for Tobramycin, 0.5 mg.mL-1 for 
Gentamicin, 64 mg.mL-1 for Kanamycin, 16 mg.mL-1 for Streptomycin, and 1024 mg.mL-1 for 
Spectinomycin.    
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2.2.5. Measurement of bacterial growth dynamics 
Overnight broth cultures grown in the media to be used for the growth analysis of strains to 
be tested were adjusted to OD600of 0.01 (estimated 1.5x10
6 CFU.mL-1) with the media the growth 
was to be measured in. 200µL aliquots were dispensed into JETbiofil® 96-well clear flat-bottom 
tissue culture plates. The microtiter plates were incubated in a BMG FLUOstar omega microplate 
reader at 37°C with shaking at 200 rpm for 18 h if measured in LB (Section 2.1.2), or 24 h if 
measured in SCFM (Section 2.1.2). Optical density (OD600nm) was recorded every 30 minutes to 
measure the growth of the isolates. Each isolate being tested had a minimum of 3 technical 
replicates per plate, and a minimum of 3 broth only controls were used as a blank value, and to 
ensure no contamination occurred. Raw comma separated value text files were exported from the 
BMG omega data analysis tool and imported into R where Area Under growth Curve (AUC) was 
calculated to give a measure of growth that included lag phase, rate of growth during log phase, and 
final cell density (Figure 2.1). Growth dynamics were calculated by using the R package 
GrowthCurver version 0.2.1 (251). Logistic area under curve was used as the metric for quantifying 
growth. Commands used to calculate AUC are available from section 8.2. 
 
Figure 2.1| Measurement of Area Under growth Curve to show changes in growth dynamic 
between bacterial isolates. Area Under growth Curve (AUC) was chosen as a means of 
measuring growth as it encompasess differences in lag phase, rate of growth during log 
phase and final cell density (hatching representing isolates with typical wild-type P. 
aeruginosa PAO1 growth (red) and a slower growing mutant of P. aeruginosa PAO1 (blue)). 
Traditional methods of predicting growth rate measure the growth rate at log phase 
expressed as a Δabsorbance/time, however this does not detect isolates that may have a 
prolonged log phase or end with different final cell density while keeping a similar log 





2.2.6. Measurement of bacterial motility via swimming motility 
Motility of the bacteria was measured according to (252). Semi-solid supplemented M8 media 
(Section 2.1.2) containing 0.3% agar to allow swimming motility was inoculated by stabbing halfway 
into the centre of an agar plate (30 mL volume) with a pipette tip dipped in an overnight bacterial 
culture adjusted to an OD600nm of 1.0 and incubated at 37 °C for 24 h. Plates were imaged at 24 h 
and area of motility was determined using the ImageJ software (253), an example of this is shown in 
Figure 5.6. 
 
2.2.7.  Measurement of cell adherence 
Measuring cell adherence via crystal violet staining was performed according to (254, 255).  
Overnight cultures of isolates to be tested were diluted to an OD600= 0.01 (estimated 1.5x10
6 
CFU/mL) with M63 media (Section 2.1.2), supplemented with 0.4 % arginine to promote biofilm 
formation (255). Cultures were grown for 24 h in U bottom 96-well plates (Corning), 37°C without 
shaking. OD600 measurements of the standing cultures before staining to account for differences in 
growth amounts. After growth measurement, planktonic bacteria were removed by shaking the 
inverted plate over a waste tray, and the plates washed by submerging in a bath of RT tap-water, and 
shaking the plate inverted over the waste tray. 125 µL of 0.1% crystal violet stain (w/v) in ddH2O, 
was added to each well and incubated at RT for 10 min. Excess stain was removed by shaking the 
inverted plate over a waste tray, and 2 additional wash steps with RT tap-water to remove any crystal 
violet not specifically staining the adherent bacteria. Plates were then inverted onto a paper towel 
and left to air dry (typically 10-15 mins, although plates at this stage can be stably stored at RT for 
up to a week). To solubilise the crystal violet stain, 125 µL 30% (v/v) glacial acetic acid in ddH2O 
was pipetted into each well and pipetted up and down vigorously to ensure all stain was solubilised. 
This mixture was transferred into clear flat-bottomed 96-well plates (JETbiofil®) and the OD550nm 
measured (BMG FLUOstar omega microplate reader). Final reported values of cell adherence were 
the OD550nm normalised to the OD600mn of the standing culture. 
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2.2.8. Measurement of pyoverdine production 
Overnight cultures of isolates to be tested were grown in KB to ensure iron limited conditions 
of growth to promote pyoverdine production. As with measuring bacterial growth (Section 2.2.5), 
broth cultures were adjusted to OD600= 0.01 (estimated 1.5x10
6 CFU/mL) with KB. 200 µL aliquots 
were dispensed into 96-well clear-bottomed, black walled tissue culture plates (Corning). The 
microtiter plates were incubated in a BMG FLUOstar omega microplate reader at 37°C with shaking 
at 200 rpm for 24 h. Optical density (OD600nm) was recorded every 30 minutes, to measure the 
growth of the isolates. Simultaneously pyoverdine production was measured spectrophotometrically 
with excitation at 410 nm and emission at 460 nm. Each isolate being tested had a minimum of 3 
technical replicates per plate, and a minimum of 3 broth only controls were used as a blank value, 
and to ensure no contamination occurred. The final pyoverdine production values used were the 
fluorescence after 24 h normalised to the OD600 of the final culture.  
 
2.2.9. Experimental evolution of antibiotic resistant bacterial mutants 
Antibiotic gradient plates were prepared, according to methodology described by Bryson and 
Szybalski (256), to evolve meropenem, tobramycin and ciprofloxacin resistant P. aeruginosa mutants. 
15mL aliquots of molten MH-agar were poured into a Petri dish tilted at an approximate incline of 
15° to ensure a slanted slope of media. When cooled, the Petri dish was placed on a flat surface and 
an additional 15mL of molten MH-agar, supplemented with the antibiotic treatment, was poured 
onto the slanted MH-agar to create an antibiotic gradient across the plate.  
Overnight broth culture prepared from a single colony subculture of reference strain P. 
aeruginosa PAO1 was adjusted to OD600 = 0.01 (1.5 × 10
6 CFU/ml) and 2 mL aliquoted onto the 
antibiotic gradient plate. Excess liquid was removed by pipette following 10-minute incubation at 
room temperature. Inoculated plates were incubated in aerobic conditions for 24 hours at 37°C. A 
single colony, isolated from an area of high antibiotic concentration from the gradient plate was 
selected and cultured overnight in LB at 37°C, shaking at 200 rpm. This inoculum was then adjusted 
as described above and used to inoculate a subsequent gradient plate containing antibiotics one 
doubling concentration greater than the previous plate. This technique was repeated with increasing 
antibiotic concentrations until it was no longer possible to identify mutants resistant to higher 





out for each antibiotic. As a control, strain PAO1 was passaged six times on agar without antibiotic. 
An overview of methods used is shown in Figure 3.1. At each selection step, overnight cultures were 
also put in long-term storage (Section 2.2.1). 
 
2.2.10. Extraction of genomic DNA from bacterial cultures 
Genomic DNA (gDNA) was extracted and purified from overnight cultures using the Qiagen 
UltraClean® Microbial DNA isolation kit, according to the manufacturer’s instructions. After 
extraction and purification, gDNA was visualised using gel electrophoresis and nucleic acid 
concentration measured using a NanoDrop (Section 2.2.3). Samples were stored at -20oC. 
 
2.2.11. Extraction of RNA from bacterial cultures 
Bacterial cultures grown overnight in SCFM were diluted to an OD600 of 0.01 (approx. 1.5x10
6 
CFU.mL-1) using fresh SCFM. These cultures were grown at 37oC shaking at 225 rpm until the 
OD600 of the culture was 0.5, where 2 mL aliquots of the log growth phase bacteria were sampled. 
The sampled bacteria were pelleted using centrifugation and resuspended in 0.2 mL of TE buffer (10 
µM Tris-HCl at pH 8.0, 1 mM EDTA, in RNase free water) before RNA extraction using a 
GeneJET RNA Purification kit (ThermoFisher Scientific), following the manufacturer’s instructions, 
using an on-column DNase I (Qiagen) treatment for 30 min at RT, and final elution with RNase free 
water. RNA concentrations were quantified using a NanoDrop (Section 2.2.3) and samples stored at 
-80oC. 
Standard RNase free working practices were adhered to during RNA extraction, including, all 
centrifugation steps done at 4oC, RNase free workbench (treated with a solution of 100 mM NaOH 
and 1 mM EDTA in ddH2O), using pipettes only used for working with RNA, and using RNase free 
pipette tips.  
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2.2.12. Whole genome sequencing 
Whole Genome Sequencing (WGS) was performed on gDNA extracted as outlined in Section 
2.2.10. Library preparation (Nextera-XT PE libraries) and sequencing was carried out by Otago 
Genomics Facility (Dunedin, New Zealand) using Illumina HiSeq2000 (2x150 bp PE-reads) and 
Illumina MiSeq (2x250 bp PE-reads). Sequencing data was supplied as raw fastq files, 1 forward 
reads and 1 reverse reads.  
 
2.2.13. RNA sequencing 
RNA sequencing (RNAseq) was performed on RNA extracted as outlined in Section 2.2.11. 
Stranded RNA sequencing ScriptSeq libraries were prepared using rRNA depleted RNA samples 
and sequenced using an Illumina HiSeq 2000 (2x 125 bp PE-reads) by Otago Genomics Facility 
(Dunedin, New Zealand). Sequencing data was supplied as raw fastq files, 1 forward reads and 1 






2.3.  Computational methods 
All codes, scripts, and pipelines outlined below are available in Section 8.2 and 
https://github.com/SJWScience/thesis_submission, with used codes and examples codes to aid 
understanding and use. 
Table 2.1|Software and programs used in this research with brief descriptions 
Program/script Version(s) 
used 
Citation Brief description (of use within this work) 
BEDtools 2.25.0 (257) Pileup and read counting of BAM files 
generated using bowtie2 and SAMtools 
BLAST+ 2.2.28+ (258) Contains all commonly used BLAST 
algorithms (e.g. BLASTn, BLASTp, tBLASTn) 
all used for localised allignments of sequences 
(or sequences to databases of sequences)  
bowtie2 2.3.3 (259) Aligner of sequencing reads to a reference 
genome 
BreSeq 0.30 (217) Pipeline for identifying variants between whole 
genome sequencing data between closely 
related bacterial isolates 
BRIG 0.95 (260) Visualisation of genome alignments in circular 
format 
cd-hit 4.7 (261) Clustering and comparing protein or 
nucleotide sequences 
CNOGpro 1.1 (262) R package to predict copy number variation in 
bacterial mapping data (BAM files) compared 
to a reference genome 
FastQC 0.11.5 (263) Provides quality information from fastq 
sequencing files (used pre- and post-trimming) 
FigTree 1.4.4 (264) Visualises phylogenetic tree files generated 
from parsnp and gingr 
Freebayes 1.1.0-3 (265) Variant calling of differences between a 
mapped genome of interest (from bowtie2 and 
SAMtools) compared to a reference genome 
GDtools 0.30 (217) Comparing outputs from multiple files 
processed using BreSeq, and for update 
variants onto reference genomes 
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genAPI 1.0 (266) Predicting gene presence and absence in 
annotated genome assemblies 
ggplot2 3.2.0 (267) R package to produce graphs/plots 
gingr 1.2 (268) Visualises outputs from parsnp 
GrowthCurver 0.2.1 (251) R package to model and quantify bacterial 
growth curves 
Kalisto 0.44.0 (269) Mapping RNAseq raw reads to an indexed 
reference gene set 
MAUVE 2.4.0 (270, 271) Visualisation of genome alignments, 
reordering of draft genome assembly contigs 
multcomp 1.4-8 (272) R package for statistical analyses 
Panseq 3.2.1 (273) Discovery of novel genomic regions when 
comparing two or more genomes (or draft 
genome assemblies) 
parsnp 1.2 (268) Compares genomes to each other and 
produces a ‘core genome’ alignment, 
phylogenetic tree and variant information 
Prokka 1.13 (274) Annotation of bacterial genes in draft genome 
assemblies 
PROVEAN 1.1 (275) Prediction of amino acid substitution impact 
on biological function of a protein 
psiBLAST 2.2.28+ (276) Position specific iterative BLAST of protein-
protein BLAST searches 
QUAST 4.4 (277) Provides assembly metrics and statistics of 
assemblies (in this research, from SPAdes) 
R 3.6.0 (278) Programming language/software for statistical 
computing and graphics (it’s R) 
ResFinder 2.3 (221) Identification of putative resistance associated 
genes in genomes (or draft genome 
assemblies) given a set of resistance associated 
sequences 
roary 3.6.0 (279) Predicting gene presence and absence in 
annotated genome assemblies 
SAMtools 0.1.19 (280) Processing, ordering, indexing, and sorting 





Sleuth 0.30.0 (281) R package to perform comprehensive 
differential gene expression analysis on 
RNAseq data 
SPAdes 3.12.0 (282) Assembles draft bacterial genomes using 
trimmed fastq sequencing data 
Trimmomatic 0.36 (283) Trims raw fastq sequencing data using quality 
and adapter information 
varEV 0.2-030320 This study, 
Section 0 
Pipeline for analysis of protein variants and 
their effects on the biological function of a 
protein 
 
2.3.1. Whole genome sequencing and RNA sequencing sample processing and 
quality control 
Raw sequencing reads (fastq format) were examined for quality pre- and post-trimming using 
FastQC version 0.11.5. Trimming was carried out to ensure that the average phred score across all 
reads was above 20 (approx. error rate >1 in 100), and there was no evidence of Illumina adapter 
contamination. 
 Trimming of raw reads was done using Trimmomatic version 0.36 (283). Trimmomatic filters 
were set to trim (if below the phred score threshold, in this case 20); 8 bp leading at the beginning of 
the sequence, 5 bp trailing at the end of the sequence, a 4 bp sliding window across the sequence 
(starting at the 5ʹ end of the read), and a minimum phred score of 20. Additionally Illumina adapters 
were trimmed using the Illuminaclip option and the pre-packaged Nextera-PE.fa (for WGS) or 
TruSeq3-PE.fa (for RNAseq) as guides for Illumina adapters. Only paired forward and reverse reads 
were used for analysis, orphan unpaired forward and reverse reads were exported to separate files 
and were not used for any analysis.  
 
2.3.2. Draft genome assembly 
For bacterial isolates needing to be assembled into a draft genome assembly for analysis, 
assemblies were created using SPAdes version 3.12.0 (282) on paired trimmed sequence reads 
(Section 2.3.1). SPAdes was used with careful mode and automatic coverage cutoff enabled. 
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Summary statistics of genome assemblies was done using QUAST version 4.4 (277). A minimum 
contig length of ≤100 bp was used and those contigs below 100 bp were excluded from analysis. 
 
2.3.3. Core genome reconstruction and phylogeny prediction 
To generate a core genome for phylogenetic tree generation, draft genome assemblies (Section 
2.3.2) were compared using parsnp version 1.2 from the Harvest suite 1.1.2 (268). For core genomes 
covering the diversity across P. aeruginosa species a coverage of approximately 60-70% was aimed for 
(% length of the reference sequence used that is present in all isolates being tested). For core 
genomes covering closely related strains or multiple clinical isolates from the same patient a 
coverage of approximately 75% or greater was aimed for. Genome comparisons from parsnp were 
visualised using gingr version 1.2 from the Harvest suite, from this an alignment was exported and a 
tree was created and visualised using FigTree version 1.4.4 (264).  
 
2.3.4. Draft genome comparison and visualisation 
Draft genome assemblies were reordered relative to the closest reference strain using MAUVE 
(270, 271). Once reordered, assemblies were compared using BRIG (260). BRIG utilises a BLAST 
based alignment method and assembles the results into an image containing concentric rings, each 
ring is a genome assembly. This allowed for comparison of draft genome assemblies scanning for 
large genomic changes, for example, large deletions. 
 
2.3.5. Draft genome gene prediction, annotation, and reference construction 
Gene prediction was performed on draft genome assemblies using Prokka version 1.13 (274), 
using all default prediction methods enabled with bacterial annotation and Gram negative settings 
enabled (for P. aeruginosa). For reference construction, if dealing with a mutant of a well characterised 
reference strain, for example experimentally evolved antibiotic resistant isolates (Section 2.2.9), 
GDtools compare was used as part of the BreSeq version 0.30 package (217). GDtools takes 





genome with the variations in the new isolate. For isolates with no closely related reference genome, 
the draft genome annotation created using Prokka was used. 
 
2.3.6. Predicting mutations in experimentally evolved antibiotic resistant 
Pseudomonas aeruginosa 
Raw sequencing reads were examined for quality pre- and post-trimming using FastQC 
version 0.11.5. Trimming of raw reads was done using Trimmomatic version 0.36 (283). The Breseq 
package (217) was used to map reads and identify variants onto P. aeruginosa PAO1-Otago. 
Mutations in the experimentally evolved resistant isolates were identified through comparison to 
PAO1-Otago using BreSeq version 0.30.0 (217). Mutations discovered through BreSeq were verified 
computationally using a pipeline consisting of mapping mutant reads onto the generated PAO1 
reference sequence using bowtie2 version 2.3.3 (259). Mapped reads were processed using SAMtools 
version 0.1.19 (280), and variants were called using Freebayes version 1.1.0-3 (265). Freebayes called 
variants were filtered based on QUAL >100, DP (coverage) >20, QR (phred score for variant) 
>100, and AO (alternative allele count) <10. Large genomic changes, including deletions were 
examined using BEDtools version 2.25.0 (257) and coverage examined using ggplot2 package in R 
(267).  
 
2.3.7. Prediction of copy number variation and large genomic duplications 
For prediction of duplicated regions within the experimentally evolved mutants, CNOGpro 
(262) was used. Hits files were generated from bam files output in the breseq (Section 2.3.6) analysis 
and parsed into CNOGpro, GC content was normalized, and 1000 bootstrap replicates were 
performed using quartiles of 0.025 and 0.975. HMM correction was performed allowing for a 
maximum of 3 possible states, allowing for an error rate of 0.01. Tables were output containing 
predicted copy number for each gene and intergenic region. Regions were called as putative 
duplications when there was a sustained increase in predicted copy number across more than 5 
genes. Known multi-copy operons were removed after comparison to the wild-type P. aeruginosa 
PAO1 coverage.  
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2.3.8. Novel region discovery  
To identify new regions of DNA obtained by clinical isolates of P. aeruginosa isolates, Panseq 
(273) was used. Novel regions were identified between an ancestral reference genome and all other 
isolates of interest. Novel regions were excluded if they were under 50 bases. To identify any 
resistance associated genes that may have been acquired in these novel regions, ResFinder (221) was 
used. Additionally, annotation of the novel regions using Prokka (Section 2.3.5) was carried out and 
predicted proteins used in a BLAST search against P. aeruginosa species for putative protein function 
annotation above those produced through Prokka.  
 
2.3.9. Prediction of large genomic deletions 
For identification of large deletions in the genomes of clinical isolates of P. aeruginosa (Section 
3.7 and Figure 3.9) an over-simplified visual analysis was performed. This was done in Mauve (270, 
271) and BRIG (260) using draft genome assemblies of clinical and environmentally sourced P. 
aeruginosa isolates (Table 8.1). Due to the deletions being examined already having been described in 
previous research (184, 239, 284) and being found in the meropenem resistant experimentally 
evolved isolates, a non-technical visual analysis of genomes was sufficient to identify 
presence/absence of these large deletions in P. aeruginosa. For predictions of large deletions in 
Acinetobacter baumanii, Burkholderia cenocepacia, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, 
and P. aeruginosa shown in 4.6, roary version 3.6.0 (279), and genAPI version 1.0 (266) were used. 
These programs gave predictions on gene presence/absence of draft genome assemblies annotated 
using Prokka. 
Genomes used for prediction of deletion in non-Pseudomonas bacteria were obtained through 
ncbi using ncbi-genome-download.py version 0.2.6 (available from https://github.com/kblin/ncbi-
genome-download/), only genomes labelled as ‘complete’ were downloaded, all downloaded 
genomes were obtained as fasta files, all downloads were done on the 01-April-2020. This resulted in 
176 A. baumanii genomes (median genome length 3.98 Mb), 16 B. cenocepacia genomes (median 
genome length 7.96 Mb), 179 E. coli genomes (median genome length 5.12 Mb), 293 K. pneumoniae 
genomes (median genome length 5.58 Mb), and 153 S. aureus genomes (median genome length 2.84 
Mb) being analysed for large deletions. The P. aeruginosa genomes used were those outlined in Table 





4.6, large deletions were defined as - predicted adjacent gene loss of 50 kb or greater found in 5% or 
more of all isolates from any species within genes present in more than 50% of all isolates from that 
species, as predicted using roary and genAPI.   
 
2.3.10. RNAseq analysis pipeline 
RNAseq was performed in triplicate and trimmed reads were mapped onto an annotated 
reference genome using Kalisto version 0.44.0 (269), using 100 bootstraps, and mapping statistics 
collected. Differential gene expression was done using Sleuth version 0.30.0 (281) in R version 3.6.0 
(278). A log2 transformation function was done in Sleuth to output log2 fold change, an FDR 
adjusted p value of ≤ 0.01 was considered to be significantly differentially expressed. Sleuth was 
used to generate MA-plots and volcano plots to better visualise the differential gene expression at a 
cell-wide level. 
 
2.3.11. Variant evaluation tool (varEV) pipeline for determining the frequency and 
effect of variations in proteins of interest  
Protein sequences of genes found to be mutated within this study were obtained from 
https://www.pseudomonas.com (84). These were used as query sequences for a tblastn search 
against compiled databases of relevant P. aeruginosa isolates. Polymorphic sites were called using a 
modified version of snp-sites version 2.3.2 (285). Non-synonymous polymorphic sites (variants) 
were extracted from vcf files (see section 7.3). The effects of variants were predicted using Provean 
version 1.1 (275) compiled using BLAST version 2.2.28+ (258), psiBLAST version 2.2.28+ (276), 
and cd-hit version 4.7 (261), and the NCBI non-redundant database (version retrieved 1 May 2019) 
(286). Variations with a score of -2.5 or below were considered as being likely to affect the biological 
functions of proteins (275). Full information about the development and implementation of variant 
evaluation tool (varEV) see section 7.3, for raw varEV code see section 8.2. 
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2.3.12. Statistical analysis 
All statistical analyses were carried out using R version 3.5.0  (278). Post-hoc Dunnett tests 
were done using R package multcomp version 1.4-8 (272). Plots were created using R package 
ggplot2 (267). All code used to generate figures is outlined in section 8.2 
 
2.3.13. Data availability 
Raw sequence reads (fastq format) of experimentally evolved mutants are available under 
BioProject PRJNA542028 on the NCBI Sequence Read Archive (SRA). All raw fastq files from the 
15 whole genome sequences and 6 RNAseq samples are available under BioProject accession 
number PRJNA588274. Accession numbers for genomes of other isolates of P. aeruginosa are listed 











3. A Large-Scale Whole-Genome Comparison 
Shows that Experimental Evolution in 
Response to Antibiotics Predicts Changes in 
Naturally Evolved Clinical Pseudomonas 
aeruginosa   




3.1. Chapter 3 preface 
The work presented within this chapter has been taken from a published manuscript (see 
section 8.1). As with all scientific pursuits this research was a team effort. I would be 
misrepresenting the study if I were to exclude the work that I did not directly complete myself. As 
such, I have kept all data in to maintain consistency to the findings presented within the published 
manuscript. All work presented on ciprofloxacin resistant P. aeruginosa was performed by co-author 
Attika Rehman. The laboratory methods used within this chapter were initially developed in our lab 
by co-author, Lois Martin, who developed mutant lines M1 and T1. Additionally, as with typical 
published manuscripts, the project conception, text, and overall flow and direction of everything was 
heavily influenced and reworked by all authors. All tobramycin and meropenem resistant P. aeruginosa 
experiments were performed by me, as are all computational analyses and figures used from the 
manuscript. This work also resulted in the development of a computational pipeline to streamline 






3.2. Abstract and Importance  
P. aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic 
infections. An increasing number of isolates have mutations that make them antibiotic resistant, 
making treatment difficult. To identify resistance-associated mutations we experimentally evolved 
the antibiotic sensitive strain P. aeruginosa PAO1 to become resistant to three widely used anti-
pseudomonal antibiotics, ciprofloxacin, meropenem and tobramycin. Mutants could tolerate up to 
2048-fold higher concentrations of antibiotic than strain PAO1. Genome sequences were 
determined for thirteen mutants for each antibiotic. Each mutant had between 2 and 8 mutations. 
For each antibiotic at least 8 genes were mutated in multiple mutants, demonstrating the genetic 
complexity of resistance. For all three antibiotics mutations arose in genes known to be associated 
with resistance, but also in genes not previously associated with resistance. To determine the clinical 
relevance of mutations uncovered in this study we analysed the corresponding genes in 558 isolates 
of P. aeruginosa from patients with chronic lung disease and in 172 isolates from the general 
environment. Many genes identified through experimental evolution had predicted function-altering 
changes in clinical isolates but not in environmental isolates, showing that mutated genes in 
experimentally evolved bacteria can predict those that undergo mutation during infection. 
Additionally, large deletions of up to 479kb arose in experimentally evolved meropenem resistant 
mutants and large deletions were present in 87 of the clinical isolates. These findings significantly 
advance understanding of antibiotic resistance in P. aeruginosa and demonstrate the validity of 
experimental evolution in identifying clinically-relevant resistance-associated mutations. 
The rise in antibiotic resistant bacteria represents an impending global health crisis. 
Understanding the genetic mechanisms underpinning antibiotic resistance will be a crucial piece of 
the puzzle in combatting it. In this research we experimentally evolved an antibiotic sensitive strain 
of the highly problematic human pathogen P. aeruginosa to become resistant to three clinically 
relevant antibiotics, allowing us to generate a catalogue of genes that contribute to resistance. We 
show that most of these genes are likely to influence the effectiveness of treatment during infection, 
by identifying gene variants in isolates of P. aeruginosa from patients. This research paves the way to 
development of improved treatment regimens by identifying early arising, key contributors to 
antibiotic resistance in P. aeruginosa. This research also shows how analysis of bacterial genome 
sequences could be used to predict the effectiveness of different antibiotics in treating P. aeruginosa 
infections through scanning these key resistance genes for antibiotic resistance associated variants. 





Figure 3.1| Overview of experimental evolution, genotypic and phenotypic characterisation, 
and in silico analysis of antibiotic resistance P. aeruginosa. Thirteen isolates were 
evolved via antibiotic gradient plates to 3 different antibiotics each (CIP - ciprofloxacin, 
MER - meropenem, TOB - tobramycin) until no further resistance was shown. Whole 
genome sequencing (WGS) was carried out to identify frequently mutated genes. These 
frequently mutated genes were compared to clinical and environmental isolates of P. 






P. aeruginosa is an opportunistic pathogen responsible for a wide range of acute and chronic 
infections. It is a frequent cause of hospital acquired infections and chronically infects the lungs of 
most adults with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (16, 
287). Although a number of antibiotics are available for treating P. aeruginosa infections many isolates 
are now resistant to one or more of these (288). The failure of antibiotic therapy to eradicate P. 
aeruginosa infection is a contributing factor to development of resistance as bacteria are likely to 
experience sub-inhibitory concentrations of antibiotics with selection for more highly resistant 
mutants (41). Treatment of infections with antibiotics that are ineffective due to resistance increases 
the length of hospital stays, increases patient morbidity and can also increase the emergence of 
resistance (289, 290). Consequently, there is a need for improved tools for determining optimal 
antibiotic treatment. One attractive option is the use of whole genome sequencing of infecting 
bacteria to determine which antibiotics are likely to be effective, an approach that has been 
developed successfully for other species (291, 292). This approach requires a thorough 
understanding of the genetic basis of antibiotic resistance.  
The basis of antibiotic resistance in P. aeruginosa has been investigated using genetic and 
biochemical approaches and is multifactorial. Mechanisms of resistance can be classified into four 
groups: reduced antibiotic uptake, enhanced antibiotic efflux, reduced affinity of antibiotics to their 
cellular targets, and inactivation of antibiotics (91, 111). Resistance mainly occurs through mutations, 
although genes obtained via horizontal gene transfer also confer a resistant phenotype.  
The emergence of whole genome sequencing (WGS) technologies has provided new 
approaches to understanding the molecular mechanisms driving antibiotic resistance (293). 
Experimental evolution of antibiotic-resistant mutants from sensitive parent strains, followed by 
whole genome sequencing to identify resistance-conferring mutations, is an approach that has been 
applied to a number of species, including P. aeruginosa (134, 138, 185, 210, 211, 215, 216). Studies to 
date have confirmed the involvement in resistance of genes previously proposed to be associated 
with resistance in P. aeruginosa. These include the fusA1 gene that encodes the EFG-1 protein and is 
associated with aminoglycoside resistance (105) and the ftsI gene that encodes a penicillin binding 
protein and is associated with carbapenem resistance (294). This approach also has high potential for 
identifying previously unknown antibiotic resistance-associated mutations and genes, but some key 




issues remain to be addressed. Experimental evolution of small numbers of mutants may overlook 
mutations that can contribute to resistance but do not always arise, making it more difficult to draw 
robust conclusions. The mutations obtained may be influenced by the selection method used – for 
example, continuous exposure to increasing amounts of antibiotic in broth culture may give 
different outcomes to intermittent antibiotic exposure, as occurs during infection in patients. Lastly 
and perhaps most importantly a rigorous comparison of experimentally evolved bacteria and those 
that have evolved naturally during infection is lacking despite the possibility of resistance mutations 
in experimentally evolved bacteria differing from those that arise in bacteria during infection. For 
example, mutations that increase resistance in the laboratory setting may not be tolerated in the 
complex environment of an infection. It is also of clinical importance to determine whether 
experimentally evolved mutants have cross resistance or increased susceptibility (i.e. collateral 
sensitivity) to other antibiotics. The overall aim of this research was to address these issues, and to 
determine the relevance of mutations arising during experimental evolution to the evolution of 






3.4. Antibiotic resistance of experimentally evolved mutants 
Our research strategy for identifying mutations causing antibiotic resistance is illustrated in 
Figure 3.1. Firstly, highly resistant mutants of P. aeruginosa PAO1 were evolved in thirteen parallel 
experiments for each of three antibiotics, tobramycin, meropenem and ciprofloxacin. Each mutant 
was selected through serial passage on antibiotic gradient agar plates containing increasing amounts 
of antibiotic, interspersed with growth in antibiotic-free broth. Mutants were considered to have 
reached maximum resistance when selection failed to give rise to any further increase in resistance 
(typically between 6 and 8 serial passages). A control culture was passaged 6 times in the absence of 
antibiotic.  
Figure 3.2 shows the MIC values for each of the 39 experimentally evolved mutants when 
tested against six different antibiotics belonging to three different classes. Compared to the parental 
strain P. aeruginosa PAO1 the evolved mutants had a minimum of 64-fold and a maximum of 2048-
fold increase in their MIC values for the selecting antibiotic. All mutants had similarly increased 
resistance to a second antibiotic of the same class (levofloxacin, imipenem and gentamicin for 
ciprofloxacin, meropenem and tobramycin-selected mutants, respectively). 
The mutants were also tested for cross-resistance to antibiotics of different classes. Most of 
the meropenem-selected mutants had increased resistance to fluoroquinolone antibiotics and were at 
or above the EUCAST clinical breakpoint for resistance in many cases (Figure 3.2). Similarly, most 
of the tobramycin-selected mutants had increased resistance to the carbapenems tested, in particular 
imipenem. Conversely, most of the ciprofloxacin-selected mutants had increased (collateral) 
sensitivity to at least one carbapenem or aminoglycoside and some of the meropenem-selected 
mutants also had increased aminoglycoside sensitivity. 





Figure 3.2| Minimum Inhibitory Concentrations of experimentally evolved antibiotic 
resistant mutants to fluoroquinolones, carbapenems and aminoglycosides. MIC 
values are shown for the parental strain P. aeruginosa PAO1 and for mutants selected for 
resistance to ciprofloxacin (C1-C13), meropenem (M1-M13) or tobramycin (T1-T13). 
MIC values are shown in mg/L, and coloured based on log2-fold change from strain 
PAO1, ranging from -4 (grey) to 11 (red). Clinical breakpoints as defined by EUCAST 
(www.eucast.org) in mg/L are: ciprofloxacin (Cip) ≥0.5, levofloxacin (Lev) ≥1, 
meropenem (Mer) ≥8, imipenem (Imi) ≥8, tobramycin (Tob) ≥4 and gentamicin (Gen) 
≥4. A control culture that underwent six serial passages in the absence of any antibiotic 






3.5. Growth of antibiotic-resistant mutants 
To assess the impact of antibiotic resistance on bacterial growth, we undertook growth 
analysis for each of the experimentally evolved mutants (Figure 3.3, Figure 3.7, Figure 3.8). Growth 
was measured as Area Under Growth Curve (AUC) in order to capture differences in both growth 
rate and bacterial cell density in stationary phase. In the absence of antibiotics, mutants in all three 
resistance groups grew significantly less well than the parental strain P. aeruginosa PAO1, with 
tobramycin-selected mutants showing the greatest reduction in growth (median values of 1147.5, 
747.5, 610.3, and 468 AUC units for strain PAO1 and for ciprofloxacin, meropenem and 
tobramycin-resistant mutants respectively). However, there was a large degree of heterogeneity in 
growth within each group, with some mutants in each group having at least twice the growth of 
others in the same group. 
 
3.6. Identification of antibiotic resistance associated mutations 
Whole genome sequencing (WGS) and variant calling of the 39 antibiotic resistant mutants 
showed that each mutant contained between 2 and 8 mutations. Mutations were present across 78 
genes; 27 genes were mutated in 2 or more mutants (Table 3.1, Table 8.3, Table 8.4, Table 8.5). In 
addition, four intergenic mutations were present in meropenem resistant mutants and 5 of the 13 
meropenem-resistant mutants contained large deletions ranging in size from 225 to 479 kb (Table 
8.4, Figure 3.4). Putative large duplications up to 600kb were identified in 2 tobramycin and 1 
meropenem resistant isolate (Figure 3.5). No mutations were present in bacteria serially passaged in 
the absence of antibiotic selection. 
 





Figure 3.3| Growth analysis of experimentally evolved mutants in the absence of antibiotics. 
Growth of each experimentally evolved mutant was measured during 18h incubation at 
37oC and Area Under Growth Curve (AUC) values determined. At least 3 biological 
replicates were carried out for each mutant, with mean AUC values shown. A one-way 
ANOVA with post-hoc Dunnett’s test was carried out on each antibiotic selection using 
PAO1 as a comparison (n=11). Bonferroni corrected P-values for Cip-, Mer-, and Tob- 
evolved mutants are 3.98x10-6, 3.36x10-7, and 2.11x10-10 respectively. Cip, ciprofloxacin; 







3.6.1. Ciprofloxacin-selected mutants 
Twenty-nine mutated genes were identified following WGS of the 13 ciprofloxacin evolved 
mutants. All of the mutants had a mutation in the gyrA gene and 9 of the mutants also had 
mutations in the parC or parE genes that encode DNA topoisomerase, known targets of 
ciprofloxacin (295). Twelve of the mutants also had mutations in nfxB that encodes an efflux pump 
regulator, with mutations in nfxB being known contributors to ciprofloxacin resistance (295). Ten of 
the mutants had mutations in pilin-encoding pil genes (Table 3.1, Table 8.3). The relationship 
between pil mutations and ciprofloxacin resistance is not clear, although very recently other 
researchers also reported an association between pil mutations and ciprofloxacin resistance (296). 
Eleven of the mutants had a mutation in a gene PA3491 that to the best of our knowledge has not 
previously been associated with antibiotic resistance. 
3.6.2. Meropenem-selected mutants 
A total of 26 genes were mutated in the 13 meropenem-selected mutants, with 8 genes 
mutated in more than one mutant (Table 3.1, Table 8.4). Many of the mutations were in genes 
previously associated with meropenem resistance. Eleven of the mutants contained mutations in the 
porin-encoding oprD gene, with mutations in this gene representing a primary mechanism for 
carbapenem resistance (113, 185, 297, 298). Ten of the mutants had mutations in nalC, nalD or 
mexR, with mutations in these genes causing upregulation of the efflux pumps and being associated 
with β-lactam resistance (65, 110, 196, 299). Mutations in ftsI, that encodes the meropenem binding 
protein PBP3A, were present in 3 mutants consistent with the known role of such mutations in 
resistance (185, 210). Mutations were also present in genes not commonly associated with 
meropenem resistance. Three of the evolved mutants contained mutations within the aroB gene that 
encodes an enzyme dehydroquinate synthase required for synthesis of aromatic amino acids. Five of 
the mutants had mutations in genes encoding tRNA ligases, with a different gene being mutated in 
each case. Five of the 13 mutants had large deletions ranging in size from 225kb up to 480kb. These 
deletions all overlapped, with the genome region between PA2022 – PA2208 being deleted in all the 
five mutants.  A smaller deletion (1986bp) spanning PA2022-PA2024 was present in one mutant. 
The deleted region contains PA2023 (galU). Insertion mutations in galU lead to increase in resistance 
to meropenem, cephalosporin and aminoglycosides (97, 113, 298). The presence of this smaller 
deletion suggests galU may contribute to the resistance measured in large-deletion containing 
isolates. 






Figure 3.4| BRIG comparison of experimentally evolved meropenem resistant mutants 
containing large deletions. Genome assemblies of experimentally evolved meropenem 
resistant mutants were compared with the parental P. aeruginosa PAO1 genome using 
BRIG. Blue rings, genome alignment of  meropenem resistant mutants containing large 






3.6.3. Tobramycin-selected mutants 
A total of 24 individual genes were mutated across the 13 tobramycin-selected mutants, with 
ten genes mutated in more than one mutant (Table 3.1, Table 8.5). All mutants had at least one 
mutation in fusA1 that encodes elongation factor G. Mutations in fusA1 have recently been reported 
to confer tobramycin resistance in laboratory-evolved mutants (105). Nine mutants also had 
mutations in the wbpL or PA5001 genes that are associated with lipopolysaccharide synthesis and ten 
mutants had mutations in genes directly involved in oxidative phosphorylation and generation of 
proton motive force (cco, nuoG, PA1549, and PA4429). Mutations affecting either of these processes 
increased aminoglycoside resistance in a whole-genome screen for resistance genes (102). Several 
other genes were mutated in a smaller number of tobramycin-selected mutants (Table 8.5). Many of 
these including PA1767, mexY, amgS and nalC have previously been implicated in aminoglycoside 
resistance (91, 102, 300, 301). 
  




Table 3.1|Genes mutated in more than one experimentally evolved antibiotic resistant 
mutant. 
Gene mutated by 
resistance to: Function if known 
No. of experimentally 
evolved mutants (n = 
13 for each antibiotic) 
Ciprofloxacin resistance 
gyrA DNA gyrase subunit A 13 
nfxB transcriptional regulator NfxB 12 
PA3491 electron transport complex subunit C 11 
parC DNA topoisomerase IV subunit A 6 
parE DNA topoisomerase IV subunit B 3 
pilT twitching motility protein PilT 3 
pilF type 4 fimbrial biogenesis protein PilF 3 
tpiA10 triosephosphateisomerase 2 
PA5001 cell surface-sugar biosynthetic glycosyltransferase 2 
   
Meropenem resistance 
oprD porin D 11 
nalC transcriptional regulator NalC 6 
Large deletion  5 
aroB 3-dehydroquinate synthase 3 
ftsI penicillin-binding protein 3 3 
nalD transcriptional regulator NalD 3 
msrA peptide methionine sulfoxide reductase 2 
mexR11 multidrug resistance operon repressor MexR 2  
phoQ two-component sensor PhoQ 2 
   
Tobramycin resistance 
fusA1 elongation factor G 13 
wbpL glycosyltransferase WpbL 7 
Δcco cytochrome C oxidase 6 
amgS two-component sensor AmgS 4 
PA1767 hypothetical protein 4 
mexY multidrug efflux protein MexY 4 
rplF 50S ribosomal protein L6 2 
PA4429 cytochrome C1 2 
PA5528 hypothetical protein 2 
Putative large duplication12 2 
PA5001 cell surface-sugar biosynthetic glycosyltransferase, ssg 2 
nalC transcriptional regulator NalC 2 
 
10 tpiA is also mutated in 1/13 meropenem resistant mutants. 
11 mexR was also mutated in 1/13 ciprofloxacin resistant mutants. 






Figure 3.5| Sequencing coverage of experimentally evolved mutants containing putative 
duplications of large regions in the genome. CNOGpro, examining the read depth 
across the P. aeruginosa PAO1 genome, was used. Putative duplications are indicated by 
increased read coverage, and deletions by absence of sequence reads. (A) P. aeruginosa 
PAO1 used in this study mapped to refseq P. aeruginosa PAO1 (NC_002516.2). Increased 
read coverage indicates regions which are either duplicated in our reference strain or are 
present in more than one copy in the genome. (B) Read coverage across tobramycin 
resistant mutant T6. (C) Read coverage across tobramycin resistant mutant T11. (D) Read 
coverage across meropenem resistant mutant M1 that contains 2 putative duplications. 




3.7. Frequencies of mutations in clinical isolates of P. aeruginosa. 
It is common for mutations that confer antibiotic resistance in P. aeruginosa to arise during 
infection in CF patients (302). We therefore addressed the question, do mutations that arose in the 
experimental evolution experiments reflect those that have arisen in clinical isolates of P. aeruginosa? 
To do so we analysed the genomes of 558 P. aeruginosa clinical isolates. For comparison we analysed 
the genomes of 172 P. aeruginosa isolated from the general environment, and which are therefore 
unlikely to have had antibiotic exposure.  All genes that were mutated in two or more of our 
experimentally evolved mutants were analysed in each genome to determine whether likely 
resistance-associated mutations had occurred. The absence of genome sequences of ancestral strains 
prevented direct identification of mutations. Instead, genetic variants that are likely to alter protein 
function by contributing to antibiotic resistance were inferred using PROVEAN, a widely used tool 
for predicting the likelihood that amino acid differences affect protein function (275).  The results 
are summarised in Table 3.2.  
Many of the genes that were mutated in our experimentally evolved mutants had higher 
frequencies of predicted function-altering variants in clinical isolates than in environmental isolates. 
For example, the antibiotic target genes gyrA (ciprofloxacin resistance), ftsI (meropenem resistance) 
and fusA1 (tobramycin resistance) all had predicted function-altering variants in over 15% of the 
clinical isolates. In many cases the variations in the clinical isolates were identical to those in 
experimentally evolved mutants. For example, the variant T83I in GyrA was present in 96 (51.3% of 
isolates containing predicted functional variants) clinical isolates.  Predicted function-altering 
variants in genes encoding regulatory proteins that are associated with antibiotic resistance such as 
nalD, mexR and amgS were also common in the clinical isolates. Predicted differences in mexY, which 
encodes an efflux pump component known to be associated with tobramycin resistance (300), were 
also frequent in the clinical isolates. Furthermore, the aroB gene, which does not have a characterised 
role in antibiotic resistance, was identified through whole genome sequencing of the experimentally-
evolved meropenem-resistant mutants and was predicted to have function-affecting differences in 
over 10% of the clinical isolates. Some genes (pilT, pilF, nalC and PA1767) that were mutated in our 
experimentally-evolved mutants had only low (<5%) frequencies of predicted function-altering 
differences in the clinical isolates implying that mutations in these genes may not be advantageous 





significantly less impact on the genomes of the environmental isolates than on the genomes of 
clinical isolates (p = 2.0 x 10-16) (Figure 3.6).  
In addition to point mutations, five of the experimentally-evolved meropenem-resistant 
mutants had large (over 200 kb) deletions. Large deletions of comparable size were also present in 
87 of the clinical isolates and only 1 of the environmental isolates (Figure 3.8, Table 3.2).  
 
Figure 3.6| Comparison of change-of-function variants in clinical and environmental 
isolates. Provean values were determined for clinical (clin) and environmental (env) 
isolates for all variants in genes that were mutated in at least two experimentally evolved 
antibiotic resistant mutants. More negative values indicate variants that are more likely to 
affect function. The dashed line represents cut-off value of -2.5, with variants below this 
value being highly likely to affect protein function. The medians and first and third 
quartiles are shown in the overlaid boxplots (whiskers showing 1.5 times the interquartile 
range above the 75th percentile and below the 25th percentile). An ANOVA test using 
TukeyHSD correction showed that there was a significant difference in the Provean 
values in the clinical group compared to the ENV group (p = 2 x 10-16). 




Table 3.2|Frequencies of predicted change of function mutations in clinical and 
environmental isolates of P. aeruginosa, for genes identified through experimental 
evolution. 
Gene mutated by resistance to: 
No. (%) of clinical 
isolates (n = 558) 
No. (%) of environmental 
isolates (n = 172) 
Ciprofloxacin resistance   
gyrA 187 (33.5) 5 (2.9) 
nfxB 74 (13.2) 7 (4.1) 
PA3491 98 (17.5) 60 (34.9) 
parC 37 (6.6) 6 (3.9) 
parE 15 (2.7) 3 (1.7) 
pilT 4 (0.7) 0 (0) 
pilF 22 (3.9) 2 (1.2) 
tpiA 15 (2.7) 6 (3.5) 
PA5001 37 (6.6) 7 (4.1) 
   
Meropenem resistance   
oprD 488 (87.5) 127 (73.8) 
nalC 7 (1.2) 0 (0) 
Large deletion 87 (15.6) 2 (1.2) 
aroB 54 (9.7) 7 (4.1) 
ftsI 92 (16.5) 4 (2.3) 
nalD 25 (4.5) 4 (2.3) 
msrA 21 (3.8) 7 (4.1) 
mexR 52 (9.3) 2 (1.2) 
phoQ 48 (8.6) 26 (15.1) 
   
Tobramycin resistance13   
fusA1 166 (29.7) 0 (0) 
amgS 53 (9.5) 9 (5.2) 
PA1767 13 (2.3) 0 (0) 
mexY 140 (25.0) 15 (8.7) 
rplF 11 (2.0) 0 (0) 
PA4429 4 (0.7) 0 (0) 
PA5528 86 (15.4) 39 (22.7) 
  
 
13 wbpL was excluded from this analysis due to the very high degree of variability of this gene in P. aeruginosa reflecting its 
role in serotype determination (303). Genome sequences were not analysed for deletion of cco genes because of the 






In this study, we have extended the understanding of the genetics of antibiotic resistance in P. 
aeruginosa. In contrast to previous experimental evolution studies we used an agar-based selection 
method interspersed with growth in antibiotic-free broth. This methodology, in conjunction with 
analysis of a large number of resistant mutants for each of three clinically-relevant antibiotics, 
identified a number of resistance-associated genes not found in other studies. Importantly, 
comparison with the genomes of P. aeruginosa isolated from chronically-infected patients as well as 
isolates from the general environment has confirmed that many mutations in experimentally-evolved 
mutants are clinically relevant while indicating that some appear to be restricted to the laboratory 
situation. 
Our approach of carrying out antibiotic selection on agar plates interspersed with periods of 
antibiotic-free growth has some parallels with the conditions faced by P. aeruginosa when it colonises 
the lungs of CF patients. In both circumstances bacterial growth is on a semi-solid surface with 
intermittent exposure to antibiotic and so selects for mutations that are stably inherited in the 
absence of antibiotics. Many of the mutations identified here were in genes that were identified in 
other experimental evolution studies. For example, mutations altering the target site proteins GyrA 
and ParC as well as the efflux pump regulator NfxB are well established contributors to 
fluoroquinolone resistance (295).  Our selection protocol and the large number of experimentally 
evolved mutants that we analysed also allowed us to identify some genes that were known to 
contribute to clinical resistance but not identified in previous experimental evolution studies. These 
included parE (ciprofloxacin resistance) (304) and amgS and wbpL (tobramycin resistance) (131).  
Importantly, experimentally evolved mutants in this study also had mutations in genes not 
usually associated with resistance. These include PA3491 and pilin-encoding genes in ciprofloxacin-
selected mutants; aroB and tRNA ligases in meropenem-selected mutants (210, 298); and PA1767, cco 
and wbpL in tobramycin-selected mutants. The occurrence of mutations in these genes in multiple 
independently-evolved lines (Table 3.1, Table 8.3, Table 8.4, Table 8.5) strongly suggests that the 
mutations increase antibiotic tolerance in our selection system. Entry of tobramycin into P. aeruginosa 
can be affected by changes to the cell surface or to membrane potential (102, 305) and mutations in 
cytochrome C oxidase or wbpL may result in such changes. How the other genes may affect 




resistance is not clear. Further research will be required to determine how mutations in these genes 
increase resistance, as well as their role (if any) in resistance of clinical isolates. 
Another noteworthy observation was the prevalence of large deletions (up to 8% of the 
genome) in mutants selected for resistance to meropenem, something that has also been observed 
previously (185). All the deletions overlapped, with PA2023 (galU) that encodes an enzyme required 
for LPS core synthesis being deleted in all cases. In a genome-wide screen, a mutation in galU 
increased meropenem tolerance (113, 298). Deletion of galU may therefore contribute to increased 
tolerance in the deletion-containing mutants obtained here, perhaps in conjunction with other 
deleted genes.  
We used PROVEAN to assess the frequency of likely change-of-function mutations in 
isolates of P. aeruginosa from patients with CF. For comparison we analysed a panel of isolates from 
the general environment (Table 3.2). A significant proportion of isolates from CF patients are 
antibiotic resistant (287, 288), whereas environmental isolates are typically sensitive to antibiotics 
(35).  
A high proportion of clinical isolates contained likely function-altering differences in genes 
that are established as contributing to clinical resistance to fluoroquinolones (gyrA and parE), 
carbapenems (mexR, nalD) and/ or aminoglycosides (mexY, amgS) (Table 3.2) (91, 111). These genes 
contained few or no predicted function-altering differences in isolates from the general 
environment, emphasising their clinical relevance as well as validating our approach. Three genes 
fusA1, ftsI and aroB that have only recently been identified as affecting antibiotic resistance (aroB in 
this study) also had predicted function-altering differences in clinical isolates but few or no 
environmental isolates (105, 185). These findings demonstrate the utility of experimental evolution 
for identifying clinically-relevant genes associated with antibiotic resistance. 
The oprD gene that is well established as being associated with carbapenem resistance had a 
high frequency of predicted function-altering differences in clinical isolates, as expected. It also had a 
high frequency of such differences in environmental isolates of P. aeruginosa consistent with earlier 
findings (297), a finding that was related to its role in environmental adaptation of P. aeruginosa. 





0.8 environmental), likely reflecting the need for more severe loss of function changes to OprD in 
contributing to carbapenem resistance. 
Conversely, the nfxB, parC and nalC genes that were previously shown to influence the 
resistance phenotype of clinical isolates (299, 304, 306) and in experimental evolution studies (Table 
3.2) (185, 215) had only low frequencies of predicted function-altering differences in the clinical 
isolates in this study. This may indicate that mutations in these genes are associated with higher 
levels of antibiotic resistance than that of the isolates in our study. Mutations in these genes may also 
have a high fitness cost in the clinical environment.  
A number of genes that were mutated in multiple experimentally evolved mutants are not 
commonly associated with antibiotic resistance. Many of these, such as pil genes, tpiA and PA1767, 
had only low frequencies of predicted function-changing differences in the clinical isolates. This 
finding suggests that mutations in these genes contribute to increased antibiotic tolerance in 
laboratory culture but likely do not do so during infection and further emphasises the importance of 
comparing experimentally-evolved mutants with clinical isolates. In contrast, mutations in genes 
such as mexZ and gyrB are well-characterised in clinical isolates (106, 123, 307-309) but were not 
identified in our experiments or in other experimental evolution studies, indicating that experimental 
evolution studies alone are not necessarily sufficient to identify all resistance-associated mutations. 
The experimentally evolved mutants had increased tolerance to antibiotics of the same class 
(Figure 3.1), as found previously (138). Many of the mutants also had altered MICs for antibiotics of 
different classes and some of these changes could be related to the mutations that were present.  For 
example many of the meropenem-selected mutants had mutations in nalC and such mutations lead 
to overexpression of mexAB-oprM (65), which may reduce susceptibility to fluoroquinolones. 
Conversely several of the ciprofloxacin-selected mutants had increased susceptibility to 
aminoglycosides and to imipenem, likely due to the presence of nfxB mutations (310).  The 
occurrence of collateral changes in antibiotic sensitivity as a result of mutations selected in response 
to antibiotic exposure has also been observed in isolates of P. aeruginosa from patients (204, 311-313). 
This has important clinical implications, because such outcomes during infection may affect 
treatment options for patients with CF or other chronic infections.  




In the absence of antibiotics the majority of the experimentally-evolved mutants showed 
significant reductions in growth relative to the wild-type control, consistent with previous studies 
(Figure 3.2) (185, 314-316). It is noteworthy that isolates of P. aeruginosa from patients are often slow 
growing (317) although the extent to which this phenotype is related to antibiotic resistance is not 
clear. 
Analysis of whole genome sequences of infecting bacteria, in order to predict which 
antibiotics will be effective in treatment, has potential to significantly improve quality of patient care 
and this approach is well advanced for some species of bacteria (291, 292). The genetic complexity 
of antibiotic resistance in P. aeruginosa makes it more challenging to develop accurate tools for 
prediction of resistance phenotype from genome sequence. However, cataloguing of the gene set 
that contributes to resistance phenotype through experimental evolution, coupled to our analysis of 
clinical isolates, will advance efforts to develop reliable genome-based prediction tools. 
In conclusion, our study demonstrates the power of experimentally evolving multiple mutants 
for identifying genes that, when mutated, contribute to increased antibiotic resistance. Evolution of 
multiple independent mutants reveals the frequencies at which mutations arise in individual genes, 
which is likely to be related to the extent to which they contribute to increased resistance in our 
selection system. Use of an agar-based method instead of the broth-based methods of earlier studies 
identified genes not previously associated with resistance and showed that the spectrum of resistance 
mutations is influenced by the selection protocol. Crucially, analysis of resistance-associated genes in 
clinical isolates of P. aeruginosa validated the clinical relevance of genes identified only through 
experimental evolution approaches, while demonstrating that some genes that are mutated in 
laboratory-based experiments are unlikely to be relevant to resistance during infection. The 
extension of our approach to other antibiotics and indeed, other bacterial species, will greatly 






3.9. Supplemental figures 
 
Figure 3.7| Growth of experimentally evolved antibiotic resistant mutants. Bacteria were 
grown in L-broth and A600 measured at 30 minute intervals. Means of 3 biological 
replicates (5 for ciprofloxacin resistant mutants) are shown +/- standard error.  (A) 
Ciprofloxacin resistant mutants. (B) Meropenem resistant mutants. (C) Tobramycin 
resistant mutants.  





Figure 3.8| Analysis of growth of experimentally evolved mutants. Area under growth curve 
(AUC) was calculated for the mean of each of the biological replicates for each mutant 
(Figure 3.7). Panels A, B, and C show the ciprofloxacin, meropenem, and tobramycin 
resistant mutants respectively. Statistical analysis was carried out using a one-way 
ANOVA with post-hoc Dunnett’s test using untreated PAO1 as a comparison. 
Bonferroni corrected P-values are indicated by * (<0.05) ** (<0.01), and *** (<0.001), 










Figure 3.9| BRIG comparison of clinical P. aeruginosa isolates containing large genome deletions. Clinical and environmental 
isolates of P. aeruginosa were compared with strain PAO1 using BRIG. Isolates containing a large deletion (>20kb) between 
regions 2.0 mb and 2.7 mb on the P. aeruginosa PAO1 genome were identified. Eighty seven of 558 clinical isolates, only one of 
the environmental isolates, met these criteria. Rings in black are the common reference genomes P. aeruginosa LESB58 and 
PA14. Rings in blue or pink are the clinical and environmental P. aeruginosa with putative large deletions, pink rings are every 5th 
ring to enable easier identification of specific rings.  










4. Phenotypic changes during experimental 
evolution of antibiotic-resistant mutants 
reveals differences between meropenem and 





4.1. Chapter 4 preface 
Chapter 3 examines P. aeruginosa isolates at the end of experimental evolution for the selection 
of antibiotic resistance. This chapter examines the changes that occur during the course of 
experimental evolution, focusing on meropenem and tobramycin resistant isolates by examining the 
mutants during the earlier evolution steps. This chapter advances the understanding of the process 
by which P. aeruginosa evolves resistance to meropenem and tobramycin by showing how specific 
gene mutations, and combinations of mutations can add together to give rise to antibiotic resistant 
bacterium.  
This chapter also studies the prevalence of large deletions identified in Chapter 3, showing the 
diversity of strains of P. aeruginosa they have been identified in, and under what different conditions 
they can arise. Furthermore, other human pathogens are examined to determine whether large 
deletions to the extent seen in P. aeruginosa are common in other bacteria species.   
 
4.2. Abstract and Importance 
In experimental evolution studies for antibiotic resistance in P. aeruginosa, typically the most 
resistant isolates are whole genome sequenced. This often overlooks the earlier stages in evolution 
and fails to identify the order in which mutations arise. By examining the mutations and the order in 
which they appear (early or late) during evolution we can identify genes that can confer antibiotic 
resistance alone, compared to genes that may require epistatic interactions with other gene mutations 
to confer resistance. To further understand how P. aeruginosa evolves tobramycin and meropenem 
resistance during experimental evolution studies, 6 experimentally evolved lines were sequenced 
during early selection with each antibiotic, MICs and growth were determined for each step. This 
revealed differences between how P. aeruginosa becomes resistant to meropenem and tobramycin. As 
meropenem resistance increases it is often associated with large reductions in growth in the absence 
of antibiotics. As tobramycin resistance increases it results in consistent reductions in growth as the 
bacteria becomes more resistant. 
To examine if the large deletions identified in Chapter 3 as being associated with meropenem 
resistance can arise in non-P. aeruginosa opportunistic human pathogens, research was carried out to 
identify large deletions in other species. Only P. aeruginosa contains large overlapping deletions at a 




high prevalence in the isolates studied, suggesting a unique antibiotic resistance mechanism to P. 
aeruginosa. 
The steps that lead to antibiotic resistance can be considered as important as the final 
antibiotic resistance itself. By examining intermediate steps in experimentally evolved antibiotic 
resistant P. aeruginosa, this research shows that some genes in resistant isolates greatly impact the 
bacteria by causing increased resistance while reducing the bacteria’s ability to grow without 
antibiotics present. This research provides insights into the process by which P. aeruginosa can 
develop resistance to tobramycin and meropenem. This can aid in the identification of bacteria that 
may become highly resistant before they become difficult to treat clinically.  
 
4.3. Introduction 
Studying the genetic basis of antibiotic resistance in P. aeruginosa via experimental evolution 
and evolution of antibiotic resistance within patients has led to understanding of which genes can 
confer resistance to specific antibiotics (Chapter 3, (135)). In P. aeruginosa mechanisms of resistance 
can loosely be grouped into four groups; reduced antibiotic uptake, enhanced antibiotic efflux, 
reduced affinity of antibiotics to their targets, and inactivation of antibiotics (66). In P. aeruginosa 
antibiotic resistance mainly arises through mutations in chromosomally encoded genes, although 
antibiotic resistance genes involved in inactivation of antibiotics can be obtained via horizontal gene 
transfer, conferring a resistant phenotype in the absence of mutations in chromosomal resistance 
mechanisms (318-320). 
By using WGS we can routinely study experimentally evolved bacteria and compare the 
evolved mutant genomes to the wild-type starting strain, an invaluable tool that can identify the 
genetic drivers of antibiotic resistance (134, 139, 144). A comprehensive introduction to 
experimental evolution is presented in Section 3.3. In summary, in the case of evolving antibiotic 
resistant bacteria, a wild-type antibiotic sensitive strain can be evolved to become resistant through 
successive exposures to increasing concentrations of an antibiotic. The resulting mutant will have 
genetic changes that confer resistance to the antibiotic used.  
Experimental evolution of bacteria to external environments or stimulus have been used to 





microbe interactions, and antibiotic resistance (321, 322). In P. aeruginosa experimental evolution has 
been used to examine the genetic basis of antibiotic resistance to many different antibiotics (134, 
138, 185, 210, 211, 215, 216). Typically, these studies examine the most resistant isolates (endpoint 
isolates) containing numerous mutated genes that contribute to resistance. While studying endpoint 
resistant isolates shows the genes that can work together to confer resistance, this can fail to identify 
genes that are large contributors to resistance alone, or genes that require mutations in other genes 
to confer resistance via epistatic interactions. Consequently, there is a need for studying the 
intermediate steps during resistance acquisition to identify the genes that are critical for developing 
resistance at an early stage.  
What is often overlooked is that during the process of selecting for these mutants there are 
multiple mutations that arise, some likely play a larger role in resistance than others. The order in 
which these mutations arise can also provide crucial insights into antibiotic resistance development. 
Typically, genes mutating frequently and early during selection can provide large phenotypic changes 
for little cost (185, 209, 321, 323-326). Genes that mutate later during selection may confer smaller 
increases in resistance or may be linked to other mutations via epistatic interactions (327). Not 
considering the order in which mutations arise during resistance can lead to the incorrect 
assumption that certain gene mutations can confer resistance, however, might be dependent on 
epistatic interactions to give resistance. Additionally, identifying the order in which mutations arise 
during resistance development can help identifying evolutionary trajectories that mutants might take 
towards resistance, leading to the identification of genes that can be determinants and predictors of 
resistance before the bacteria becomes too difficult to treat (137, 328-331). By understanding the 
genes required for P. aeruginosa to become antibiotic resistance and the order of mutations which can 
confer resistance can provide critical insight into the genetic basis of identifying and predicting 
antibiotic resistance. To that end, Chapter 4 aims to study the intermediate steps of experimental 
evolution of meropenem and tobramycin resistant P. aeruginosa mutants, determining the relevant 
mutations that arise early during evolution and studying their effect on the growth and resistance of 
the bacterium.  
  




4.4. Experimentally evolved meropenem resistant isolates show steady increase 
in resistance and large decreases in growth during selection 
In chapter 3, Figure 3.2 and Figure 3.3 showed the end of line mutants after experimental 
evolution (experimental evolution experiment is outlined in Section 2.2.9, and Figure 3.1). Studying 
highly resistant mutants gives a good overview of the changes that occurred during selection with 
antibiotics. It does not accurately capture the order in which the mutations occurred and what might 
have happened to result in observations presented in Chapter 3. Examination of a subset of 
experimentally evolved antibiotic resistant P. aeruginosa throughout the process of selection gives a 
much greater insight into the changes occurring. To this end, growth dynamics and resistances were 
measured for each selection step for 6 meropenem evolved P. aeruginosa lines (M3, M7, M8, M9, 
M10, and M11) (Table 4.1, Figure 4.1). Additionally, earlier steps in the evolution of these lines were 
whole genome sequenced to understand the order in which mutations might arise during selection 
(Table 4.1). 
It was expected that as selection continued within the experimental evolution experiments, 
antibiotic resistance (as measured by the MIC) would increase, due to doubling the concentration of 
antibiotic after each selection step. Surprisingly, resistance (the MIC) of many lines did not increase 
at each selection step. Meropenem evolved resistant line M3 reached its maximum resistance of 64 
mg.L-1 to meropenem after 5 selection steps, resistance did not increase beyond 64 mg.L-1 even after 
5 further selections steps (Table 4.1). Meropenem-evolved lines M8, M9, and M11 also reached a 
final MIC before the end of the selection process (Table 4.1).  
Measuring resistance to other antibiotics in these experimentally evolved lines provides insight 
into how meropenem resistance overlaps with other resistance mechanisms. All lines measured for 
MIC showed an increase in the carbapenem imipenem resistance as meropenem resistance 
increased. In contrast, tobramycin resistance did not increase in any of the lines tested. Rather, there 
was increases in tobramycin sensitivity within the isolates tested, although they are within 
experimental error by the end of line. Strikingly, four of the six lines tested showed increase 
ciprofloxacin resistance, with lines M3 and M7 showing up to an 8-fold increase in ciprofloxacin 







During the analysis of growth in intermediate meropenem resistant isolates it was observed 
there were large decreasing jumps in the mutant’s ability to grow without antibiotics (Figure 4.1). 
Some of the large decreasing jumps in growth rate are explained by large deletions arising during 
selection. Lines M8, M9, and M10 all show marked decreases in growth rate when deletions arise 
(Table 4.1). Line M10 (Δ462kb, PA1821-PA2221) shows a 37% reduction in growth and an 8-fold 
increase in meropenem resistance compared to the step before that does not contain a deletion 
(Figure 4.1E; M10.3 compared to M10.4, Table 4.1). However, in line M11 when a 276Kb deletion 
occurs (between M11.4 and M11.5), although the MIC for meropenem increases from 16 to 64 
mg.L-1, the growth rate does not decrease (Figure 4.1F, Table 4.1).  
Not all large decreases in growth can be attributed to mutants gaining deletions during 
experimental evolution, other large decreases in growth co-occur with mutations in genes critical to 
growth, in line M8 a 30% reduction in growth and 8-fold increase in meropenem resistance 
compared to the wild-type starting strain is observed when a mutation in glyQ arises, glyQ encodes 
for a glycyl-tRNA synthetase. In line M3 a sudden 65% reduction in growth happens between M3.4 
and M3.5, the only mutations in the M3 line between M3.3 and M3.10 are mutations in nalD and 
cysS. nalD has a well-established role as a transcriptional regulator that is often mutated in antibiotic 
resistance isolates, cysS however, encodes a cysteinyl-tRNA synthetase which may be contributing to 
a large decrease in growth as is seen with the glyQ mutation in line M8. In line M9 the deletion of 
galU results in a 13.8% reduction in growth and 2-fold increase in meropenem resistance compared 
to the step before that does not contain the deletion (Figure 4.1D; M9.3 compared to M9.4). In line 
M7 there is also big decreases in growth as resistance increases, in this line there is a mutation in aroB 
which encodes 3-dehydroquinate synthase, a protein critical in aromatic amino acid synthesis in P. 
aeruginosa, this could explain some of the reduction in growth as mutant line M7 becomes 
auxotrophic and requires supplementation with aromatic amino acids to grow in minimal media 
when the aroB mutation occurs (data not shown). This suggests that meropenem resistance in P. 
aeruginosa might be a complex interplay between decreases in growth to aid in resistance as well as 
mutations in key genes known to confer resistance. 




Table 4.1| Experimentally evolved meropenem resistant mutants resistances, growth change, and mutations 
 MIC mg.L-1    
Line MerR ImiR CipR TobR AUC 
% growth 
change 
relative to WT mutation specific mutation14 
M3.0 0.5 2 0.0625 0.25 1388    
M3.1 0.5 2 0.0625 0.25 1389 0.0   
M3.2 1 4 0.25 0.25 1392 -0.3   
M3.3 8 32 0.25 0.25 1398 -0.7 oprD, nalC oprD (G314D), nalC (ins ( C)) 
M3.4 16 64 0.25 0.25 1418 -2.1   
M3.5 64 128 0.5 0.25 488 64.9   
M3.6 64 128 0.5 0.25 462 66.7   
M3.7 64 128 1 0.25 452 67.4   
M3.8 64 128 1 0.25 482 65.3   
M3.9 64 128 1 0.25 487 64.9   
M3.10 64 128 1 0.25 381 72.6 nalD, cysS nalD (T11N), cysS (A114V) 
         
M7.0 1 2 0.0625 0.25 1392    
M7.1 2 4 0.0625 0.25 1396 -0.3   
M7.2 16 32 0.25 0.25 1410 -1.3   
M7.3 16 32 0.25 0.25 1393 0.0 oprD, nalC oprD (S251*), nalC (ins(T)) 
M7.4 16 32 0.25 0.25 1390 0.2   
M7.5 23 32 0.25 0.25 1410 -1.3   
M7.6 64 128 0.5 0.25 1020 26.8   
M7.7 64 256 1 0.25 975 30.0   
M7.8 128 256 1 0.25 583 58.1 
aroB, msrA, intergenic 
(rpsJ|tufA) aroB (D134N), msrA (G71D), intergenic (rpsJ|tufA) (ΔC) 
         
M8.0 0.5 2 0.0625 0.25 1339    
M8.1 1 8 0.125 0.25 1332 0.5   
M8.2 4 32 0.125 0.25 1345 -0.5   
M8.3 4 32 0.125 0.25 1337 0.2 oprD, ampD oprD (W6*), ampD (Δ1bp) 
M8.4 32 64 0.25 0.125 923 31.1 glyQ glyQ (D34E) 
M8.5 32 64 0.25 0.125 925 30.9   
M8.6 128 256 0.125 0.125 586 56.3 480kb del 480kb del (ldcA-pslB) 
M8.7 128 256 0.125 0.125 605 54.8   
         
 
14 Samples highlighted indicate mutants which were whole genome sequenced. Each set of mutations indicated at the relevant steps are those found in addition to 
those present at earlier mutation steps in the same line. For example, mutant M3.3 contains mutations in oprD and nalC, whereas mutant M3.10 contains mutations in 
oprD, nalC, nalD, and cysS. Mutants that were whole genome sequenced (highlighted) that have no mutations listed had no additional mutations to the earlier 





M9.0 0.5 2 0.0625 0.25 1350    
M9.1 1 2 0.125 0.25 1360 -0.8   
M9.2 8 16 0.25 0.25 1364 -1.0   
M9.3 8 16 0.25 0.25 892 33.9 oprD, intergenic(PA3720|nalC) oprD (Δ1bp), intergenic (PA3720|nalC) (T>C 130bp) 
M9.4 16 32 0.25 0.125 707 47.7 galU del PA2022-PA2024 (Δ1986) 
M9.5 32 32 0.25 0.125 818 39.4   
M9.6 32 32 0.25 0.125 768 43.1   
M9.7 32 32 0.25 0.125 827 38.7   
         
M10.0 0.5 2 0.0625 0.25 1145    
M10.1 2 16 0.125 0.25 1088 4.9   
M10.2 2 16 0.125 0.25 1087 5.0   
M10.3 2 16 0.125 0.25 1081 5.5 oprD, nalD oprD (S223P), nalD (T158P) 
M10.4 16 64 0.25 0.125 659 42.5 462kb del 462kb del (PA1821-PA2221) 
M10.5 16 128 0.25 0.125 700 38.9   
M10.6 16 128 0.125 0.125 663 42.1   
M10.7 32 128 0.125 0.125 670 41.4 wbpL wbpL (ins (C )) 
         
M11.0 0.5 2 0.0625 0.25 1240    
M11.1 2 16 0.125 0.25 1227 1.0   
M11.2 4 16 0.125 0.25 1186 4.3   
M11.3 16 16 0.125 0.25 1128 9.0 
ftsI, intergenic (mexR|mexA), 
copS ftsI (V471G), intergenic (mexR|mexA) (C>T -92bp), copS (E271*) 
M11.4 16 16 0.25 0.25 1060 14.4   
M11.5 64 32 0.25 0.0625 981 20.9 276kb del 276kb del (PA1968-PA2208) 
M11.6 64 32 0.25 0.0625 868 30.0   
M11.7 64 32 0.25 0.0625 900 27.4   
M11.8 64 32 0.25 0.125 1037 16.4   
 





Figure 4.1| Growth dynamics of experimentally evolved meropenem resistant P. aeruginosa. 
Values presented are biological replicates (n = 3 for all except line M10 where n=4) of 
Area Under growth Curve (AUC) values for steps during selection. Growth 
measurements are described in Section 2.2.5. Lines begin with a MX.0 which is the wild-
type starter strain P. aeruginosa PAO1. (A) represnts line M3, (B) represents lime M7, (C) 
represents line M8, (D) represents line M9, (E) represents line M10, and (F) represents 






4.5. Early mutations in experimentally evolved meropenem resistant isolates 
show strong increases in resistance 
In the meropenem resistant mutant lines examined, 4 of 6 lines contained an oprD and a nalC 
or nalD mutation after 3 selection steps with meropenem. The types of mutations in oprD and nalC 
or nalD vary between mutants, for example, line M10 contains non-synonymous changes for both 
genes, whereas line M7 contains a nonsense mutation in oprD and a frameshift mutation in nalC. 
Antibiotic resistance of lines with oprD and nalC mutations is also varied and seemingly clear loss of 
function mutations in both genes results in the highest level of resistance to meropenem and 
imipenem (Table 4.1). In line M7 the oprD (S251*) and nalC (ins(T)) mutations lead to meropenem 
and imipenem resistance of 16 and 32 mg.L-1, however, in line M10, the oprD (S223P) and nalD 
(T158P) resistance to meropenem and imipenem is 2 and 16 mg.L-1 respectively, implying these 
mutation do not completely abolish function. These results are consistent with known roles of nalC 
and nalD, which regulate expression of the MexAB-OprM efflux system (197, 332), and loss of 
function mutations in nalC and nalD increase resistance to carbapenems (65). OprD is a well-
characterised porin which meropenem passes through to get into the cell (188, 333). In the lines 
examined in this study suggest the carbapenem resistance caused by mutations in nalC, nalD, and 
oprD are influenced by the severity of the mutation in those genes, with clear loss of function 
mutations (e.g., frameshifts and nonsense mutations) resulting in a higher increase in resistance than 
single residue non-synonymous changes. In lines with mutations in oprD and nalC or nalD, there is 
no evidence of these mutations causing large reduction in growth of isolates in the absence of 
antibiotics (Figure 4.1A, B, D, E and Table 4.1) 
  




4.6. Large deletions in Pseudomonas aeruginosa arise in different P. aeruginosa 
strains under many different environments 
Large deletions were identified in experimentally evolved meropenem resistant P. aeruginosa 
isolates. All of these deletions overlapped with each other (Figure 3.4). Large deletions in P. 
aeruginosa have previously been identified both in experimental evolution studies and clinical isolates 
(Figure 4.2). A remarkable feature of these deletions is that they can arise in different strains of P. 
aeruginosa (Figure 4.2B, C) and can occur when challenged with different molecules (Figure 4.2B). 
Additionally, large deletions in P. aeruginosa can occur in clinical isolates from CF and non-CF 
infections (Figure 4.2A). It is unknown if all the deletions found in clinical isolates within this study 
(Table 3.2, Figure 3.9) can contribute to antibiotic resistance. However, they all exist within a range 
in the chromosome corresponding from 1.9 – 2.9 Mb in the P. aeruginosa PAO1 genome. There are 
multiple genes within this region which have associations with antibiotic resistance, and with 
maintaining infections in patients (e.g., exoY encodes an adenylate cyclase that acts as virulence factor 
and is often lost during long-term infections, galU encodes a UTP-glucose-1-phosphate 
uridylyltransferase involved in LPS production and mutations in galU have been shown to increase 










Figure 4.2| Large deletions in P.aeruginosa are typically in overlapping regions. (A) Section 
of P. aeruginosa PAO1 genome from base 1.9Mb – 2.9Mb, deletion-containing genomes 
are aligned. Key genes are annotated. Experimentally evolved isolates in blue are from 
Chapter 3 of this thesis (135) and are evolved to be resistant to meropenem. Isolates in 
brown are a small selection of clinical isolates from patients with non-CF bronchiectasis, 
considered evolved naturally (239). Isolates in green are from clinical isolates from 
persons with CF, considered evolved naturally (60), including an isolate from work 
carried out in Chapter 5. Isolates in red are from P. aeruginosa PAO1 isolates selected for 
phage resistance (184). Isolates in yellow are P.aeruginosa PAO1 experimentally evolved to 
be resistant to meropenem (different method from this study) (185). Isolates in purple are 
clinical isolates in persons with CF showing deletions that develop during infection (61). 
(B) Section of P. aeruginosa PA14 genome from base 3.73mb – 2.73mb, genes annotated 
are homologs to those annotated in strain PAO1. P. aeruginosa PA14 genome is ordered 
relative to the PAO1 genome. Isolates in purple are P. aeruginosa PA14 experimentally 
evolved for resistance to ceftazidime (334). Isolates shown in green are P. aeruginosa PA14 
experimentally evolved for resistance to piperacillin (144). (C) Section of P. aeruginosa 
Pcyll-10 genome from base 3.63mb – 2.63mb, genes annotated are homologs to those 
annotated in PAO1 and PA14. P. aeruginosa Pcyll-10 is ordered relative to the PAO1 








4.7. Discovery of large deletions in non-Pseudomonas aeruginosa human 
pathogens 
 Given the large deletions present within a specific region in 15.6% of clinical P. aeruginosa 
isolates studied within this research (Table 3.2), and the identification of large deletions in 
experimentally evolved antibiotic resistant P. aeruginosa (Figure 4.2, Figure 3.4), we searched for large 
deletions in non-P. aeruginosa common human pathogens. 
Complete genomes from NCBI (‘complete’ is a definition of genome assembly level from 
NCBI) for A. baumanii, B. cenocepacia, E. coli, K. pneumoniae, and S. aureus were scanned for large 
deletions (Section 2.3.9). These species were used due to their high level of antibiotic resistance, 
ability to cause chronic infections, and rarely causing severe infections in immunocompetent 
persons. The criteria for deletions was strict to avoid natural genetic variation across strains or strain 
specific differences; deletions were considered if there was a predicted adjacent gene loss of 50 Kb 
or greater in 5% or more of all isolates from any species. Using a threshold for deletions of 50 Kb or 
larger reflected a minimum deletion size of 1.8% of the smallest species median genome size (see 
section 2.3.9). Additionally, the region deleted had to be present in 50% or more of all isolates for 
the species. This ensured deletions were of sufficient size compared to those seen in P. aeruginosa and 
only identified genes deleted that were in the majority of isolates for a species. 
In total 176 A. baumanii, 16 B. cenocepacia, 179 E. coli, 293 K. pneumoniae, and 153 S. aureus 
genomes were analysed for large deletions. There was no evidence of widescale large deletions in any 
of the non-P. aeruginosa species studied. This contrasts with the 558 clinical P. aeruginosa isolates 
studied in which 87 had deletions greater than 50 Kb found in more than 5% of isolates in a region 
present in more than 50% of remaining isolates (all deletions were found within 1.9 – 2.9 Mb, 
relative to P. aeruginosa PAO1 genome coordinates). An example of a subset of clinical isolates 
showing deletions is shown in Figure 4.3. Even when incorporating environmental isolates of P. 
aeruginosa large deletions were present in 12.2% of all isolates (89/730 genomes). This suggests that 
large deletions to the extent observed in P. aeruginosa might be specific to this species.  






Figure 4.3| Large deletions in clinical isolates of P. aeruginosa compared to 3 strains lacking large deletions. Output from 
genAPI (266) of large deletions predicted within a small subset of clinical isolates of P. aeruginosa. Orange boxes represent predicted genes 
(using prokka (274)) absent compared to present genes represented in purple. Predicted genes from prokka are listed along x-axis, and 
different clinical genomes along the y-axis. This only represents genes predicted as absent between isolates, this is not representing an 
entire genome or the boundaries of a deletion in genomic context. The deletion shown in this example maps to PA2229-PA2359 of the P. 








4.8. Experimentally evolved tobramycin resistant isolates show steady increase in 
resistance and decrease in growth during selection 
Following from Section 4.4, an examination of growth dynamics and resistances for each 
selection step for 6 tobramycin resistant experimentally evolved P. aeruginosa lines (T6, T7, T8, T10, 
T11, and T13) was carried out (Table 4.2, Figure 4.4). Additionally, earlier steps in the evolution of 
these lines were whole genome sequenced to understand which mutations arise earlier during 
selection (Table 4.2, highlighted rows). 
In contrast to the full line analysis of meropenem resistant isolates (Table 4.1), tobramycin 
resistant isolates showed a more consistent increase in resistance (as measured by MIC) as selection 
continued. In the 6 tobramycin resistant lines tested, the end point sample for each line was the 
most tobramycin resistant isolate (Table 4.2). In all lines tested there were selection steps where the 
MIC did not increase. Much like the meropenem resistant lines, growth in the absence of antibiotics 
showed reductions as resistance increased (Figure 4.4). However, unlike meropenem resistant lines, 
the reductions in tobramycin resistant isolates’ growth was a steadier decrease, with less large jumps 
in growth reduction.  
The resistance to other antibiotics was tested for the full line tobramycin resistant isolates. 
Four aminoglycosides (tobramycin, gentamicin, kanamycin, and streptomycin), an aminoglycoside-
like aminocyclitol antibiotic (spectinomycin), a carbapenem (meropenem), and a fluoroquinolone 
(ciprofloxacin) were tested. Kanamycin, streptomycin, and spectinomycin are not clinically relevant 
for P. aeruginosa infections, however, the resistances to these molecules were tested to understand 
how mutations conferring resistance to tobramycin can apply to other aminoglycosides, and 
aminoglycoside-like aminocyclitols. Resistance to the three remaining aminoglycosides tested 
increased as selection progressed, and tobramycin resistance increased (Table 4.2). However, 
sensitivity to spectinomycin increased during selection in 4 of the 6 lines tested (up to an 8-fold 
increase in sensitivity to spectinomycin), although spectinomycin resistance was measured at wild-
type levels or higher by the end of selection in 3 of 6 lines. This suggests some the resistance 
mechanisms for aminoglycoside resistance can cause spectinomycin sensitivity, although this can be 
overcome by other mutations by the end of some lines. Slight increases in resistance to meropenem 
and ciprofloxacin were identified in all 6 lines tested, the largest increase being in end of line T7 
which had a 4-fold increase in meropenem and ciprofloxacin resistance. 




Linking mutations in specific genes to decreases in the bacteria’s ability to grow in the absence 
of antibiotics is less straight-forward in tobramycin resistant mutants than the meropenem resistant 
mutants in Section 4.4. For example, in line T6, growth remains largely consistent with wild-type up 
to a tobramycin resistance of 8 mg.L-1. In line T6.3 a fusA1 (encoding elongation factor G) and 
PA1549 mutation are present, these mutations show no effect on the bacteria’s growth in the 
absence of antibiotics. However, by end of line another fusA1 mutation arises and the growth 
decreases markedly (48% reduction compared to wild-type), suggesting this specific fusA1 mutation 
may effect growth of the bacteria (Figure 4.4B). Comparing lines T6 and T11, both contain a fusA1 
R680C mutation by selection step 3, T6.3 has growth comparable to the wild-type starting P. 
aeruginosa PAO1, whereas line T11.3 has a frameshift mutation in cytochrome C1 (a critical 
component in the electron transport chain), this leads to a 38% reduction in growth compared to 
the wild-type starting strain (Figure 4.4A, E), suggesting this cytochrome C1 mutation reduces 
growth of the bacteria.  
Line T11 shows the largest decrease in growth in the absence of antibiotics of any mutant line 
developed (Figure 3.3, Figure 4.4E, an 84% reduction in growth relative to the starting wild-type 
strain), suggesting the mutations within line T11 conferring tobramycin and gentamicin resistance 
have a high cost. This is in contrast to line T10 which has a higher tobramycin resistance that line 
T11 (128 mg.L-1) and only a 62% reduction in growth relative to the starting strain. This suggests 
that evolutionary trajectories might be important in the development of specific resistance associated 
mutations for tobramycin resistance, especially considering when resistance mechanisms are 
involved in critical cellular functions such as the ribosome (rplF mutation in line T11) and the 







Table 4.2| Experimentally evolved tobramycin resistant mutants resistances, growth change, and mutations 
 MIC mg.L
-1       
Line TobR GentR KanR StrR SpeR MerR CipR AUC 
% growth change 
relative to WT Mutation Specific mutation15 
T6.0 0.25 1 128 16 1024 0.5 0.0625 1181 0.0   
T6.1 1 1 256 32 1024 0.5 0.0625 1084 8.2   
T6.2 4 8 1024 64 512 0.5 0.0625 1127 4.6   
T6.3 4 8 1024 64 512 1 0.25 1165 1.4 fusA1, PA1549 fusA1 (R680C), PA1549 (ins 9bp) 
T6.4 4 8 1024 64 512 1 0.25 1181 0.0   
T6.5 8 16 2048 64 512 1 0.25 1097 7.1   
T6.6 16 16 2048 128 512 1 0.25 810 31.4   
T6.7 32 32 2048 512 1024 1 0.25 613 48.1 fusA1 fusA1 (L438Q) 
            
T7.0 0.25 1 64 16 1024 0.5 0.0625 1197 0.0   
T7.1 1 2 128 32 256 0.5 0.0625 1034 13.6   
T7.2 4 8 512 64 128 0.5 0.0625 878 26.6   
T7.3 4 8 512 64 128 1 0.125 893 25.4 fusA1, amgS fusA1 (T671A), amgS (V121G) 
T7.4 8 16 512 64 128 1 0.125 869 27.4   
T7.5 8 16 1024 64 128 1 0.125 771 35.6   
T7.6 16 16 1024 64 128 2 0.25 782 34.7   
T7.7 32 32 1024 128 256 2 0.25 434 63.7 wbpM wbpM (ins 1bp) 
            
T8.0 0.25 1 64 16 1024 0.5 0.0625 1208 0.0   
T8.1 0.5 2 128 32 256 0.5 0.0625 1085 10.2   
T8.2 2 8 512 32 256 1 0.0625 980 18.9   
T8.3 2 8 1024 32 128 1 0.0625 935 22.6 fusA1, amgS fusA1 (G584A), amgS (T109P) 
T8.4 4 8 1024 64 128 1 0.0625 910 24.7   
T8.5 4 8 1024 64 128 1 0.0625 838 30.6   
T8.6 4 8 1024 64 128 1 0.0625 812 32.8   
T8.7 8 16 2048 128 128 1 0.0625 458 62.1   
T8.8 64 128 4096 1024 1024 1 0.0625 429 64.5 
fusA1, wbpL, ccoO1-
ccoO2, amgS, mexY, 
PA5528 
fusA1 (Q678L), wbpL (Δ1bp), ccoO1-ccoO2 
(Δ3455bp), amgS (P381S), mexY (G287S), PA5528 
(Δ4bp) 
            
 
15 Samples highlighted indicate mutants which were whole genome sequenced. Each set of mutations indicated at the relevant steps are those found in addition to 
those present at earlier mutation steps in the same line. For example, mutant T6.3 contains mutations in fusA1 and PA1549, whereas mutant T6.7 contains mutations 
in PA1549 and two fusA1 mutations. TobR = Tobramycin, GentR = Gentamicin, KanR = Kanamycin, StrR = Streptomycin, SpeR = Spectinomycin, MerR = 
meropenem, and CipR = Ciprofloxacin.   




T10.0 0.25 0.5 128 32 1024 0.5 0.0625 1126 0.0   
T10.1 0.5 2 128 64 256 0.5 0.0625 1058 6.0   
T10.2 2 4 512 64 256 1 0.125 729 35.3   
T10.3 2 8 1024 64 128 1 0.125 763 32.2 fusA1, amgS fusA1 (Q678L), amgS (P381S) 
T10.4 4 8 1024 64 128 1 0.125 727 35.4   
T10.5 4 16 1024 128 128 1 0.25 546 51.5   
T10.6 8 16 2048 128 512 1 0.25 479 57.5   
T10.7 16 32 2048 256 512 1 0.25 513 54.4   
T10.8 64 64 4096 2048 2048 1 0.25 378 66.4   




wbpL (Δ1bp), ccoO1-ccoO2 (Δ3461bp), mexY (G287S), 
phaF (T186N), PA5527-PA5530 (Δ5249bp) 
            
T11.0 0.25 1 128 16 1024 0.5 0.0625 1190 0.0   
T11.1 1 4 256 32 1024 0.5 0.0625 1126 5.4   
T11.2 4 8 1024 128 256 0.5 0.125 679 42.9   
T11.3 4 8 1024 128 128 0.5 0.125 734 38.3 
fusA1, PA4429 
(cytochrome C1) fusA1 (R680C), PA4429 (cytochrome C1 Δ11bp) 
T11.4 16 32 2048 256 128 1 0.125 587 50.7   
T11.5 16 32 2048 512 128 1 0.125 543 54.4   
T11.6 32 64 >4096 512 128 1 0.25 506 57.5   
T11.7 64 64 >4096 1024 128 1 0.25 450 62.2   
T11.8 64 64 >4096 1024 128 1 0.25 187 84.3   
T11.9 64 64 >4096 1024 128 1 0.25 190 84.0 wbpL, mexY, rplF wbpL (Δ1bp), mexY (K79T), rplF (G93A) 
            
T13.0 0.25 0.5 128 32 1024 0.5 0.0625 1223 0.0   
T13.1 0.5 1 128 64 1024 0.5 0.125 1131 7.5   
T13.2 1 4 512 64 512 0.5 0.125 1135 7.2   
T13.3 1 4 512 64 512 1 0.125 1123 8.2 fusA1, ccoN1, ssg fusA1 (Q455R), ccoN1 (Δ1bp), ssg (Q69*) 
T13.4 4 4 1024 64 1024 1 0.125 845 30.9   
T13.5 4 16 1024 128 1024 1 0.125 863 29.4   
T13.6 4 32 1024 128 1024 1 0.125 739 39.6   
T13.7 16 64 2048 256 1024 1 0.125 670 45.2   
T13.8 32 128 2048 256 256 1 0.125 404 67.0 
PA1767, rpmI, rpsD, 
intergenic (pgsA|uvrC) 
PA1767 (Δ6bp), rpmI (ins(T)), rpsD (G87A), 








Figure 4.4| Growth of experimentally evolved tobramycin resistant P. aeruginosa. Values 
presented are biological replicates (n = 3 for all except line T10 and T13 where n=5) of 
Area Under growth Curve (AUC) values for steps during selection. Growth 
measurements are described in Section 2.2.5. Lines begin with a TX.0 which is the wild-
type starter strain P. aeruginosa PAO1. (A) represents line T6, (B) represents line T7, (C) 
represents line T8, (D) represents line T10, (E) represents line T11, and (F) represents 
T13. Error bars represent ± SEM. 
  




4.9. Association between mutations in experimentally evolved tobramycin 
resistant isolates and increases in resistance 
In all the tobramycin resistant mutant lines examined, fusA1 mutations were present, and 
consistently found during the early stages of selection. Mutations in fusA1 were present in all 13 
evolved tobramycin resistant isolates (Table 3.1). In the 6 full lines analysed, there were 6 different 
mutant fusA1 alleles. Three of the 6 full lines contained a combination of fusA1 and amgS mutations 
by selection step 3, all containing different mutant alleles for fusA1 and amgS (Table 4.2, lines T7, T8, 
and T10). In the lines studied, the combination of fusA1 and amgS mutations confers an 8 to 16-fold 
increase in tobramycin resistance, an 8-fold increase in gentamicin resistance, an 8 to 16-fold 
increase in kanamycin resistance, and a 2 to 4-fold increase in streptomycin resistance (Table 4.2). 
Both fusA1 and amgS mutations in P. aeruginosa have been shown to confer aminoglycoside resistance 
(105, 301). Remarkably, a combination of fusA1 and amgS mutations results in 8-fold increase in 
sensitivity to spectinomycin. This suggests that in the isolates tested there is discrete resistance 
mechanisms between aminoglycosides and the aminoglycoside-like aminocyclitol spectinomycin. 
Four of the 6 tobramycin resistant lines tested had mutations that impair the electron 
transport chain. Lines T8 and T10 have in-frame deletions of a cytochrome C oxidase operon 
(Figure 4.5). These deletions are homologous recombination between two adjacent cco operons (cco1 
and cco2), the deletion creates a functional hybrid operon between cco1 and cco2 under the control of 
the promotor for cco2. Lines T8 and T10 were two of the most resistant tobramycin resistant lines 
tested (MIC of 64 and 128 mg.L-1 respectively). Line T13 has a frameshift mutation in ccoN1 which 
would likely result in an impaired cco1 operon, and line T11 has a frameshift mutation in PA4429 
which is annotated as a cytochrome C1. These four lines containing mutations in the electron 
transport chain are likely to impair its function and could result in changes in proton-motive forces 
between the periplasm and cytoplasm, changes in membrane potential have established links to 







Figure 4.5| Mutations in the cytochrome C operon in tobramycin resistant experimentally 
evolved P. aeruginosa isolates. In lines T8 and T10 a deletion in the cytochrome C 
oxidase operons is present. (A) represents a wild-type cco1-cco2 operon under the control 
of 2 different promotor regions (P1 and P2). (B) represents the tobramycin resistant 
mutant lines T8 and T10 which have an in-frame deletion between the cco1 and cco2 
operons. This results in a single operon under the control of the cco2 promotor region 
(P2). Genomic coordinates are relative to P. aeruginosa PAO1. In all tobramycin resistant 
experimentally evolved isolates 6 of 13 mutant lines contained similar cco1-cco2 fusions 
(although different sizes and gene hybrids (Table 3.1). 
 
 
4.10.  Discussion 
This study has furthered the understanding of the process by which P. aeruginosa becomes 
resistant to tobramycin and meropenem. Contrasting previous experimental evolution studies, we 
examined the intermediate steps of evolution to understand the genes that mutate early to confer 
resistance. Although the genes identified to mutate early in this study (fusA1, amgS, PA1549, oprD, 
nalC) are known resistance associated genes, this research shows they are important early predictors 
of resistance in P. aeruginosa. Additionally, identifying the impact on growth and resistance of large 
deletions in experimentally evolved meropenem resistant P. aeruginosa has given insight into the 
conditions which can select for large deletions to occur, and show these deletions are likely unique 
to P. aeruginosa. 
 




4.10.1. Experimental evolution of meropenem resistance in Pseudomonas 
aeruginosa results in large decreases in growth in the absence of antibiotics 
By studying the intermediate steps during evolution of meropenem resistance in P. aeruginosa 
we have been able to gain insights into how mutations that confer resistance to meropenem result in 
large changes in the bacteria’s ability to grow in the absence of antibiotics. There were large 
decreases in growth in 5 of the 6 full lines studied. Line M11 is an outlier in the effect a large 
deletion had on its ability to grow, the remaining isolates with deletions all showed a large drop in 
growth co-occurring with the deletion. In clinical isolates of P. aeruginosa genome large differences in 
gene numbers, loss of genes, and genome reduction to continue infections is well established (61, 63, 
227, 338). Other large decreases in growth were associated with mutations in aroB, cysS, and glyQ. 
None of these genes have a well-established link to antibiotic resistance. Mutations in aroB have 
previously been found in carbapenem resistant P. aeruginosa although resistance is likely due to 
epistatic interactions with other resistance associated genes (210, 298). Remarkably, in the 
experimentally evolved meropenem resistant isolates evolved in Chapter 3, 5 of 13 lines contained 
mutations in a tRNA ligase (M1 thrS, M3 cysS, M4 metG, M5 argS, M8 glyQ), to the best of our 
knowledge no one else has found mutations in tRNA-ligases to the extent we observe associated 
with resistance. A role in resistance cannot be determined, however, it is possible mutations in 
tRNA-ligases causing reduction in growth is the mechanism of resistance. Changes in growth rate 
and replication frequency can be associated with reduced effects of β-lactam based antibiotics (339). 
Especially given that this experimental evolution study only selects for resistant mutants, not the 
fastest growing mutants (Section 2.2.9).   
  
4.10.2. Large deletions in Pseudomonas aeruginosa occur commonly in 
experimental evolution studies evolving resistance to β-lactam based 
molecules 
As shown in Figure 4.2 and Figure 3.9 large deletions in P. aeruginosa isolates occur quite 
frequently in experimental evolution to different β-lactam based antibiotic resistance and in clinical 
isolates naturally evolved within patients (60, 61, 144, 184, 185, 239, 334, 335). What remains to be 
understood is the precise mechanism of resistance for these large deletions. It is likely that there are 
multiple genes within the deleted regions that confer resistance. One such genes that has previously 





unlikely galU is the only gene contributing to resistance in these deletions. Deletions were also 
identified in P. aeruginosa selected for phage resistance (184, 335). It is unknown the relationship 
between phage evasion and antibiotic resistance. It is worth noting that these large deletions that 
occur happen via non-homologous end joining, and not via homologous recombination as perhaps 
would be expected, and deletions are managed by a DNA mismatch repair protein, MutL (184). In 
meropenem resistant experimentally evolved mutants in this study there was as few as 3bp up to 8bp 
overlapping at the 3ʹ and 5ʹ of the large deletions.  
 
4.10.3. Large deletions are only found in Pseudomonas aeruginosa 
To understand if large deletions like those found in experimentally evolved and clinical isolates 
of P. aeruginosa occur in other non-P. aeruginosa human pathogens, we examined complete genomes 
from 5 different species and P. aeruginosa. Deletions to the extent seen in P. aeruginosa are not present 
in the species studied, strongly suggesting these deletions may be a P. aeruginosa specific resistance 
mechanism, or that large deletions in other species is lethal, especially for smaller more compact 
genomes. Identifying large deletions only looked at gene presence-absence in predicted protein 
encoding genes. The criteria to find deletions was set intentionally quite conservative, this was to 
reduce the effects of natural genetic diversity and accessory genes present in a small number of 
isolates. A more comprehensive analysis of deletions in non-P. aeruginosa species would include two 
additional steps. Firstly, analyse genomes for large deletions using different thresholds and less-
stringent requirements. It is possible deletions to the extent seen in P. aeruginosa are present in some 
of these isolates, but they are rare events. Secondly, any further analysis would incorporate known 
clinical isolates and draft genome assemblies of the species analysed, this was not done in this case, 
only complete genomes were used due to fragmented draft genome assemblies giving errors in 
predictions of protein coding genes and determining gene presence or absence (61, 266).  
It must be emphasised that although large deletions the size and frequency seen in P. aeruginosa 
in this study were not observed in other species, deletions can occur in these species to adapt to 
their environment. For example, gene reduction and smaller deletions have been found in B. 
cenocepacia infection in CF lungs (340) but affect genomic islands and nonessential replicons. 
Additionally, large chromosomal rearrangements and gene deletions have been observed in E. coli 
adapting to glucose limited media (341). Large genomic changes are not unique to P. aeruginosa, but 




large deletions to the extent observed in clinical and experimentally evolved P. aeruginosa are, 
amongst the strains analysed. Possible reasons for only identifying large deletions in P. aeruginosa 
could be, the larger genome size of P. aeruginosa compared to the other organisms studied, P. 
aeruginosa has the highest GC content of the bacteria studied, and has the fewest number of plasmids 
and horizontally acquired antibiotic resistance associated genes (342). P. aeruginosa large genome size 
allows for more adaptation and redundancy (63) within the genome that could accommodate such 
large deletions, unlike the smaller more compact genomes of the other species tested. Although P. 
aeruginosa does not have the highest mutation rate amongst the species tested (343), a higher GC 
content genome might lead to more deletions due to its highly repetitive nature. P. aeruginosa having 
the fewest plasmids and horizontally acquired antibiotic resistance associated genes (342), suggests 
that P. aeruginosa has a higher reliance on chromosomally encoded resistance mechanism, one of 
these could be large deletions. Suggesting a larger genome size, higher GC content, and a higher 
reliance on chromosomally encoded resistance mechanisms might be key reasons why such large 
deletions are found so commonly in P. aeruginosa isolates. 
It is worth noting that in many deletions in P. aeruginosa included loss of the hmgA gene which 
encodes a protein homogentisate-1,2-dioxygenase that when lost leads to hyperproduction of 
pyomelanin, a brown, dark-red pigment (344). Hyperproduction of pyomelanin has been found in 
up to 13% of clinical isolates of P. aeruginosa (345-347). Researchers have used pyomelanin 
hyperproduction in experimental evolution as a biomarker of deletions, we find large deletions in 
15% of clinical P. aeruginosa, this is remarkably close to the 13% of clinical isolates previously 
identified to have pyomelanin hyperproduction. However, in experimentally evolved isolates in this 
study one contained a large deletion that did not contain hmgA but still overlapped with the other 
deletions, suggesting that pyomelanin hyperproduction is not present in all large deletions, and not a 
cause of resistance.  
 
4.10.4. Experimentally evolved tobramycin resistant Pseudomonas aeruginosa 
shows steady decrease in growth in the absence of antibiotics as resistance 
increases 
By studying intermediate steps during evolution of tobramycin resistance we have given new 





mutations that arise early in tobramycin resistance typically do not cause large reduction in the 
bacteria’s ability to grow in the absence of antibiotics (Figure 4.4, Table 4.2), instead later occurring 
mutations seem to lead to a consistent decreases in growth.  
All tobramycin resistant experimentally evolved isolates had mutations in fusA1 encoding 
elongation factor G, mutations in EF-G have been shown to confer resistance to aminoglycosides 
(105, 133-136) via MexXY-OprM overexpression (145). Three of the 6 isolates analysed also had 
amgS mutations, amgS mutations are associated with activation of the AmgRS two-component 
system leading to increased expression of MexXY-OprM and MexAB-OprM efflux systems through 
signalling in intermediate genes PA5528 (mutated in lines T8 and T10) and htpX (130-132). This 
suggests that fusA1 mutations alone are unable to increase MexXY-OprM expression sufficiently to 
confer high enough resistance. It is well established that overexpression of the MexXY-OprM efflux 
system provides aminoglycoside resistance (65), however, there is no conclusive evidence that 
MexAB-OprM does the same. This suggests either an expression dependent resistance associated 
with mexXY overexpression or suggests that mutations in fusA1 can confer resistance via additional 
resistance mechanisms (145).  
It is worth noting that spectinomycin resistance decreases, fusA1 only increasing MexXY-
OprM production is inconsistent with what is known about the MexXY-OprM and spectinomycin, 
as spectinomycin susceptibility increases when mexXY is impaired (348). It is possible that mutations 
in EF-G may be interacting with the aminoglycosides bound within the 16S rRNA in the ribosome 
P-site, a place that EF-G is known to come into close contact with (although not directly bind 
aminoglycosides (349)) (146, 350). It is possible interactions within the ribosome between EF-G and 
spectinomycin may result in the enhanced sensitivity observed with fusA1 mutations. Another 
explanation of the increased spectinomycin sensitivity could be due to changes in the electron 
transport chain, deficiencies in the electron transport chain are known to change proton motive 
forces and increase resistance to aminoglycosides (71, 73), but the opposite effect has been observed 
to spectinomycin (351). Mutations in electron transport chain proteins were in 4 of 6 full lines 
analysed and 8 of 13 experimentally evolved tobramycin resistant lines (Table 4.2, Table 3.1). 
 




4.10.5. Summary  
By studying the intermediate steps during experimental evolution, we have been able to 
further understand the genetic basis of meropenem and tobramycin resistance in P. aeruginosa. In 
meropenem resistance, mutations in the porin oprD is an early sign of resistance, additionally large 
deletions and reductions in growth rate might contribute to higher level carbapenem resistance as a 
final effort to enhance resistance. In tobramycin resistant isolates fusA1 mutations are a hallmark of 
aminoglycoside resistance, however they also confer increased sensitivity to spectinomycin. It is 
possible screening for mutations in oprD and fusA1 in clinical isolates of P. aeruginosa can provide 
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5.1. Chapter 5 preface 
The work presented within this chapter has been taken from a prepared manuscript. As with 
all scientific pursuits this research was a team effort. I would be misrepresenting the study if I were 
to exclude the work that I did not directly complete myself. As such, I have kept all data in to 
maintain consistency to the findings presented within the prepared manuscript. Except for the 
original isolation of the strains used in this study and the information on clinical results (e.g., FEV1 
% predicted), all analyses and figure generation were performed by me. Additionally, as with typical 
manuscripts the project conception, text, and overall flow and direction of everything was heavily 






5.2. Abstract and Importance 
The opportunistic pathogen P. aeruginosa is a common cause of chronic infections in the lungs 
of patients with cystic fibrosis (CF). Here we examine genomic, regulatory, and phenotypic changes 
in 15 isolates of a P. aeruginosa lineage obtained from a CF patient over more than 20 years of 
chronic infection. Whole genome sequencing showed that the bacteria went through a genetic 
bottleneck during infection. Hundreds of mutations occurred during the evolution of the bacteria in 
the lung, many in genes associated with infection or antibiotic resistance, with an average rate of 19 
mutations per year. Comparison of the transcriptomes of an earlier and a later isolate identified 
differences in gene expression that likely contribute to continuing infection, including lowered 
expression of flagellar machinery and up regulation of genes for antibiotic resistance, as well as 
altered expression of a large number of genes of unknown function. Phenotypic studies showed that 
relative to earlier isolates, later isolates had enhanced cell adherence, antibiotic resistance, reduced 
motility, and reduced production of pyoverdine siderophore, consistent with genomic and 
transcriptomic data. The integration of genomic, transcriptomic, and phenotypic analyses reveals the 
plethora of changes that allow P. aeruginosa to adapt to the environment of the CF lung during a 
chronic infection.  
 
5.3. Author summary 
P. aeruginosa is a bacterium that can cause serious infections in already ill people, such as those 
with the genetic disease CF. In patients with CF P. aeruginosa infects the airways, impairing lung 
function, reducing quality of life and shortening life expectancy. Infections can last for years or even 
decades, and the bacteria adapt and evolve to maximise their survival and growth in the lungs, 
although how this happens is not fully understood. We have looked at samples of P. aeruginosa 
isolated from the infection of a CF patient over more than twenty years. We used a range of 
different approaches to examine the differences in P. aeruginosa genes and their regulation over the 
twenty years, and to look at changes in different physical and biochemical characteristics of the 
bacteria. We observed changes in gene expression, antibiotic resistance, metabolism, movement, and 
adherence. This research makes a significant contribution to our understanding of P. aeruginosa 
adaptation during infection and may help develop new treatment strategies. 




P. aeruginosa is a Gram-negative bacterium present in a range of environments. It is also an 
opportunistic human pathogen, commonly infecting immune-compromised patients (16, 287, 352). 
P. aeruginosa is a major cause of increased morbidity in individuals with cystic fibrosis (CF), where it 
colonises the lungs (287). Patients are typically infected by P. aeruginosa from the environment, which 
can act as a reservoir for infection (35). Infections in CF patients commonly become chronic, with 
the infecting bacteria adapting to survive antibiotic treatment and the environment of the host lung 
(41). 
In P. aeruginosa, antibiotic resistance is multifactorial with a range of genetic events responsible 
for the development of resistance (64, 353). Mutations altering target proteins reduce the binding 
affinities of antibiotics. For example, mutations in gyrA or gyrB that encode subunits of DNA gyrase 
lead to fluoroquinolone resistance (295), and mutations in ftsI that encodes penicillin-binding protein 
3 contribute to meropenem resistance (65, 135). Decreased uptake of antibiotics can occur due to 
changes in membrane permeability. For example, mutations in oprD that encodes a porin contribute 
to carbapenem resistance (354) and changes to lipopolysaccharide (LPS) increase tolerance to 
polymyxins and aminoglycosides (71, 355). Increased antibiotic efflux can arise due to increased 
expression of efflux systems, arising from mutations affecting regulatory proteins such as MexZ 
(64), and increased production of AmpC -lactamase can result from mutations in genes such as mpl 
(64, 356).  Although antibiotic resistance in P. aeruginosa in CF predominantly occurs through 
mutations in chromosomally encoded genes, horizontal gene transfer can also introduce genes that 
confer a resistant phenotype (91, 357). 
As well as resisting antibiotic treatment, during chronic infection in CF patients P. aeruginosa 
adapts to other challenges of the lung environment, including oxidative stress, the immune system, 
host withholding of micronutrients such as iron and zinc, and competition from other microbiota  
(224, 225). The bacteria can undergo multiple phenotypic changes including loss of motility, 
increased production of the extracellular polysaccharide alginate, reduced virulence factor and 
siderophore production, emergence of auxotrophs, and occurrence of small colony variants and 
hypermutator strains (41, 226-232) (Figure 1.3). The advent of high throughput DNA sequencing 
technologies has allowed analysis of the genetic changes that underlie phenotypic changes during P. 





antibiotic resistance and immune evasion over the course of eight years of infection (233). 
Subsequent studies have also followed the progression of genomic changes undergone by P. 
aeruginosa during chronic infection in CF (106, 226, 228, 229, 235-238) and non-CF patients (239) 
and have identified many other genes that undergo mutation during the course of infection. 
Although some studies have also investigated associated phenotypic changes (229, 358) 
understanding of the relationship between genome-wide genetic changes, consequent changes to the 
transcriptome, and the resulting phenotypic changes that facilitate adaptation to the lung 
environment is limited. The aim of this study was to investigate in detail the evolution of P. aeruginosa 
during infection over the course of 20 years in the lungs of a patient with CF, comparing multiple 
isolates and merging phenotypic, transcriptional, and genotypic changes to understand how P. 
aeruginosa evolved during the course of the infection. 
 
5.5. Whole genome comparisons between isolates obtained suggest shared 
ancestry between early and late infecting isolates 
Four earlier (1991 - sample prefix E), and 11 later (2012-2013 - sample prefix L) isolates of P. 
aeruginosa were obtained from an individual with CF (Table 5.1, Table 5.4). The patient was treated 
with a wide range of antibiotics (Tables 5.4, 5.5) and the later isolates had on average higher 
antibiotic resistance than the earlier isolates (Table 5.1). The genome sequences of the isolates were 
determined, and a summary of draft genome assemblies and gene predictions is shown in Table 5.6. 
A phylogeny was constructed based on the core genome shared between isolates (Figure 5.1A; 
Figure 5.3). This showed that one isolate, E-S2239-15, is a genetic outlier and the remaining isolates 
are clonal. The three other earlier isolates are closely related, with a median of 33 non-synonymous 
differences and 97 synonymous or intergenic differences (Table 5.7 and Table S1). The later isolates 
are genetically very similar to three of the earlier isolates (Figure 5.1B; Figure 5.3; Table S1) although 
they had higher genetic diversity (median of 123 non-synonymous differences) than the three clonal 
earlier isolates. There was no evidence of later isolates descended from E-S2239-15, nor was there 
any evidence of isolates that had been independently acquired after the earlier infecting strains. 
These findings indicate the presence of a single infecting lineage through the course of the infection. 
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Table 5.1|Minimum Inhibitory Concentration of clinical isolates examined within this 
study.  
  Minimum Inhibitory Concentration (mg.L-1)16 
Isolate Collection date 
(MM/YY) 
Ciprofloxacin Meropenem Tobramycin Ceftazidime 
E-S2239-16 12/91 0.5 0.25 0.25 1 
E-MSB2949 12/91 1 0.25 0.25 1 
E-MSB3405 12/91 1 0.125 0.25 0.5 
E-S2239-15 12/91 1 1 2 1 
L-001-1A 08/12 2 16 8 4 
L-001-1B 08/12 4 16 2 16 
L-001-1C 08/12 2 8 8 4 
L-001-2A 10/12 2 8 8 8 
L-001-2B 10/12 2 8 8 4 
L-001-3A 11/12 2 8 4 4 
L-001-3B 11/12 2 8 2 4 
L-001-4 01/13 2 8 2 4 
L-001-5A 04/13 1 16 4 4 
L-001-5B 04/13 2 8 2 16 
L-001-6 05/13 2 16 2 8 
 
Acquisition and loss of DNA in the later isolates was analysed. All later isolates have lost a 
127 kb region of the genome (Figure 5.1B). This region includes 130 predicted genes, corresponding 
to PA2229-PA2359 in P. aeruginosa PAO1. All later isolates have a sequence of approximately 44 kb 
that shares 98% identity to Pseudomonas phage LKA5 and was evidently acquired during the infection. 
There was no evidence of acquisition of genes associated with antibiotic resistance or genes 
predicted to play roles in bacterial pathogenicity. 
 
16 Antibiotic resistance is shown in bold. Resistance breakpoints (eucast.org) are ciprofloxacin, >0.5; meropenem >8; 






Figure 5.1| Whole genome analysis of earlier and later isolates. (A) Phylogenetic 
relationship between isolates, with branch lengths representing the number of 
nucleotide differences (scale bar, 5.0x10-5 nucleotide differences per site). Strain E-
S2239-15 branch is not to scale as it is distinct from all other isolates (Figure 5.3). 
(B) Genome comparison of earlier (orange) and later (blue) isolates. Genomes were 
aligned using BRIG with the innermost ring being reference strain E-S2239-16. 
Grey hatching indicates absence of DNA that is present in the reference strain. 
Regions in darker shades are 100% identical, with a lighter shade being 99% 
identical. 
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5.6. Analysis of differences between isolates reveals gene changes which 
enhance P. aeruginosa ability to maintain infection 
Identification of all genetic differences between the 15 clonal isolates was performed using an 
earlier isolate as a reference. There were 1076 different variants identified across all 15 isolates with 
an average of 360 variants per isolate (Table S1). Of these, 626 were non-synonymous differences 
that affected a total of 519 genes. The remaining variants were either synonymous or changes in 
intergenic regions of the genome. 479 variants were only present in later isolates and are very likely 
to be mutations that have arisen during infection. 
The later isolates had an average of 412 mutations (of which an average of 220 were non-
synonymous) relative to an earlier isolate. This corresponds to a rate of approximately 20 mutations 
a year, although this value may be an underestimate due to the likely population bottleneck between 
the earlier and later isolates. 
Later isolates in our study contain a different variant than ancestral isolates (M185K) in the 
mutY gene. The MutY protein reduces the frequency of GC > TA transversions that can arise 
following oxidation of guanine bases in DNA, and mutY mutants of P. aeruginosa have up to a 7.5-
fold higher mutation rate than wild-type (359). A high proportion of the single nucleotide mutations 
(65.5%) were GC > TA transversions (Table S1; Table 5.8) so that it is likely that the MutY M185K 
variant has reduced, or no function.  
A large number of genes can undergo mutation to increase antibiotic tolerance as P. aeruginosa 
evolves during infection in CF (106, 226, 229, 360). Comparison of earlier and later isolates showed 
that many of these genes underwent mutation during infection (Table 5.2; Table S1). For example, 
resistance to meropenem is associated with mutations in the porin-encoding gene oprD (188) and all 
later isolates had a nonsense mutation in this gene. Most of the later isolates also had at least one 
mutation in the ftsI gene that encodes a meropenem target protein PBP3 (203, 361) and mutations in 
this gene also contribute to meropenem resistance (65). Similarly, mutations in mpl contribute to 
ceftazidime resistance and all later isolates have a mutation in this gene. All later isolates also have a 
mutation in fusA1 that encodes elongation factor G, and 9 later isolates have a mutation in fusA2. 
Mutations in fusA1 confer resistance to aminoglycosides (105, 106) and fusA2 mutations have also 
been suggested to be involved in aminoglycoside resistance (208). All later isolates contained a DNA 





(295). Curiously, none of the later isolates had mutations in gyrA associated with fluoroquinolone 
resistance, whereas two of the earlier isolates contained a gyrA variant (T83A) that increases 
tolerance to fluoroquinolones (65, 362, 363). Overall, the mutations that were present in the later 
isolates were consistent with higher resistance of the bacteria to antibiotics. 
Mutations in the later isolates (Table S1; Table 5.2) revealed other genes with a role in 
adaptation of P. aeruginosa to the lung environment. Isolates of P. aeruginosa from chronic infections 
can lack O-antigen polysaccharide (303) and all later isolates have a frameshift mutation in wbpL, 
likely preventing O-antigen synthesis. All later isolates had mutations in the global regulators lasR 
and mvaT that influence a range of phenotypes, including biofilm formation and production of 
virulence factors. The later isolates also had mutations in the muc and alg genes that are associated 
with alginate production, in fleQ and fliA associated with flagella production, and in genes associated 
with iron acquisition such as pvdD and other pvd genes that are involved in the production of a 
siderophore, pyoverdine.  
Although many mutations were in genes with known functions, over half of the mutations 
were in genes of unknown function, or for which a possible function has been assigned on the basis 
of sequence similarity but not experimentally investigated. It is likely that mutations in some of these 
uncharacterised genes contribute to the phenotypes described above, and others may contribute to 
different phenotypic changes associated with adaptation to the lung environment or to different 
microniches within the lung.  
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ftsI penicillin-binding protein 3 
  






G63C G63C G63C  G63C 
fusA1 elongation factor G  
  
G611V G611V G611V G611V G611V G611V G611V G611V G611V G611V G611V 
fusA2 elongation factor G   G252V  G252V G252V G252V G252V G252V G252V G252V  G252V 
gyrA DNA gyrase subunit A A83T  A83T A83T A83T A83T A83T A83T A83T A83T A83T A83T A83T 
gyrB DNA gyrase subunit B   E468D E468D 
G89V 
E468D E468D E468D E468D E468D E468D E468D E468D 
G89V 
E468D 
mexB RND multidrug efflux transporter MexB   *643L *643L *643L *643L *643L *643L *643L *643L *643L *643L *643L 




E126* A20D E126* E126* E126* E126* E126* E126* E126* A20D E126* 
oprD outer membrane porin OprD 
  









E140* E140* E140* E182* E140* 
               
Physiology 
























algU sigma factor AlgU Q48* Δ1bp  Q30K    A193S    Q30K  
ccoN1 Cytochrome C oxidase cbb3-type CcoN 
subunit 
  S78* S78* S78* S78* S78* S78* D48G S78* S78* S78* D48G 
fleQ transcriptional regulator FleQ   G382W G382W G382W G382W G382W G382W G382W G382W G382W G382W G382W 
fliA sigma factor FliA      D49A D49A  D49A      
lasR transcriptional regulator LasR Q45* 
 
W195L G31* W195L W195L W195L W195L W195L W195L W195L G31* W195L 
mucA anti-sigma factor MucA   *118Q *118Q *118Q *118Q *118Q *118Q 
R168C 
*118Q *118Q *118Q *118Q *118Q 
 
17 *Variants in key genes are listed here. A complete listing of gene variants is given in Table S1. Sample E-S2239-15 was not included in this analysis due to  being too 






mucB negative regulator for alginate biosynthesis 
MucB  
  
ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp 
mvaT transcriptional regulator MvaT 
  
W107R W107R W107R W107R W107R W107R W107R W107R W107R W107R W107R 
pvdA L-ornithine N5-oxygenase Q327*        E195*     
pvdD pyoverdine synthetase D  C1559Y  A306S Δ12bp   C1559Y    A306S  
pvdH L-2,4-diaminobutyrate:2-ketoglutarate 4-
aminotransferase 
         ins 4bp    
pvdN aminotransferase PvdN        V274G Δ1bp    Δ1bp 
pvdS sigma factor PvdS    E85*        E85*  
wbpL Glycosyltransferase WbpL  ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp ins 1bp 
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5.7. Differential gene expression between E-S2239-16 and L-001-1C pathways 
RNAseq of an earlier and a later isolate was carried out on bacteria grown in a synthetic CF 
sputum medium to identify pathways and genes that had altered expression following 20 years of 
infection. Of 5359 genes expressed in both isolates, 28 genes had significantly lower expression in 
the later isolate and 155 genes had significantly higher expression (Figure 5.4; Table S2). Genes of 
known function showing high differences in expression are summarised in Table 5.3. Most of the 
genes that have reduced expression are involved in flagellar synthesis, consistent with the presence 
of a mutation in the transcriptional regulator fleQ. The gene with the most highly reduced 
expression, sfnG, encodes an enzyme involved in oxygenation of dimethylsulfone (364) but the 
biological significance of its reduced expression in the context of infection in CF is not clear.  
Genes that had significantly increased expression in the later strain reveal a wide range of 
functions associated with host pathogen interactions, including genes involved in nutrient 
acquisition. Amongst those with the highest increase in expression are multiple genes involved in 
zinc scavenging (zrmA-D, also known as cntI-O) and the zinc starvation response (dksA2 and rpmE2), 
consistent with high levels of expression of these genes by P. aeruginosa during chronic lung infection 
(365). Genes required for synthesis and uptake of an iron-scavenging siderophore, pyochelin, also 
had higher expression in the later isolate. The aceA gene that encodes isocitrate lyase also had higher 
expression in the later isolate, consistent with the key role of this gene in utilisation of acetate and 
fatty acids as carbon sources (366).  
As well as genes involved in nutrient acquisition and utilisation, multiple genes involved in 
biofilm formation and adhesion to host cells had higher expression in the later isolate. The later 
isolate had higher expression of genes associated with synthesis of cell-surface molecules, including 
lecB (lectin), cdrA (an adhesin) and lptF (an outer membrane protein associated with host cell 
attachment). Some though not all genes involved in alginate production also had higher expression 





Table 5.3|Differentially expressed genes between earlier isolate E-S2239-16 and later isolate L-001-1C 
Gene Log2 fold-change FDR adjusted p-value18 Gene Description 
Reduced expression in later isolate 
Motility 
flgG -3.79 2.31x10-03 flagellar basal-body rod protein FlgG 
flgF -3.71 5.82x10-03 flagellar basal-body rod protein FlgF 
flgH -3.43 1.47x10-03 flagellar L-ring protein precursor FlgH 
flgI -3.34 5.18x10-05 flagellar P-ring protein precursor FlgI 
flgK -3.16 6.09x10-04 flagellar hook-associated protein 1 FlgK 
fleR -2.97 2.59x10-04 two-component response regulator 
flgJ -2.91 1.79x10-04 flagellar protein FlgJ 
fliF -2.68 1.16x10-06 Flagella M-ring outer membrane protein precursor 
    
Physiology 
snfG -4.93 5.24x10-08 FMNH2-dependent monooxygenase, SfnG 
mexI -2.85 1.99x10-04 RND efflux transporter 
    
Increased expression in later isolate 
 
Nutrient acquisition and utilisation 
aceA 4.14 3.94x10-07 isocitrate lyase AceA 
fptA 2.95 5.93x10-03 Fe(III)-pyochelin outer membrane receptor 
pchA 2.61 8.72x10-03 salicylate biosynthesis isochorismate synthase 
pchB 2.45 9.90x10-06 salicylate biosynthesis protein PchB 
pchC 2.77 9.06x10-06 pyochelin biosynthetic protein PchC 
pchD 3.01 1.79x10-03 pyochelin biosynthesis protein PchD 
pchG 2.27 3.67x10-03 pyochelin biosynthetic protein PchG 
rpmE2 4.69 3.43x10-07 Zinc-independent paralog of ribosomal L31 protein 
dskA2 4.23 4.05x10-11 Transcriptional regulator 
 
18 RNAseq was carried out on earlier isolate E-S2239-16 and later isolate L-001-1C. Only genes with an FDR-adjusted p-value of less than 0.01 are listed here. A 
complete listing of all genes is given in Supplementary Table S2. 
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zrmD 3.10 1.11x10-06 Secretion of zinc metallophore 
zrmC 2.93 2.70x10-03 Biosynthesis of zinc metallophore 
zrmB 4.26 1.86x10-10 Biosynthesis of zinc metallophore 
zrmA 4.40 3.63x10-10 Outer membrane receptor for zinc metallophore 
    
Cell surface and adhesion 
algA 3.34 2.52x10-06 guanosine 5'-diphospho-D-mannose pyrophosphorylase 
algD 2.43 2.65x10-03 GDP-mannose 6-dehydrogenase AlgD 
cdrA 2.28 4.27x10-03 cyclic diguanylate-regulated TPS partner A 
lecB 3.02 7.13x10-05 fucose-binding lectin PA-IIL 
lptF 3.80 3.96x10-06 Lipotoxin F, LptF 
mucB 2.80 1.05x10-06 negative regulator for alginate biosynthesis MucB 
    
Pathogenicity 
aprA 3.24 4.67x10-04 alkaline metalloproteinase 
hcp1 2.67 8.28x10-14 Hcp1 
tagQ1 2.71 8.46x10-09 TagQ1 
tssB1 2.25 7.17x10-06 TssB1 
tssC1 2.44 4.37x10-07 TssC1 
    
Antibiotic resistance 
ampC 2.97 1.12x10-08 beta-lactamase 
mexZ 2.73 2.22x10-08 negative regulator of mexXY efflux pump genes MexZ 
    
Stress response 
ibpA 3.50 1.40x10-05 heat-shock protein IbpA 
katE 2.98 8.17x10-07 catalase HPII 
lexA 3.62 6.51x10-06 repressor protein LexA 
sulA 3.38 7.57x10-04 SulA 
    
Lifestyle regulation 
pqsA 2.48 2.61x10-05 PqsA 
pqsB 2.32 2.29x10-03 PqsB 





pqsD 2.44 2.03x10-05 3-oxoacyl-[acyl-carrier-protein] synthase III 
pqsE 2.29 1.93x10-04 Quinolone signal response protein 
sbrI 1.51 2.06x10-03 SbrI 
sbrR 1.33 2.12x10-03 SbrR 
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Several genes associated with stress responses (lexA, sulA, katE, pfpI and ibpA) had higher 
expression in the later isolate, likely reflecting at least in part ongoing exposure of the bacteria to the 
host immune system. Perhaps as part of this response, or perhaps reflecting interactions with other 
bacteria, some Type VI secretion system genes (tssB1, tssC1, hcp1 and tagQ1) as well as the protease-
encoding aprA gene had higher expression in the later strain. The complex nature of bacterial 
adaptation to the environment of the host long is also shown by the higher expression of genes 
required for synthesis of the Pseudomonas quinolone signal (PQS). PQS is a quorum sensing molecule 
that contributes to regulation of a range of different functions, but is also cytotoxic, alters the host 
immune response, and contributes directly to iron acquisition (367). The SbrIR sigma/antisigma 
factor system that controls swarming activity also had higher expression in the later isolate.  
Altered gene expression can also contribute to resistance of P. aeruginosa to antibiotics. Isolates 
of P. aeruginosa from chronically infected patients often have increased expression of the ampC gene, 
that is associated with resistance to cephalosporins such as ceftazidime, the later isolate had higher 
expression of ampC. A major factor in the resistance of P. aeruginosa to antibiotics is increased 
expression of efflux pump genes (64). None of the efflux genes had significantly higher expression 
in the later isolate. The mexXY genes had increased expression, consistent with the presence of a 
mutation in the regulator gene mexZ, but this did not reach statistical significance (Table S2).  
Transcriptomic differences between the earlier and later isolate demonstrate the wide range of 
changes that P. aeruginosa undergoes while adapting to the host lung environment. It is important to 
note that the majority of the 155 genes that had significantly higher expression in the later isolate, 
including some of those with the biggest differences in expression, do not have well defined 
functions. Intriguingly, two of the genes showing highest increase in expression are a non-coding 
RNA of unknown function (P8) and a tRNA gene (PA4581.1) but the biological significance of this 






5.8. Phenotypic changes between early and late isolates 
The patient was treated with a wide range of antibiotics during infection (Tables 5.4 and 5.5). 
Genome analysis (Table 5.2; Table S1) showed that later isolates had acquired mutations likely to 
increase the ability of the bacteria to tolerate carbapenem, fluoroquinolone and aminoglycoside 
antibiotics. Resistance to meropenem (a carbapenem), ciprofloxacin (a fluoroquinolone), and 
tobramycin (an aminoglycoside) was therefore tested for all isolates. Of the eleven later isolates four 
were clinically resistant to all antibiotics tested (Table 5.1). Only two later isolates were not resistant 
to more than one class tested. Earlier isolates were all sensitive to tobramycin and meropenem and 
were inhibited by lower concentrations of ciprofloxacin than later isolates.  
P. aeruginosa commonly adapts to the lung environment through altered biofilm formation, 
reflected in altered adherence properties and associated with reduced motility (41, 233). None of the 
later isolates showed swimming motility whereas all three of the ancestral isolates were motile 
(Figure 5.2A). Nine of the 11 later isolates also showed increased adherence in an in vitro assay 
whereas all earlier isolates showed no detectable adherence (Figure 5.2B).  
Following long term infection, P. aeruginosa can have altered growth in laboratory culture due 
to development of auxotrophy or of small colony variants (368, 369). Isolates were tested for growth 
in nutrient-defined SCFM medium that is representative of the chemical composition of CF sputum 
(248). Three of the later isolates showed reduced growth in SCFM compared to earlier isolates 
(Figure 5.2C). There was no clear pattern of difference in growth between the earlier and later 
isolates in nutrient rich medium, although one later isolate grew more slowly than any other (Figure 
5.2D).  
During the early stages of infection P. aeruginosa acquires iron by secreting a siderophore, 
pyoverdine, but during chronic infections the bacterium becomes less dependent on pyoverdine, 
transitioning to utilizing heme and other iron sources (370-373). Earlier and later isolates were tested 
for pyoverdine production in an iron limited growth environment. Two earlier isolates showed high 
amounts of pyoverdine production. All later isolates, and one earlier isolate, showed impaired 
production of pyoverdine consistent with reduced dependence on pyoverdine-mediated iron 
acquisition as infection progresses (Figure 5.2E).  
 




Figure 5.2|Phenotypic analysis of isolates. Earlier samples are shown in orange, and later 
in blue. Three biological replicates were carried out for each experiment, with each 
point representing a biological replicate and median values shown as crossbars. (A) 
Swimming motility of isolates on M8 media containing 0.3% agar. (B) Cell 
adherence in a microtitre plate assay. Crystal violet staining of standing cultures was 
normalised to culture OD600. (C) Growth of isolates in synthetic cystic fibrosis 
media (SCFM), summarised as Area Under Curve (AUC). (D) Growth of isolates in 
L broth. (E) Pyoverdine production normalised to culture OD600 following 







The availability of isolates of P. aeruginosa from the same patient over a 20-year timeframe has 
allowed us to integrate genomic, transcriptomic and phenotypic approaches to shed light on the 
changes that occur in these bacteria during prolonged infection. All of the later isolates in our study 
shared a high amount of genetic similarity with 3 of the earlier isolates, making it extremely likely 
that the later isolates are descended from a common ancestor closely related to the earlier group 
(Figure 5.1A; Figure 5.3). There was no evidence of superinfection by genetically distinct isolates 
during infection. Instead, a genetically distinct co-infecting earlier isolate was not represented in the 
later isolates and was likely lost from the infection. These findings are consistent with other studies 
(226-228), showing that CF patients acquire a colonising strain of P. aeruginosa that evolves 
throughout the course of infection, but do not repeatedly acquire new superinfecting strains. 
Genome sequencing data indicate that a population bottleneck occurred during infection. All 
later isolates contain an identical 127 kb deletion not present in earlier isolates (Figure 5.1B) and 
many genes in these isolates had identical alleles that are different from any of the ancestral isolates 
(Table 5.2, Table S1). This bottleneck could have occurred due to a major but temporary reduction 
in the number of infecting bacteria, or because a mutation arose that conferred a significant 
competitive advantage. Bottlenecks significantly reduce genetic diversity within a population, and it 
remains to be determined whether such bottlenecks occur during infections in other patients. 
Nonetheless the later isolates have a significant degree of genetic diversity (Table 5.7, Table S1), 
consistent with diversification of P. aeruginosa after the bottleneck event and with generation of 
different morphotypes and adaptation to microniches during chronic infection within the lung (231, 
236, 238, 374).  In comparison the genetically related earlier isolates have relatively little genetic 
diversity, consistent with a shorter amount of time for adaptation to the lung environment. 
Deletions have recently been identified as occurring at a significant frequency in clinical isolates of P. 
aeruginosa, with up to 15% of isolates containing large deletions (135, 239, 284, 375). Large deletions 
in the P. aeruginosa genome can contribute to phage resistance (184) and to resistance to carbapenems 
and other β-lactam based antibiotics (185, 356). The 127 kb deletion identified here overlaps with 
the deleted regions identified in earlier studies but whether this deletion confers resistance to phage 
or antibiotics has not yet been determined.  
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The mean mutation rate for P. aeruginosa during infection in CF has been estimated to be 
between 2.6 and 10 mutations per year (226, 228) but this rate is higher in strains with defects in 
DNA repair (so-called “hypermutators”) (205). Later isolates contain a different variant than earlier 
isolates of the MutY protein that normally reduces the incidence of GC > TA transversions (359). 
The relatively high mutation rate of P. aeruginosa in this patient is likely due to reduced activity of 
MutY, with the consequent increase in mutation rate facilitating an increased rate of genetic 
diversification and adaptation of the bacteria during the course of the infection. One of the genes 
with the highest increases in expression in the later isolate is the anti-mutator gene pfpI that is 
upregulated in response to mutY mutations (376), consistent with the MutY variant present in later 
isolates being dysfunctional. 
Transcriptomic profiling of one earlier and one later isolate showed that extensive changes in 
gene expression occurred during the course of infection. This contrasts with the high similarity in 
transcriptomic profiles of different isolates of P. aeruginosa collected at the same time from a CF lung 
(377). Many of the genes with higher expression in the later isolate have been noted in studies 
comparing P. aeruginosa in laboratory culture with those in late-stage infections within CF lungs (378, 
379). Although many of the genes with altered expression levels in the later isolate have known 
functions, a large proportion of these genes have undefined or unconfirmed functions consistent 
with other studies and demonstrating the complex nature of CF lung adapted P. aeruginosa (377-379). 
During infection P. aeruginosa became resistant to all the antibiotic classes routinely used in 
treatment of the patient (Table 5.1) and both genome and transcriptome analysis were used to 
understand the basis of resistance. Resistance arose though mutations, with no evidence of 
acquisition of antibiotic resistance genes. All later isolates have non-synonymous mutations in 
resistance-related genes including gyrB, fusA1, mpl and oprD that are associated with resistance to 
fluoroquinolones, aminoglycosides, cephalosporins, and carbapenems respectively. The later isolate 
also had significantly increased expression of ampC, a change that is associated with increased 
resistance to cephalosporins. It is likely that increased expression is due to mutations in mpl that are 
present in all later isolates, as mutations in this gene increase expression of ampC and contribute to 
ceftazidime resistance (356, 380). Antibiotic resistance in P. aeruginosa is also commonly associated 
with increased expression of efflux pump genes (64) but we did not observe widespread differences 
in efflux gene expression between an earlier and a later isolate. One exception was expression of the 





isolate consistent with the presence of a frameshift mutation in the mexZ repressor-encoding gene. 
Expression of mexXY genes is highly varied in P. aeruginosa isolated from patients with CF due in 
part to mutations in mexZ, which are associated with aminoglycoside resistance (381-383). Curiously, 
early isolates contain a premature stop codon in mexB that encodes a component of the MexAB-
OprM efflux pump, which is involved in resistance of P. aeruginosa to a range of antibiotics (384, 
385). This stop codon has undergone mutation to a leucine codon in later isolates, potentially 
reflecting selection for a functional efflux pump. Our findings demonstrate the multifactorial nature 
of antibiotic resistance development during chronic infection, with a complex interplay between 
mutations and changes to gene expression. 
All the later isolates in our study had lost flagellar-mediated motility (Figure 5.2A), a 
phenotype commonly associated with altered biofilm formation. Transcriptomic analysis 
demonstrated a significant reduction of expression of flagellar genes in a later isolate (Table 5.3; 
Table S2) consistent with a lack of motility. All of the later isolates have a mutation in fleQ that 
encodes a sigma factor required for expression of flagellar synthesis genes (386), providing a 
molecular explanation for loss of motility. Most of the later isolates showed enhanced adherence in a 
microtitre plate assay, a common property of P. aeruginosa isolated from chronic infections (387). The 
genetic basis for this complex phenotype is not clear although it is noteworthy that a number of 
genes that may influence biofilm formation, including global regulators (PQS, Las and Sbr) and cell 
surface adhesins (LecB and CdrA), had higher expression in the later isolate. Later isolates also had 
mutations in genes required for synthesis of lipopolysaccharide, Pel polysaccharide and alginate, all 
of which might influence attachment and biofilm formation.  
P. aeruginosa from chronic infections often produce copious amounts of extracellular alginate 
due to mutations in regulatory genes such as mucA and mucB that control the alginate synthesis 
pathway (388) but the only isolate to have a mucoid phenotype was the early isolate E-S2239-16. 
Indeed, a premature stop codon in mucA in that strain has been replaced by a glutamine-coding 
codon that would restore production of full-length protein with potential to repress alginate gene 
expression in later isolates. All later isolates also have mutations in the alginate regulatory gene mucB 
and in some cases the regulatory gene algU, as well as mutations in genes encoding alginate encoding 
enzymes required for alginate synthesis. Expression of some alginate synthesis genes was 
upregulated in the later isolate although this did not result in mucoid phenotype. The relationship 
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between alginate genotype, gene expression and phenotype is clearly complex in the isolates studied 
here.  
Host colonisation is also influenced by quorum sensing, which controls production of a range 
of virulence factors. Later isolates had mutations in the quorum-sensing regulator lasR that is often 
mutated in chronically infected patients (41, 389-391), and expression of the LasR-regulated apr gene 
that encodes alkaline protease was higher in the later isolate. Expression of the pqs genes that encode 
the PQS quorum sensing molecule, which regulates a wide range of infection-associated phenotypes 
(391), was also higher in the later isolate. Later isolates also contained a mutation in mvaT that is 
associated with quorum sensing and virulence factor production, as well as with biofilm formation 
(392, 393). Clearly, quorum sensing pathways evolve during chronic infection, although the complex 
interplay between quorum sensing pathways mean that further work will be needed to dissect out 
the effects of these changes on phenotype.  
Adaptation to the host environment was also reflected in metabolic changes. The later isolate 
had much higher expression of isocitrate lyase, a key enzyme in the glyoxylate pathway, reflecting the 
use of lipids as a carbon source during infection (366). During infections P. aeruginosa counter zinc 
starvation by upregulating expression of zinc acquisition genes (365), and these genes were amongst 
those with the greatest increase in expression in the later isolate. P. aeruginosa has multiple 
mechanisms to acquire iron. Genes for synthesis of an iron-scavenging siderophore, pyochelin, also 
had higher expression in the later isolate indicating that pyochelin has an important role in iron 
acquisition during the later stages of infection. Conversely, during infection in the CF lung P. 
aeruginosa transitions away from the use of the siderophore pyoverdine for iron acquisition, instead 
using other sources of iron (370-373). Two of the earlier isolates but none of the later ones have a 
high production of pyoverdine (Figure 5.2E). The later isolates have mutations in different 
pyoverdine genes (Table S1) indicating that loss of pyoverdine production has occurred 
independently on several occasions although transcription of pvd genes was similar in the earlier and 
later isolate (Table S2).  
In conclusion, this study reveals the relationship between genomic, transcriptomic, and 
phenotypic changes undergone by P. aeruginosa during long-term infection in the lungs of a person 
with CF. Adaptations included a trend towards increased antibiotic resistance, altered nutrient 





While many of the genomic and transcriptomic alterations affect known phenotypes, many affect 
genes with no known function, showing that understanding of how P. aeruginosa evolves during 
infection in CF is still far from complete. Comparable studies of infections in other patients, 
combined with experimental and bioinformatic approaches, can be expected to shed further light on 
how P. aeruginosa adapts and maintains infections in the CF lung.
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5.10. Supplemental figures 
 
Figure 5.3|Phylogenetic tree of isolates used in this study. Clinical isolates of P. aeruginosa obtained from a person with CF 
shown in red. Reference strains of P. aeruginosa are shown in black. Zoomed in area shows the positioning of the closely 





Table 5.4|Summary of isolates taken for study, patient details and antibiotic treatment at 







19 FEV1 % predicted was derived using methodology outlined in: 
Sinclair SW, Avery SF, Brady DM, Smith DA, Holst PE, O'Donnell TV. Prediction formulae for normal pulmonary 
function values in New Zealand European subjects. N Z Med J. 1980;91(651):1-5. 
20 Precise FEV1 % predicted is not available at time of sampling, number presented is an average FEV1 % predicted 
across the 2nd half of 1991. 
Sample 
Date of Collection 
(MM/DD/YY) 
Patient age 
FEV1 % predicted19 
at sputum sampling 
Anbiotic treatment at 















15/08/12 46 18 Azithromycin 
L-001-2A 
L-001-2B 






21/11/12 47 21 No Data 





18/04/13 47 17 No Data 
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Table 5.5|Summary of antibiotics administered to the patient at time of, or between 
sampling of early and late isolates of P. aeruginosa. 


















21 This is not an exhaustive list of all antibiotics the patient received but covers those administered at time of sampling or 














E-S2239-16 30 406966 6 6277859 66.47 5708 
E-MSB2949 17 498069 4 6298620 66.45 5726 
E-MSB3405 22 477887 5 6284793 66.47 5726 
E-S2239-15 27 591763 5 6363296 66.51 5815 
Late Isolates 
L-001-1A 25 406981 6 6233923 66.34 5680 
L-001-1B 24 432548 6 6232272 66.34 5701 
L-001-1C 23 479468 5 6235513 66.34 5690 
L-001-2A 25 499495 5 6229724 66.34 5688 
L-001-2B 25 496018 5 6231364 66.34 5696 
L-001-3A 25 562198 5 6233697 66.34 5688 
L-001-3B 22 499494 5 6234827 66.34 5693 
L-001-4 20 1377003 2 6235635 66.34 5692 
L-001-5A 18 563163 4 6238703 66.34 5691 
L-001-5B 22 557909 5 6238048 66.34 5702 
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E-S2239-16 - 32 33 214 261 229 226 236 232 265 226 255 282 251   Number of 
non-synonymous changes E-MSB2494 - - 33 214 261 223 220 228 228 255 226 247 280 249   
E-MSB3464 - - - 219 264 224 227 233 235 258 229 248 289 250   0 
L-001-1A - - - - 197 77 78 40 80 131 86 61 214 117   10 
L-001-1B - - - - - 210 205 219 209 244 209 236 61 238   50 
L-001-1C - - - - - - 19 91 37 134 101 102 227 122   100 
L-001-2A - - - - - - - 94 28 135 100 105 224 121   200 
L-001-2B - - - - - - - - 100 143 110 75 234 131   400 
L-001-3A - - - - - - - - - 141 102 107 224 129     
L-001-3B - - - - - - - - - - 103 156 231 62     
L-001-4 - - - - - - - - - - - 123 226 87     
L-001-5A - - - - - - - - - - - - 251 144     
L-001-5B - - - - - - - - - - - - - 253     





Table 5.8| Prevalence of specific nucleotide changes across all single nucleotide in all P. 
aeruginosa isolates analysed in this study 
    Mutant allele (freq)       










A 0 5 46 10       
T 6 0 9 49   freq (%) 
G 86 310 0 21   0 0 
C 301 82 10 0   10 1 
             50 5 
   Mutant allele (%)   100 10 










A 0.0 0.5 4.9 1.1   400 40 
T 0.6 0.0 1.0 5.2       
G 9.2 33.2 0.0 2.2       

















E-S2239-16     
01 3446702 20-125 100 77.4 











L-001-1C     
01 5021309 20-125 100 80.6 
02 4928204 20-125 100 85.7 









Figure 5.4| Summary plots of RNAseq analysis of L-001-1C and E-S2239-16. (A) MA plot showing the relative gene transcript 
abundance (log of the average count per gene) plotted against the log2 fold-change. Positive fold change indicates genes 
with higher expression in the later isolate L-001-1C, negative fold change indicates genes with higher expression in the 
earlier isolate E-S2239-16. Red points indicate genes with a significantly different expression (False Discovery Rate 






Figure 5.5| Heatmap showing significantly differentially expressed genes from RNAseq of 
L-001-1C and E-S2239-16. Expression quantified as log of the counts per gene. Triplicates of L-
001-1C RNAseq are shown in the left columns, triplicates of E-S2239-16 RNAseq are shown in the 
right columns. 




Figure 5.6| Representative images indicating swimming motility on M8 media 
containing 0.3% agar. (A) Reference lab strain P. aeruginosa PAO1, this strain is 
known to have swimming motility. (B) Early isolate E-S2239-16 swimming 













6. Conclusions and perspectives 
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Understanding how bacteria evolve antibiotic resistance can allow an exploitation of this 
process, predict antibiotic resistance before it becomes unmanageable, and identify pathways to 
resistance which may have not been known to identify new druggable targets. To this end, using P. 
aeruginosa as a model for the evolution of antibiotic resistance serves to aid understanding of 
antibiotic resistance in general, and not just in this bacterium. The genomic complexity and intrinsic 
resistance mechanisms present within P. aeruginosa makes the bacteria adaptable, able to survive in a 
wide array of environments and under conditions that other bacteria find inhospitable. This work 
exploits the inherent adaptability of P. aeruginosa and its genome to further the understanding of the 
genetic basis of antibiotic resistance, and adaptation to chronic infections.  
 
6.1. Summary 
This thesis describes work carried out to understand the genetic basis of the evolution of 
antibiotic resistance in P. aeruginosa. Chapters 3 and 4 of this research describe the genetic basis of 
meropenem and tobramycin resistance in P. aeruginosa through experimental evolution studies, 
showing how the bacteria adapt to continue growth even when challenged with exponentially 
increasing doses of antibiotics. Chapter 5 describes the process of evolution of P. aeruginosa during a 
chronic infection in the lungs of a person with CF, clearly illustrating a single infecting lineage of 
bacteria adapting over decades to be able to resist treatment and survive within a patient. Both 
examples, evolving antibiotic resistance in vitro and evolving to maintain infection in vivo clearly 
demonstrate the adaptability of P. aeruginosa and emphasise the importance of understanding these 
processes. 
 
6.2. The use of experimental evolution in identifying antibiotic resistance genes 
The role of experimental evolution to understand how bacteria can adapt to a given 
environment is a powerful tool. Experimental evolution has been used to study many different 
environments, ranging from the long-term experimental evolution experiments pioneered by 
Richard Lenski examining how E. coli evolves under nutrient limited conditions (321, 394), to the 
numerous studies on the experimental evolution of antibiotic resistance in P. aeruginosa (134, 138, 





promotes and selects for adaptation provides researchers with genetic basis underpinning the 
evolution. More importantly, by identifying all the genes that provide resistance to an antibiotic 
through experimental evolution, researchers can understand possible epistatic interactions between 
genes that alone confer no resistance, but when in combination with other gene mutations can. This 
provides a much more detailed understanding of how the bacteria can adapt to become resistant and 
can provide possible new druggable targets. Largely experimental evolution studies examining 
antibiotic resistance in P. aeruginosa have discovered genes contributing to resistance that were 
already suspected to be involved through examining resistant clinical isolates. However, there are 
some exceptions to this, for example, the role of fusA1 mutations in aminoglycoside resistance in P. 
aeruginosa (105), and ftsI mutations associated with carbapenem resistance (294) were identified 
through experimental evolution. In this study, many of the genes found mutated in response to 
antibiotic selection are consistent with those discovered before, although there were also multiple 
genes mutated that had no clear role in antibiotic resistance (Chapter 3). 
Experimental evolution selecting for tobramycin and meropenem resistance in P. aeruginosa has 
been performed before (134, 136, 185). The research presented in chapters 3 and 4 differs from 
these studies significantly. Chapter 3 details evolving a much higher number of mutant lines, 
evolving mutants on solid media. Chapter 4 details studying intermediate steps during selection, and 
empirically determined the clinical relevance of the genes identified mutated.  
Evolving a higher number of mutant lines shows rare genetic mutations and mutations in 
genes which are not frequently mutated to confer resistance (Table 3.1). Larger sample sizes also 
further reinforce the key genes involved in resistance development. Additionally, larger sample sizes 
can identify specific resistance associated alleles in antibiotic resistance associated genes, assuming 
the pre-requisite of the gene to confer resistance is not through loss of function.  
Carrying out antibiotic selection on agar plates interspersed with periods of antibiotic-free 
growth (Figure 3.1) has some parallels with the conditions P. aeruginosa faces during colonisation 
within lungs of CF patients. In both circumstances bacterial growth is on a semi-solid surface with 
intermittent exposure to antibiotic, therefore selecting for mutations that are stably inherited in the 
absence of antibiotics. This differs from more commonly implemented experimental evolution 
experiments which take serially passaged bacteria within liquid culture. Typically, the bacteria are 
consistently exposed to an antibiotic. This results in a community of many different mutant bacteria 
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which later must be sub-cultured to separate a resistant mutant. This work avoids that issue by 
selecting for single colonies on an agar plate and growing in the absence of antibiotics to allow the 
mutant to grow. 
Studying experimentally evolved lines throughout the selection process (Table 4.1 and 4.2) 
shows which mutations are critical to resistance development and occur early during selection 
compared to mutations that occur towards the end of selection. Measuring resistance and growth of 
earlier steps in selection maps out how the bacteria evolves, showing the additive effect each gene 
mutation has on the fitness of bacteria in the absence of antibiotic, and can identify collateral 
sensitivity or cross-resistance mechanisms. 
Finally, incorporating an analysis on the clinical relevance of any genes identified associated 
with resistance provides a comprehensive understanding of how the resistance mechanisms within a 
laboratory setting can inform what is occurring within a patient (Table 3.2). 
 
6.3. Using computational approaches to find resistance associated genes 
In experimental evolution studies in P. aeruginosa a collection of mutations is identified after 
selection that confer resistance. However, conditions within the lab during selection are drastically 
different from the environment P. aeruginosa naturally evolves under. In patients P. aeruginosa adapts 
to other challenges, including oxidative stress, the immune system, host withholding of 
micronutrients such as iron and zinc, and competition from other microbiota (224, 225). It is 
possible that many of the mutations identified within experimental evolution studies for resistance in 
P. aeruginosa are not compatible for evolving resistance within a patient. 
By studying isolates from clinical sources for mutations in the key genes identified through 
experimental evolution studies, inferences can be made as to which mutations are most clinically 
relevant for developing antibiotic resistance. In Table 3.2 this is illustrated well, where mutations in 
fusA1 encoding elongation factor G was identified to contain putative functional variants in 29.7% 
of the clinical P. aeruginosa isolates studied. In environmental P. aeruginosa there was none. This result 
strongly suggests that clinically fusA1 is a key driver of aminoglycoside resistance (105, 136). Results 
like this rationalised the creation of the varEV pipeline (Chapter 7), by rapidly being able to analyse 





evolution studies can be compared to clinical isolates and conclusions can be made about their 
importance clinically. 
However, this is very much a candidate gene approach for identifying resistance. Experimental 
evolution studies identify genes of interest for further analysis and study. This is not the only way of 
identifying resistance associated genes. Association studies are increasing in popularity, by 
comparing the genomes of known antibiotic resistant isolates to genomes from antibiotic sensitive 
isolates, genes can be predicted to be associated with antibiotic resistance. These studies can apply a 
genome wide associated approach, or can use machine learning for predicting genes associated with 
resistance (137, 330, 331). The predicted resistance genes from this approach can then be used as 
candidate genes for further studying the genetic basis of resistance. 
 
6.4. Large deletions in Pseudomonas aeruginosa antibiotic resistant isolates 
reveal that large genomic changes can contribute to resistance 
The identification of large deletions in P. aeruginosa during exposure to β-lactam based 
antibiotics is relatively new (60, 61, 144, 185, 334). Currently a precise mechanism of how these 
deletions confer resistance has not been determined. Part of the problem with these deletions is 
although they all occur within a similar region of the P. aeruginosa genome, they are highly varied in 
size and precise location making determining which genes are critical to resistance development 
difficult. However, given that these deletions can occur under numerous different environments 
(Figure 4.2), and are present in 15% of clinical P. aeruginosa isolates (Table 3.2) there is strong 
evidence that they are important in antibiotic resistance. 
Interestingly, although these deletions are observed commonly in P. aeruginosa experimental 
evolution studies, and in clinically derived isolates of P. aeruginosa, they show no evidence of being 
present in non-P. aeruginosa opportunistic human pathogens. This suggests that whatever mechanism 
underlies the resistance associated with these deletions is not relevant in non-P. aeruginosa strains to 
the extent seen within P. aeruginosa, or large deletions in these species are deleterious.     
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6.5. Within patient evolution of Pseudomonas aeruginosa reveals the genes 
essential to adaptation to continuing infection 
Studying how P. aeruginosa adapts to survive within patients provides crucial insight into the 
genetic basis of how P. aeruginosa can persist and continue to cause chronic infections. In Chapter 5, 
tracking how a single lineage of P. aeruginosa adapts to the host via examining changes in the genome, 
regulation of genes, and phenotypic differences, allows for the identification of pathoadaptive genes 
that are critical for continuing infection (Table 5.2 and Table S1). Studying within host evolution of 
P. aeruginosa has been critical to further the understanding of the adaptation to continue infection 
(106, 226, 228, 229, 235-238). Many of the genes reported mutated and are contributing to antibiotic 
resistance in the isolates studied in Chapter 5 (gyrA, ftsI, fusA1, oprD, aroB, galU, nalC) (Table 5.2, 
Table S1) were found frequently mutated in research presented in Chapter 3 (Table 3.1). This shows 
a strong selection clinically for mutations in these genes to provide resistance, this supports research 
shown in Chapter 4, where mutations in fusA1 and oprD were consistently mutated early during 
resistance (Table 4.1, Table 4.2). 
Additionally, large deletions were identified in late stage infection isolates presented in Chapter 
5, that developed during infection (Figure 5.1), overlapping with deletions identified through 
experimental evolution shown in Chapter 3 (See Figure 4.2, clinical isolate L-001-1C, is an isolate 
from Chapter 5, and has an overlapping deletion with deletions identified in the research conducted 
in Chapter 3). These clinical isolates gaining a deletion during evolution within a patient that 
overlaps with deletions identified through experimental evolution screens further supports these 
deletions may play an important role in antibiotic resistance. 
A feature of the analysis carried out in Chapter 5 that provides additional insights is through 
the incorporation of whole genome sequencing, RNAseq and phenotypic studies to gain a greater 
insight into the changes that occur during infection. With additional data comes additional 
questions, close to 50% of the genes found to be mutated and differentially expressed between early 
and late infecting isolates have no clear role in adapting to continue infection (Table S1 and Table 
S2). It is unknown if this is due to hypermutator isolates (Figure 5.7 and Figure 5.8) resulting in 
mutations in genes of little significance or selective disadvantage within the lung, or if we are 
observing undiscovered adaptation methods. Increasing the number of infecting lineages and 
patients, looking for co-occurrence of specific genes commonly mutating or showing differential 





6.6. Future work and future perspectives 
Following on from the research presented in Chapters 3 and 4, a natural experimental 
progression would be to manufact specific antibiotic resistance associated mutations into a wild-type 
antibiotic sensitive P. aeruginosa strain to understand the effect the mutations have in a clean genetic 
background. Doing this will allow for the understanding of epistatic interactions between resistance 
associated alleles and identify mutations capable of conferring resistance alone. Specifically, looking 
at the effect of large deletions in antibiotic sensitive strains may give insights into the genes that 
could be playing a role in resistance. Additionally, examining mutations in genes like aroB and the 
different tRNA-ligases identified (Table 4.1, Table 8.4) in this context could provide understanding 
to how these mutations increase meropenem resistance, whether through reductions in growth, or 
through a previously uncharacterised resistance mechanism. 
The methods successfully used in Chapter 3 to evolve resistant bacteria and to study the 
relevance of mutations conferring resistance in clinical isolates can be broadly applied to different 
antibiotic selection pressures, and to different bacteria and strains. Chapter 3 provides a working 
blueprint of how experimental evolution studies can be conducted moving forward. The limitation 
of this study is that resistance mechanisms were only studied in the context of P. aeruginosa and 
within an antibiotic sensitive laboratory strain (PAO1). Additionally, by only exposing the bacteria to 
one antibiotic these experiments do not represent the conditions faced by P. aeruginosa within 
infections, where combinatory antibiotic treatment is used to repress the infection more effectively. 
It is possible many of the specific mutations identified within this study are not viable in 
combination within clinical isolates, as gene-gene interactions could cause a synthetic lethality or 
severe selective disadvantage when within a patient or exposed to multiple antibiotics. Further study 
within this field should focus on examining the mutations that can arise under combination 
treatment with synergistic and clinically relevant combinations of antibiotics. Furthermore, by 
studying how antibiotic resistance can arise within adapted clinical isolates of P. aeruginosa as opposed 
to laboratory strains could provide a greater insight into mutations that may increase resistance in 
vivo.   
Following the evolution of P. aeruginosa within a chronic infection as present in Chapter 5 
provides a well-rounded and concise study. The limitations of this study are that ultimately it 
examines only one lineage of bacteria and although spans a large period of time, only has two 
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sampling windows 20 years apart. Tracking P. aeruginosa evolution across multiple patients at a more 
regular interval would provide a much more comprehensive view on the genetic basis of evolution 
and reveal short term adaptation strategies. Ultimately, sampling at more regular intervals across 
more patients could provide insights into convergent evolution of P. aeruginosa isolates across 
patients, revealing the genes essential to adapting within the lung. There are already numerous 
studies that track within host evolution of P. aeruginosa, and a meta-analysis of genetic changes could 
be carried out. However, most studies lack information on the expression of genes in infecting 
isolates and phenotype analysis. By doing more transcriptomic profiling of P. aeruginosa adapted to 
the lung will provide a more comprehensive view of the genes essential to maintaining infection. 
Additionally, by using multi-omics approaches and incorporating metabolomic and proteomic 
studies alongside genomic and transcriptomic data would provide unparalleled understanding of 
how P. aeruginosa adapts within the lung in patients with CF. 
By incorporating the discoveries within this research, an understanding of how P. aeruginosa 
evolves antibiotic resistance, in vitro and in vivo emerges. Using the information regarding early 
mutating genes (e.g., oprD, fusA1) predictions of resistance can be made. By knowing the genes 
integral to resistance development in vitro and in vivo it is possible treatment strategies for P. aeruginosa 
infections can change to prevent further resistance arising, improving infection management and 
outcomes for patients. 
 
6.7. Concluding statement 
In this thesis the research carried out forms the basis for furthering the understanding of the 
evolution of antibiotic resistance in P. aeruginosa. Experimentally evolving P. aeruginosa to be resistant 
to different classes of antibiotics identified the genes that can mutate to confer resistance, and by 
determining the relevance of these genes in clinical isolates of P. aeruginosa further understanding of 
how antibiotic resistance arises within clinical isolates was gained. Studying intermediate steps during 
experimental evolution identified the specific genetic changes that occur early during antibiotic 
resistance development and those that can provide large increases in resistance. This understanding 
can be used to identify the early stages of antibiotic resistance and can act as potential biomarkers 





Tracking the genetic, regulatory, and phenotypic changes that occur during a chronic infection 
has given a much greater insight into the evolution of P. aeruginosa goes through during infection, 
understanding the effects specific mutations has on the expression of and phenotype of infecting P. 
aeruginosa isolates. Ultimately more study is required to fully understand what effect (if any) changes 
in uncharacterised genes and seemingly unrelated gene mutations can play in the evolution of P. 
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7. Supplementary Chapter – Development of the 
VARiant EValuation pipeline for identifying 
functional variants within genes associated 







7.1. Chapter 4 preface 
This chapter describes the development of a pipeline for identifying and predicting 
functionality of variants within proteins of interest in a database of genomes. The variant evaluation 
tool (varEV) uses well established sequence analysis software and creates a user-friendly pipeline that 
can be applied to any bacterial species and any number of proteins of interest. Within this thesis, this 
tool has been used to identify variants within genes associated with antibiotic resistance in P. 
aeruginosa.  
 
7.2. Abstract and Importance 
Experimental evolution studies are powerful tools that have successfully been used to identify 
genes responsible for antibiotic resistance in opportunistic human pathogens. One such 
opportunistic pathogen commonly experimentally evolved to have antibiotic resistance is P. 
aeruginosa. Typically, these experimental evolution studies identify mutations in genes that in a 
laboratory environment can confer resistance. What remains to be studied is if these genes are 
relevant for antibiotic resistance development during infections clinically. To identify how the genes 
identified in experimental evolution studies translate to clinical isolates of P. aeruginosa a 
computational pipeline was developed, the variant evaluation tool (varEV). This pipeline varEV uses 
well-established programs for analysing sequencing data. Genes of interest are compared to a 
database of bacterial genomes and variants within those genes identified and then a computational 
prediction is made on the significance of each variant. The assumption is that genes with roles in 
continuing infection or antibiotic resistance would be significantly overrepresented in clinical isolates 
of P. aeruginosa compared to environmental isolates of P. aeruginosa. This pipeline has been 
successfully deployed in two independent research projects.  
 
7.3. Developing varEV to predict functional protein changes in proteins of interest 
As detailed in Section 3.7, identifying the frequency, and predicting functionality of, mutations 
in proteins of interest can be a powerful tool to aid in supporting findings discovered through 
experimental evolution. This can also be applied to any protein or gene of interest. Currently, there 
is no rapid way to screen these differences and predict functionality, rather it is typically a series of 
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steps and manual manipulation of data to adjust file formats to pass onto the next program. To this 
end, a tool named the ‘variant evaluation tool’ or varEV was created for the purpose of making this 
analysis a more user-friendly experience, and to facilitate the comparisons of an unlimited number of 
proteins at once with user generated databases of genomes. 
The basis of this tool is outlined in Section 2.3.11, and a flow diagram of the varEV tool is 
shown in Figure 7.1. The raw varEV code is available online (see Section 8.2, and associated readme 
for usage instructions) and can be implemented on most machines or servers running linux or mac 
OS. 
varEV utilises well-established programs (Section 2.3.11) to process input protein files (fasta 
format), parsing through a pipeline (Figure 7.1) to give a prediction of functional variations from 
that protein sequence. Users give varEV; an ‘input directory’ that contains their proteins/genes of 
interest in fasta format (one protein/gene per fasta file); a ‘file suffix’, this can be anything, and is 
only asked for to ensure the user doesn’t accidentally try to run varEV on files they don’t intend to; 
an ‘output directory’ that all output files will be exported to; and a ‘blast database’ containing any 
number of genomes of interest to the user. There is a documentation and help menu built in the 






Figure 7.1| varEV pipeline used to determine the frequency and predict the effects of 
variants in proteins of interest.  




Figure 7.2| varEV help menu.  varEV help menu is called using the -h option. This help option 
will also appear if there is not an input present, or if the dependencies are not installed in 
a usable path. 
 
As outlined in Figure 7.1, a protein sequence is passed into varEV and used as a query 
sequence in a tBLASTn search against the user provided BLAST database. This database can be 
generated from a concatenated multi fasta file of genomes of interest using the makeblastdb 
command present with command line implementations of BLAST+. An example of this is provided 
in Table 3.2, where two databases, an environmental (n=172) P. aeruginosa and a clinical (n=558) P. 
aeruginosa were used. This enabled the contrast between isolates from patients compared to those 
naïve to human infection. 
Currently, in varEV the -max_hsps option in tBLASTn is set to 1. This means only the 
highest scoring match (or pair) will be output from BLAST per genome in the database. This 
prevents matches from paralogs that might otherwise have a high similarity percent match that can 
add non-relevant variations to the analysis. However, this also has limitations as if a gene is not 
present, or is substantially different from the query protein sequence, a paralog can be matched if it 
is the lowest E-value hit. The only other change from a default tBLASTn search is to allow for up to 
5000 alignments through the -num_alignments option. This is an arbitrary choice and is only in 
place as the default number is 500, any database containing over 500 genomes would exclude all 
matches after this limit was reached, the value can be customised if a user is analysing more than 
5000 genomes at once. The tBLASTn output is in standard pairwise output (-outfmt 0), this is the 
equivalent of an output a user is given when doing a BLAST online, and as such, this is the most 





The next step takes the BLAST output and converts it to a multi fasta file using the program 
mview (395). Although a multi fasta file can be output directly from tBLASTn, the format is not 
ideal for downstream steps, therefore mview is used at this step. The resulting output file from 
mview contains all hits from the BLAST in an aligned multi-fasta file. 
Using this multi fasta file, the program snp-sites (285), identifies where the hits from the 
BLAST differ from the query sequence and outputs them in a variant call format (vcf) file (Figure 
7.3, BLAST output example shown in Figure 7.4). This vcf file lists the REF (query) allele and the 
ALT (variant) allele along with all the genomes that had hits, 0 meaning the REF allele was present 
(i.e. same as the query), a value of 1 or above indicates which allele was present instead of the REF 
allele. As shown in Figure 7.3, even a cursory glance at these vcf files can provide insight, as with 
this example at position 87 in the protein there is 5 alternative alleles detected, suggesting this site 
are highly variable in the database used. However, snp-sites as published was not designed for 
protein analysis and was initially only tested on DNA. Some modifications to the snp-sites source 
code were done to allow for residues that in DNA have an alternative meaning (e.g. N in nucleotide 
sequences means any base, N in protein sequences means asparagine). This modified snp-sites is 
available as outlined in Section 8.2. 
  




Figure 7.3| Example of vcf files generated through the varEV pipeline. This representative 
snapshot of a vcf file for the protein GyrA shows positions at which variations occurr. 
(A) Shows the vcf version 4.1 headers, including protein length and chromosome 
identifiers. (B) CHROM or chromosome, P. aeruginosa has one chromosome, for other 
species with more chromosomes, or eukaryotes this number can be more than 1. (C) 
Position in the protein of interest, in this case GyrA is being used as an example. (D) 
Shows REF and ALT alleles, REF or reference allele is the amino acid present in the 
reference protein sequence at the position shown in C. ALT is the alternative allele 
present in a genome, all alleles found within the genomes being analysed are listed but 
most genomes will only have zero, one, or two differences from the reference allele. (E) 
Genomes being analysed, all genomes within a pre-created blast database are compared to 
the reference sequence, each column is 1 genome. A zero in the column indicates that 
genome has the reference allele in that position, a 1 or higher in the column shows an 
alternative allele. (F) QUAL, FILTER, INFO columns are required in vcf version 4.1 
files, these colums are typically used when predicting variants from mapping data of 
whole-genome sequencing. These columns will include percentage of reads with 
alternative alleles, any filtering added and additional info. Because this pipeline uses draft-
genome assemblies there is no read data and all possible variants for any position are 
collapsed into a single allele prediction by the assembly software, and thus, there is no 
information required for these columns. (G) An example genome to illustrate differences 
from the reference sequence of GyrA, this genome has a 1 in two rows showing it has 
two differences from the reference sequence, A67S and T83A. This genome is shown as 
an example blast output in Figure 7.4. (H) An example genome illustrating a variant in a 
position that has multiple different alleles in the database analysed, in this genome the 
varaiant is D87H. If a genome had a 3 at this position, the variant would be D87V, as V 






Figure 7.4| Matching blast output results to variants compiled in vcf files. Standard pairwise 
tblastn output for the genome identified in Figure 7.3G, showing the changes from blast 
outputs are carried across to vcf files before parsed into PROVEAN.   
 
The final program used after snp-sites is PROVEAN (275), to predict which variants might be 
deleterious and to assign a prediction of likeliness. PROVEAN dependencies and conditions are 
outlined in Section 2.3.11. However, PROVEAN requires variants to be imported in HGVS 
(Human Genome Variation Society) format. The vcf output from snp-sites does not support this. 
Therefore, a combination awk, translate and sed command is used to extract the relevant variants 
from the vcf files and put them into a PROVEAN-readable format (Figure 7.5). During the original 
design of PROVEAN a cutoff of -2.5 was the crossing point between sensitivity and specificity 
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(275). However, this determination was done on an NCBI nr database from 2011, to re-test if this 
value was appropriate, the training dataset from the original PROVEAN paper (275) was used on a 
more recent NCBI non-redundant (nr) database (Section 2.3.11), it was found that a score of -2.5 
was still consistent on a newer database compared to the original predictions. 
 
 
Figure 7.5| Example of PROVEAN outputs from the varEV pipeline. This representative 
snapshot of a PROVEAN output file for the protein GyrA shows variants and their 








Creating a user-friendly pipeline for analysing variants in proteins of interest within genomes 
being studies, we have been able to provide a powerful tool for researchers to apply to their own 
research. The varEV pipeline has already been successfully deployed on two separate research 
project (Section 3.7, (35, 135)). Using this pipeline for examining the prevalence and the predicted 
severity of mutations in genes associated with antibiotic resistance in P. aeruginosa has allowed us to 
understand genes which are critical to resistance within patients. Many of the findings using this 
pipeline are consistent with other studies identifying genes crucial to antibiotic resistance in P. 
aeruginosa (65, 73, 111, 134, 166, 201) (Table 1.1, 1.2, and 3.2). 
Currently, varEV version 0.2 requires users to install all dependencies themselves. This is the 
simplest way to avoid conflicts with different operating systems and different versions of dependent 
programs. Future updates to varEV will include creating a docker image that will include the 
modified SNP-sites codes as well the other dependencies preloaded for a more user-friendly 
experience. The decision to use the PROVEAN tool as the means of predicting functional variants 
was done due to ease of use, widespread uptake from researchers, and its extensive benchmarking 
against other commonly used tools (275, 396). varEV using PROVEAN is not an acknowledgement 
that it is the best tool for predicting functional variants, there are many other tools that could in 
theory be substituted for PROVEAN (219, 397-402). However, like PROVEAN these other tools 
were originally optimised and developed for predicting variants in eukaryotic organisms, there are 
tools available that are specifically designed for prokaryotes (403). PROVEAN has the advantage 
that it has previously been used to study variants in P. aeruginosa (208, 404). 
The varEV pipeline can be applied to any bacterial species and any number of proteins. By 
using the NCBI nr database all non-redundant proteins are represented and can be used to predict 
functional variants. Given the rise of experimental evolution studies, varEV can be used as a 
powerful tool to examine if the mutations identified in the lab are relevant clinically. Another 
advantage of using the varEV pipeline is being able to rapidly find the diversity of non-synonymous 
variants within a protein of interest. This can give insights into potential variant “hotspots” that 
might be critical for antibiotic resistance. An example of this is shown in Figure 7.3, showing 
variants in GyrA in clinical isolates of P. aeruginosa, position 87 in the GyrA protein has 6 possible 
alleles in the clinical isolates (1 ‘wild-type’ allele found in P. aeruginosa PAO1, and 5 other variant 
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alleles). Mutations in position 87 in GyrA have been shown to contribute to fluroquinolone 
resistance (295, 304, 405, 406), all of these variants are considered to be functional variants by 
PROVEAN (Figure 7.5, below -2.5).  
By analysing whole genome sequences of infecting bacteria with varEV on relevant antibiotic 
resistance associated genes, we can identify variants that may contribute to antibiotic resistance that 
remain to be experimentally validated. These putative functional variants can be tested by mutating 
the wild-type allele in a reference P. aeruginosa strain. Identifying the specific mutations which may be 
functional in contributing to antibiotic resistance has the potential to significantly improve the 
quality of patient care. Knowing which specific mutations are associated with antibiotic resistance 
can give better insight into the resistance of the bacteria and can better inform treatment strategies, 
acting as molecular diagnostic tools, methods like this are already in use with other organisms (137, 
291, 292). 
In conclusion, by developing a pipeline which can rapidly predict functional variants in 
proteins of interest within genomes being studied we have been able to predict variants in genes that 
are critical to antibiotic resistance in clinical isolates of P. aeruginosa. Crucially, by using varEV on 
genes found to be mutated in experimental evolution studies we have been able to examine the 
prevalence and predicted effect of those mutations in clinical isolates of P. aeruginosa compared to 
antibiotic naïve environmental P. aeruginosa isolates. The natural extension of this approach is to 
examine genes mutated to give resistance to other antibiotics and other bacterial species. This has 























8.1.  Published work during PhD research 
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Chemotherapy. 2019;63:e01619-19. 
 
Below are works published during PhD study that are not presented within this thesis. 
Ramsay KA, Wardell SJT, Patrick WM, Brockway B, Reid DW, Winstanley C, Bell SC, 
Lamont IL. Genomic and phenotypic comparison of environmental and patient-derived isolates 
of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment. Journal 
of Medical Microbiology. 2019;68(11):1591-95. 
Lim CS, Wardell SJT, Kleffmann T, Brown CM. The exon–intron gene structure upstream of 
the initiation codon predicts translation efficiency. Nucleic Acids Research. 2018:4575-91. 
 
8.2.  Codes used 
All R codes used for figures shown in Chapter 3 are available from  
https://github.com/SJWScience/PP-31570397  
this includes an R-markdown file (LEP_Rmarkdown.Rmd), and a more user-friendly HTML 
file (LEP_Rmarkdown.html) containing a summary of codes used and figures generated. Some 
modifications to figures have been performed in Adobe Illustrator. For example, the heatmap of 
MIC data (Figure 3.2) had a table containing MIC values (mg.L-1) overlaid for clarity in the published 
manuscript.  
As outlined in Supplementary Chapter 7, during this research a computational tool was 
produced called varEV (variant EValuation tool). varEV was used as a rapid method to determine 
the frequency of and the predicted effect of variations in protein sequences of a given set of 





a user generated BLAST database and extracts variants, processing them through a series of 
programs until a prediction of variant impact can be generated using PROVEAN. A flow chart of 
varEV is shown in Figure 7.1. The varEV source code is available at  
https://github.com/SJWScience/varEV 
All R codes used for Chapter 5 are available from  
https://github.com/SJWScience/PP-pat1  
this includes an R-markdown file, and a more easily read HTML file containing a summary of 
codes used and figures generated. 
All programs and codes referred to in Chapter 2 are outlined and available from  
https://github.com/SJWScience/thesis_submission 
 
8.3.  Bacterial strains used 
Throughout the work contained within this document many strains of P. aeruginosa were used 
and generated. Table 8.1 summarises all strains used for data generations and all strains created 
during this work. A lot of the P. aeruginosa isolates used are from the International Pseudomonas 
Consortium Database (IPCD), who kindly provided strains for sequencing and made sequences 
publicly available. 
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Table 8.1|Bacterial strains used and generated in this work 
BioSample or 
BioProject Isolate name Isolate source Citation 
SAMN10478389 1 clinical (60, 407) 
SAMN10478390 2.1 clinical (60, 407) 
SAMN10478391 3 clinical (60, 407) 
SAMN10478392 4 clinical (60, 407) 
SAMN10478393 5 clinical (60, 407) 
SAMN10478394 6 clinical (60, 407) 
SAMN10478395 7 clinical (60, 407) 
SAMN10478396 8 clinical (60, 407) 
SAMN10478397 9 clinical (60, 407) 
SAMN10478398 10 clinical (60, 407) 
SAMN10478399 11 clinical (60, 407) 
SAMN10478400 12 clinical (60, 407) 
SAMN10478401 13 clinical (60, 407) 
SAMN10478402 14.1 clinical (60, 407) 
SAMN10478403 14.2 clinical (60, 407) 
SAMN10478404 15 clinical (60, 407) 
SAMN10478405 16 clinical (60, 407) 
SAMN10478406 17 clinical (60, 407) 
SAMN10478407 18 clinical (60, 407) 
SAMN10478408 19 clinical (60, 407) 
SAMN10478409 20 clinical (60, 407) 
SAMN10478410 21 clinical (60, 407) 
SAMN10478411 22.1 clinical (60, 407) 
SAMN10478412 22.2 clinical (60, 407) 
SAMN10478301 5985 clinical (60, 407) 
SAMN10478302 5987 clinical (60, 407) 
SAMN10478303 5988.2 clinical (60, 407) 
SAMN10478304 5988.3 clinical (60, 407) 
SAMN10478305 5989 clinical (60, 407) 
SAMN10478306 5990.1 clinical (60, 407) 
SAMN10478307 5990.2 clinical (60, 407) 
SAMN10478308 5990.3 clinical (60, 407) 
SAMN10478309 5991 clinical (60, 407) 
SAMN10478310 5992 clinical (60, 407) 
SAMN10478311 5993 clinical (60, 407) 
SAMN10478312 5994 clinical (60, 407) 
SAMN10478313 5995 clinical (60, 407) 
SAMN10478314 5996 clinical (60, 407) 
SAMN10478315 5997 clinical (60, 407) 





SAMN10478317 5999.1 clinical (60, 407) 
SAMN10478318 5999.2 clinical (60, 407) 
SAMN10478319 5999.3 clinical (60, 407) 
SAMN10478320 6000.1 clinical (60, 407) 
SAMN10478321 6000.2 clinical (60, 407) 
SAMN10478322 6000.3 clinical (60, 407) 
SAMN10478323 6001 clinical (60, 407) 
SAMN10478324 6003 clinical (60, 407) 
SAMN10478325 6004 clinical (60, 407) 
SAMN10478326 6085 clinical (60, 407) 
SAMN10478327 6086.1 clinical (60, 407) 
SAMN10478328 6086.2 clinical (60, 407) 
SAMN10478329 6087 clinical (60, 407) 
SAMN10478330 6088 clinical (60, 407) 
SAMN10478331 6089 clinical (60, 407) 
SAMN10478332 6090 clinical (60, 407) 
SAMN10478333 6091 clinical (60, 407) 
SAMN10478334 6092.2 clinical (60, 407) 
SAMN10478335 6092.3 clinical (60, 407) 
SAMN10478336 6093 clinical (60, 407) 
SAMN10478337 6095 clinical (60, 407) 
SAMN10478338 6096 clinical (60, 407) 
SAMN10478339 6097.1 clinical (60, 407) 
SAMN10478340 6097.3 clinical (60, 407) 
SAMN10478341 6098 clinical (60, 407) 
SAMN10478342 6099 clinical (60, 407) 
SAMN10478343 6102 clinical (60, 407) 
SAMN05226610 6822 clinical (60, 407) 
SAMN10478374 110238627 clinical (60, 407) 
SAMN10478363 2032935751 clinical (60, 407) 
SAMN10478369 2042723558 clinical (60, 407) 
SAMN10478382 3020837212 clinical (60, 407) 
SAMN10478388 3052425557 clinical (60, 407) 
SAMN10478362 4044301968 clinical (60, 407) 
SAMN10478354 4064320487 clinical (60, 407) 
SAMN10478360 4064321111 clinical (60, 407) 
SAMN10478384 4084334344 clinical (60, 407) 
SAMN10478387 4084336477 clinical (60, 407) 
SAMN10478361 4094341901 clinical (60, 407) 
SAMN10478350 4094345258 clinical (60, 407) 
SAMN10478351 4094345290 clinical (60, 407) 
SAMN10478385 4104355315 clinical (60, 407) 





SAMN10478344 4124363505 clinical (60, 407) 
SAMN10478386 5014375233 clinical (60, 407) 
SAMN10478380 5014375428 clinical (60, 407) 
SAMN10478379 5023272159 clinical (60, 407) 
SAMN10478381 5024383182 clinical (60, 407) 
SAMN10478358 5034388513 clinical (60, 407) 
SAMN10478383 5054408345 clinical (60, 407) 
SAMN10478373 5054408352 clinical (60, 407) 
SAMN10478364 9092533235 clinical (60, 407) 
SAMN10478347 41004355322 clinical (60, 407) 
SAMN07424124 001-5A clinical (60, 407) 
SAMN07424125 001-5B clinical (60, 407) 
SAMN07424126 001-6 clinical (60, 407) 
SAMN07424134 010-4 clinical (60, 407) 
SAMN07424136 014-2A clinical (60, 407) 
SAMN07424139 020MIC clinical (60, 407) 
SAMN10478367 1042828174-20 clinical (60, 407) 
SAMN10478368 1042828174-21 clinical (60, 407) 
SAMN10478145 128S180412BSL_PA2 clinical (60, 407) 
SAMN10478146 136S260811BSL_PA1 clinical (60, 407) 
SAMN10478147 136S260811BSL_PA2 clinical (60, 407) 
SAMN10478148 136S260811BSL_PA3 clinical (60, 407) 
SAMN10478149 144S190811BSL_PA1 clinical (60, 407) 
SAMN10478150 144S190811BSL_PA2 clinical (60, 407) 
SAMN10478151 145S200511BSL_PA2 clinical (60, 407) 
SAMN10478152 175S070312EX2DAY21_PA1 clinical (60, 407) 
SAMN10478153 175S070312EX2DAY21_PA2 clinical (60, 407) 
SAMN10478154 192S190811BSL_PA1 clinical (60, 407) 
SAMN10478155 192S190811BSL_PA2 clinical (60, 407) 
SAMN10478156 192S190811BSL_PA3 clinical (60, 407) 
SAMN10478157 197S020911BSL_PA1 clinical (60, 407) 
SAMN10478158 197S020911BSL_PA2 clinical (60, 407) 
SAMN10478159 197S020911BSL_PA3 clinical (60, 407) 
SAMN10478160 197S020911BSL_PA4 clinical (60, 407) 
SAMN05226628 1BAE clinical (60, 407) 
SAMN10478161 201s070911bsl_PA1 clinical (60, 407) 
SAMN10478162 201s070911bsl_PA2 clinical (60, 407) 
SAMN10478163 259S240811BSL_PA1 clinical (60, 407) 
SAMN10478164 259S240811BSL_PA2 clinical (60, 407) 
SAMN10478165 266S141211BSL_PA1 clinical (60, 407) 
SAMN10478166 272S250511BSL_PA1 clinical (60, 407) 
SAMN10478167 274S010611BSL_PA1 clinical (60, 407) 





SAMN10478169 278S180511BSL_PA2 clinical (60, 407) 
SAMN10478170 286S270711BSL_PA1 clinical (60, 407) 
SAMN10478171 293S080611BSL_PA1 clinical (60, 407) 
SAMN10478172 293S080611BSL_PA2 clinical (60, 407) 
SAMN10478173 295s071211BSL_PA1 clinical (60, 407) 
SAMN10478174 295s071211BSL_PA2 clinical (60, 407) 
SAMN10478175 298S020611BSL_PA1 clinical (60, 407) 
SAMN10478140 29S030611BSL_PA1 clinical (60, 407) 
SAMN05226614 2A42 clinical (60, 407) 
SAMN05226631 2C22 clinical (60, 407) 
SAMN05226616 2D9A clinical (60, 407) 
SAMN10478139 2S030611BSL_PA1 clinical (60, 407) 
SAMN10478176 313s141011BSL_PA1 clinical (60, 407) 
SAMN10478177 318S170811BSL_PA1 clinical (60, 407) 
SAMN10478178 318S170811BSL_PA2 clinical (60, 407) 
SAMN10478179 320S290711BSL_PA1 clinical (60, 407) 
SAMN10478180 320S290711BSL_PA2 clinical (60, 407) 
SAMN10478181 326S290611BSL_PA1 clinical (60, 407) 
SAMN10478182 326S290611BSL_PA2 clinical (60, 407) 
SAMN10478183 326S290611BSL_PA3 clinical (60, 407) 
SAMN10478184 333S200112BSL_PA1 clinical (60, 407) 
SAMN10478141 37s051011BSL_PA1 clinical (60, 407) 
SAMN05226630 3C52 clinical (60, 407) 
SAMN05226608 3C52(K) clinical (60, 407) 
SAMN05226617 4012(0) clinical (60, 407) 
SAMN10478376 4104355340-13 clinical (60, 407) 
SAMN10478375 4104355340-15 clinical (60, 407) 
SAMN10478366 4124363474-14 clinical (60, 407) 
SAMN10478365 4124363474-15 clinical (60, 407) 
SAMN10478142 44s031011BSL_PA1 clinical (60, 407) 
SAMN10478143 44s031011BSL_PA2 clinical (60, 407) 
SAMN10478348 5024379144-14 clinical (60, 407) 
SAMN10478349 5024379144-15 clinical (60, 407) 
SAMN10478378 5024382738-25 clinical (60, 407) 
SAMN10478377 5024382738-26 clinical (60, 407) 
SAMN10478370 5024382749-13 clinical (60, 407) 
SAMN10478371 5024382749-14 clinical (60, 407) 
SAMN10478352 5034388498-20 clinical (60, 407) 
SAMN10478353 5034388498-21 clinical (60, 407) 
SAMN10478345 5054407658-16 clinical (60, 407) 
SAMN10478355 5054408350-18 clinical (60, 407) 
SAMN10478356 5054408350-20 clinical (60, 407) 





SAMN07424046 5BR2 clinical (60, 407) 
SAMN10478144 66S100212BSL _PA1 clinical (60, 407) 
SAMN05226602 6D92(H) clinical (60, 407) 
SAMN05226622 6D92(H) clinical (60, 407) 
SAMN05226621 6D92(H) clinical (60, 407) 
SAMN05226604 6D92(H) clinical (60, 407) 
SAMN05226603 6D92(H) clinical (60, 407) 
SAMN07423907 934436V clinical (60, 407) 
SAMN07424142 A3 clinical (60, 407) 
SAMN07424216 AA43 clinical (60, 407) 
SAMN07424217 AA44 clinical (60, 407) 
SAMN05226620 AF9A clinical (60, 407) 
SAMN07424009 AMT0005-1 clinical (60, 407) 
SAMN10478460 AMT0005-135 clinical (60, 407) 
SAMN10478461 AMT0005-136 clinical (60, 407) 
SAMN10478462 AMT0005-137 clinical (60, 407) 
SAMN07424010 AMT0005-138 clinical (60, 407) 
SAMN07424011 AMT0006-1 clinical (60, 407) 
SAMN10478463 AMT0006-64 clinical (60, 407) 
SAMN10478464 AMT0006-65 clinical (60, 407) 
SAMN07424012 AMT0006-66 clinical (60, 407) 
SAMN07424014 AMT0020-1 clinical (60, 407) 
SAMN10478465 AMT0020-83 clinical (60, 407) 
SAMN07424013 AMT0020-84 clinical (60, 407) 
SAMN10478466 AMT0026-1 clinical (60, 407) 
SAMN10478467 AMT0026-2 clinical (60, 407) 
SAMN07424015 AMT0026-3 clinical (60, 407) 
SAMN07424016 AMT0026-67 clinical (60, 407) 
SAMN07424017 AMT0046-1 clinical (60, 407) 
SAMN10478468 AMT0046-107 clinical (60, 407) 
SAMN10478469 AMT0046-108 clinical (60, 407) 
SAMN07424018 AMT0046-109 clinical (60, 407) 
SAMN10478470 AMT0047-125 clinical (60, 407) 
SAMN10478471 AMT0047-2 clinical (60, 407) 
SAMN07424019 AMT0071-76 clinical (60, 407) 
SAMN07423904 AT19 clinical (60, 407) 
SAMN07423905 AT31 clinical (60, 407) 
SAMN07423906 AT40 clinical (60, 407) 
SAMN07423903 AT7 clinical (60, 407) 
SAMN06320145 ATCC BAA-2108 clinical (60, 407) 
SAMN06320146 ATCC BAA-2109 clinical (60, 407) 
SAMN06320147 ATCC BAA-2110 clinical (60, 407) 





SAMN06320149 ATCC BAA-2112 clinical (60, 407) 
SAMN06320150 ATCC BAA-2113 clinical (60, 407) 
SAMN06320151 ATCC BAA-2114 clinical (60, 407) 
SAMN07424000 AUS021 clinical (60, 407) 
SAMN07423951 AUS026 clinical (60, 407) 
SAMN07423952 AUS029 clinical (60, 407) 
SAMN07423990 AUS050 clinical (60, 407) 
SAMN07423954 AUS054 clinical (60, 407) 
SAMN07423944 AUS058 clinical (60, 407) 
SAMN07423955 AUS066 clinical (60, 407) 
SAMN07423956 AUS073 clinical (60, 407) 
SAMN10478455 AUS074 clinical (60, 407) 
SAMN07423957 AUS077 clinical (60, 407) 
SAMN07423929 AUS083 clinical (60, 407) 
SAMN07423930 AUS088 clinical (60, 407) 
SAMN07423958 AUS089 clinical (60, 407) 
SAMN07423959 AUS093 clinical (60, 407) 
SAMN07423961 AUS105 clinical (60, 407) 
SAMN07423962 AUS106 clinical (60, 407) 
SAMN07423909 AUS127 clinical (60, 407) 
SAMN07423969 AUS148 clinical (60, 407) 
SAMN07423950 AUS304 clinical (60, 407) 
SAMN07424003 AUS305 clinical (60, 407) 
SAMN07423943 AUS327 clinical (60, 407) 
SAMN07423991 AUS434 clinical (60, 407) 
SAMN07423992 AUS436 clinical (60, 407) 
SAMN07423933 AUS476 clinical (60, 407) 
SAMN07423979 AUS489 clinical (60, 407) 
SAMN07423980 AUS491 clinical (60, 407) 
SAMN07423981 AUS496 clinical (60, 407) 
SAMN07423982 AUS499 clinical (60, 407) 
SAMN07423989 AUS537 clinical (60, 407) 
SAMN07423997 AUS595 clinical (60, 407) 
SAMN07423986 AUS631 clinical (60, 407) 
SAMN07423987 AUS674 clinical (60, 407) 
SAMN07423988 AUS675 clinical (60, 407) 
SAMN07423953 AUS702 clinical (60, 407) 
SAMN10478459 AUS717 clinical (60, 407) 
SAMN07424008 AUS719 clinical (60, 407) 
SAMN07424007 AUS720 clinical (60, 407) 
SAMN10478458 AUS727 clinical (60, 407) 
SAMN10478557 BJ2 clinical (60, 407) 





SAMN07424144 C3 clinical (60, 407) 
SAMN07424047 C3128 clinical (60, 407) 
SAMN07424041 C5311 clinical (60, 407) 
SAMN07424192 CF127 clinical (60, 407) 
SAMN07424191 CF27 clinical (60, 407) 
SAMN07424190 CF5 clinical (60, 407) 
SAMN07424119 DUN-001-2A clinical (60, 407) 
SAMN07424120 DUN-001-2B clinical (60, 407) 
SAMN07424121 DUN-001-3A clinical (60, 407) 
SAMN07424122 DUN-001-3B clinical (60, 407) 
SAMN07424123 DUN-001-4 clinical (60, 407) 
SAMN07424141 DUN-001A clinical (60, 407) 
SAMN07424117 DUN-001B clinical (60, 407) 
SAMN07424118 DUN-001C clinical (60, 407) 
SAMN07424127 DUN-002C clinical (60, 407) 
SAMN07424128 DUN-003B clinical (60, 407) 
SAMN07424129 DUN-004 clinical (60, 407) 
SAMN07424130 DUN-006 clinical (60, 407) 
SAMN07424131 DUN-007-2 clinical (60, 407) 
SAMN07424132 DUN-008 clinical (60, 407) 
SAMN07424133 DUN-009B clinical (60, 407) 
SAMN07424135 DUN-013 clinical (60, 407) 
SAMN07424137 DUN-015A clinical (60, 407) 
SAMN07424138 DUN-018 clinical (60, 407) 
SAMN07424140 DUN-024-1 clinical (60, 407) 
SAMN07424146 E2_H133420224 clinical (60, 407) 
SAMN05226618 E82A clinical (60, 407) 
SAMN05226619 EC22 clinical (60, 407) 
SAMN05226623 EC2A clinical (60, 407) 
SAMN05226629 F429 clinical (60, 407) 
SAMN05226607 F69A clinical (60, 407) 
SAMN05226606 F69A clinical (60, 407) 
SAMN10478558 FM4 clinical (60, 407) 
SAMN07424148 G2 clinical (60, 407) 
SAMN07424149 H3 clinical (60, 407) 
SAMN10478546 HCF100 clinical (60, 407) 
SAMN10478542 HCF19 clinical (60, 407) 
SAMN10478547 HCF238 clinical (60, 407) 
SAMN10478548 HCF331 clinical (60, 407) 
SAMN10478549 HCF336 clinical (60, 407) 
SAMN10478550 HCF367 clinical (60, 407) 
SAMN10478551 HCF410 clinical (60, 407) 





SAMN10478552 HCF5 clinical (60, 407) 
SAMN10478544 HCF55 clinical (60, 407) 
SAMN10478553 HCF591 clinical (60, 407) 
SAMN10478554 HCF73 clinical (60, 407) 
SAMN10478545 HCF86 clinical (60, 407) 
SAMN10478528 HJ2 clinical (60, 407) 
SAMN07424095 JD303 clinical (60, 407) 
SAMN07424163 LiP10a clinical (60, 407) 
SAMN07424164 LiP10b clinical (60, 407) 
SAMN07424165 LiP11 clinical (60, 407) 
SAMN07424166 LiP12 clinical (60, 407) 
SAMN07424167 LiP13 clinical (60, 407) 
SAMN07424168 LiP14 clinical (60, 407) 
SAMN07424150 LiP1a clinical (60, 407) 
SAMN07424151 LiP1c clinical (60, 407) 
SAMN07424152 LiP1d clinical (60, 407) 
SAMN07424153 LiP2a clinical (60, 407) 
SAMN07424154 LiP2b clinical (60, 407) 
SAMN07424155 LiP2c clinical (60, 407) 
SAMN07424156 LiP3 clinical (60, 407) 
SAMN07424157 LiP4 clinical (60, 407) 
SAMN07424158 LiP5 clinical (60, 407) 
SAMN07424159 LiP6 clinical (60, 407) 
SAMN07424160 LiP7 clinical (60, 407) 
SAMN07424161 LiP8 clinical (60, 407) 
SAMN07424162 LiP9 clinical (60, 407) 
SAMN10478525 MCF104 clinical (60, 407) 
SAMN10478522 MCF134 clinical (60, 407) 
SAMN10478523 MCF149 clinical (60, 407) 
SAMN10478524 MCF178 clinical (60, 407) 
SAMN10478526 MCF182 clinical (60, 407) 
SAMN07424242 MCF191 clinical (60, 407) 
SAMN10478527 MCF199 clinical (60, 407) 
SAMN10478516 MCF206 clinical (60, 407) 
SAMN07424243 MCF363 clinical (60, 407) 
SAMN10478518 MCF430 clinical (60, 407) 
SAMN07424244 MCF561 clinical (60, 407) 
SAMN10478519 MCF879 clinical (60, 407) 
SAMN10478520 MCF922 clinical (60, 407) 
SAMN07424100 MSB2949 clinical (60, 407) 
SAMN07424102 MSB3405 clinical (60, 407) 
SAMN10478560 NN5 clinical (60, 407) 





SAMN10478556 OY3 clinical (60, 407) 
SAMN10478204 PAC106A clinical (60, 407) 
SAMN10478200 PAC107A clinical (60, 407) 
SAMN10478230 PAC108A clinical (60, 407) 
SAMN10478198 PAC10A clinical (60, 407) 
SAMN10478199 PAC10B clinical (60, 407) 
SAMN10478249 PAC112A clinical (60, 407) 
SAMN10478231 PAC115A clinical (60, 407) 
SAMN10478208 PAC117A clinical (60, 407) 
SAMN10478209 PAC117B clinical (60, 407) 
SAMN10478232 PAC118A clinical (60, 407) 
SAMN10478201 PAC11A clinical (60, 407) 
SAMN10478245 PAC127A clinical (60, 407) 
SAMN10478246 PAC127B clinical (60, 407) 
SAMN10478205 PAC13A clinical (60, 407) 
SAMN10478206 PAC13B clinical (60, 407) 
SAMN10478207 PAC13C clinical (60, 407) 
SAMN10478210 PAC14B clinical (60, 407) 
SAMN10478211 PAC15A clinical (60, 407) 
SAMN10478212 PAC15B clinical (60, 407) 
SAMN10478213 PAC17A clinical (60, 407) 
SAMN10478216 PAC18A clinical (60, 407) 
SAMN10478217 PAC18B clinical (60, 407) 
SAMN10478222 PAC22A clinical (60, 407) 
SAMN10478225 PAC23A clinical (60, 407) 
SAMN10478233 PAC31A clinical (60, 407) 
SAMN10478234 PAC31B clinical (60, 407) 
SAMN10478218 PAC33A clinical (60, 407) 
SAMN10478219 PAC33B clinical (60, 407) 
SAMN10478243 PAC38A clinical (60, 407) 
SAMN10478244 PAC38B clinical (60, 407) 
SAMN10478192 PAC39A clinical (60, 407) 
SAMN10478235 PAC42A clinical (60, 407) 
SAMN10478226 PAC44A clinical (60, 407) 
SAMN10478227 PAC44B clinical (60, 407) 
SAMN10478228 PAC44C clinical (60, 407) 
SAMN10478229 PAC44D clinical (60, 407) 
SAMN10478188 PAC46A clinical (60, 407) 
SAMN10478185 PAC54A clinical (60, 407) 
SAMN10478214 PAC56A clinical (60, 407) 
SAMN10478215 PAC56B clinical (60, 407) 
SAMN10478186 PAC5A clinical (60, 407) 





SAMN10478247 PAC60A clinical (60, 407) 
SAMN10478189 PAC61A clinical (60, 407) 
SAMN10478190 PAC6A clinical (60, 407) 
SAMN10478191 PAC6B clinical (60, 407) 
SAMN10478236 PAC70A clinical (60, 407) 
SAMN10478237 PAC70B clinical (60, 407) 
SAMN10478193 PAC74A clinical (60, 407) 
SAMN10478248 PAC76A clinical (60, 407) 
SAMN10478220 PAC78A clinical (60, 407) 
SAMN10478221 PAC78B clinical (60, 407) 
SAMN10478202 PAC79A clinical (60, 407) 
SAMN10478203 PAC79B clinical (60, 407) 
SAMN10478238 PAC80A clinical (60, 407) 
SAMN10478250 PAC81A clinical (60, 407) 
SAMN10478251 PAC81B clinical (60, 407) 
SAMN10478223 PAC84A clinical (60, 407) 
SAMN10478252 PAC91A clinical (60, 407) 
SAMN10478194 PAC93A clinical (60, 407) 
SAMN10478195 PAC93B clinical (60, 407) 
SAMN10478196 PAC93C clinical (60, 407) 
SAMN10478224 PAC94A clinical (60, 407) 
SAMN10478253 PAC95A clinical (60, 407) 
SAMN10478254 PAC95B clinical (60, 407) 
SAMN10478255 PAC97A clinical (60, 407) 
SAMN10478239 PAC98A clinical (60, 407) 
SAMN10478240 PAC98B clinical (60, 407) 
SAMN10478241 PAC98C clinical (60, 407) 
SAMN10478242 PAC98D clinical (60, 407) 
SAMN10478197 PAC9A clinical (60, 407) 
SAMN10478531 PD1 clinical (60, 407) 
SAMN07424101 S1983 clinical (60, 407) 
SAMN07424097 S2239_15 clinical (60, 407) 
SAMN07424098 S2239_16 clinical (60, 407) 
SAMN07424099 S2820 clinical (60, 407) 
SAMN10478559 SC1 clinical (60, 407) 
SAMN10478566 SMC1585 clinical (60, 407) 
SAMN10478567 SMC1587 clinical (60, 407) 
SAMN10478568 SMC1595 clinical (60, 407) 
SAMN10478569 SMC1596 clinical (60, 407) 
SAMN10478570 SMC5450 clinical (60, 407) 
SAMN10478571 SMC5451 clinical (60, 407) 
SAMN10478530 SS1 clinical (60, 407) 





SAMN07424104 U0284 clinical (60, 407) 
SAMN07424105 U0288B clinical (60, 407) 
SAMN07424106 U0306 clinical (60, 407) 
SAMN07424107 U0310A clinical (60, 407) 
SAMN07424108 U0330A clinical (60, 407) 
SAMN07424109 U350 clinical (60, 407) 
SAMN07424110 U372 clinical (60, 407) 
SAMN07424111 U397A clinical (60, 407) 
SAMN07424112 U413A clinical (60, 407) 
SAMN07424113 U421 clinical (60, 407) 
SAMN07424114 U435 clinical (60, 407) 
SAMN07424115 U451 clinical (60, 407) 
SAMN07424116 U454A clinical (60, 407) 
SAMN10478539 Zw115 clinical (60, 407) 
SAMN10478533 Zw31 clinical (60, 407) 
SAMN10478534 Zw49 clinical (60, 407) 
SAMN10478540 Zw5 clinical (60, 407) 
SAMN10478535 Zw64 clinical (60, 407) 
SAMN10478562 Zw64_2 clinical (60, 407) 
SAMN10478541 Zw70 clinical (60, 407) 
SAMN10478565 Zw73_1 clinical (60, 407) 
SAMN10478563 Zw73_2 clinical (60, 407) 
SAMN10478564 Zw75_2 clinical (60, 407) 
SAMN10478538 Zw9 clinical (60, 407) 
SAMN11606715 PAO1 lab reference (135) 
SAMN11606716 PAO1(6) lab control (135) 
SAMN11606717 T1 experimental evolution (135) 
SAMN11606718 T2 experimental evolution (135) 
SAMN11606719 T3 experimental evolution (135) 
SAMN11606720 T4 experimental evolution (135) 
SAMN11606721 T5 experimental evolution (135) 
SAMN11606722 T6 experimental evolution (135) 
SAMN11606723 T7 experimental evolution (135) 
SAMN11606724 T8 experimental evolution (135) 
SAMN11606725 T9 experimental evolution (135) 
SAMN11606726 T10 experimental evolution (135) 
SAMN11606727 T11 experimental evolution (135) 
SAMN11606728 T12 experimental evolution (135) 
SAMN11606729 T13 experimental evolution (135) 
SAMN11606730 M1 experimental evolution (135) 
SAMN11606731 M2 experimental evolution (135) 
SAMN11606732 M3 experimental evolution (135) 





SAMN11606734 M5 experimental evolution (135) 
SAMN11606735 M6 experimental evolution (135) 
SAMN11606736 M7 experimental evolution (135) 
SAMN11606737 M8 experimental evolution (135) 
SAMN11606738 M9 experimental evolution (135) 
SAMN11606739 M10 experimental evolution (135) 
SAMN11606740 M11 experimental evolution (135) 
SAMN11606741 M12 experimental evolution (135) 
SAMN11606742 M13 experimental evolution (135) 
SAMN11606743 C1 experimental evolution (135) 
SAMN11606744 C2 experimental evolution (135) 
SAMN11606745 C3 experimental evolution (135) 
SAMN11606746 C4 experimental evolution (135) 
SAMN11606747 C5 experimental evolution (135) 
SAMN11606748 C6 experimental evolution (135) 
SAMN11606749 C7 experimental evolution (135) 
SAMN11606750 C8 experimental evolution (135) 
SAMN11606751 C9 experimental evolution (135) 
SAMN11606752 C10 experimental evolution (135) 
SAMN11606753 C11 experimental evolution (135) 
SAMN11606754 C12 experimental evolution (135) 
SAMN11606755 C13 experimental evolution (135) 
SAMN11606756 BAXA_008A1 clinical (135) 
SAMN11606757 BEHO_003A1 clinical (135) 
SAMN11606758 DUN_021A3 clinical (135) 
SAMN11606759 LINA_007A1 clinical (135) 
SAMN11606760 STCA_006A2 clinical (135) 
SAMN11606761 ORME_001A1 clinical (135) 
PRJEB14952 A1 clinical (239) 
PRJEB14952 A2 clinical (239) 
PRJEB14952 A3 clinical (239) 
PRJEB14952 A12 clinical (239) 
PRJEB14952 A19 clinical (239) 
PRJEB14952 A36 clinical (239) 
PRJEB14952 A46 clinical (239) 
PRJEB14952 A100 clinical (239) 
PRJEB14952 A106 clinical (239) 
PRJEB14952 A119 clinical (239) 
PRJEB14952 A163 clinical (239) 
PRJEB14952 B3 clinical (239) 
PRJEB14952 B16 clinical (239) 
PRJEB14952 B34 clinical (239) 





PRJEB14952 B62 clinical (239) 
PRJEB14952 B113 clinical (239) 
PRJEB14952 B114 clinical (239) 
PRJEB14952 B199 clinical (239) 
PRJEB14952 C2 clinical (239) 
PRJEB14952 C3 clinical (239) 
PRJEB14952 C6 clinical (239) 
PRJEB14952 C7 clinical (239) 
PRJEB14952 C8 clinical (239) 
PRJEB14952 C10 clinical (239) 
PRJEB14952 C11 clinical (239) 
PRJEB14952 C12 clinical (239) 
PRJEB14952 C13 clinical (239) 
PRJEB14952 C18 clinical (239) 
PRJEB14952 C20 clinical (239) 
PRJEB14952 C21 clinical (239) 
PRJEB14952 C25 clinical (239) 
PRJEB14952 C29 clinical (239) 
PRJEB14952 C30 clinical (239) 
PRJEB14952 C31 clinical (239) 
PRJEB14952 C36 clinical (239) 
PRJEB14952 C42 clinical (239) 
PRJEB14952 C43 clinical (239) 
PRJEB14952 C49 clinical (239) 
PRJEB14952 C51 clinical (239) 
PRJEB14952 C54 clinical (239) 
PRJEB14952 C55 clinical (239) 
PRJEB14952 C61 clinical (239) 
PRJEB14952 C63 clinical (239) 
PRJEB14952 C64 clinical (239) 
PRJEB14952 C69 clinical (239) 
PRJEB14952 C71 clinical (239) 
PRJEB14952 C73 clinical (239) 
PRJEB14952 C74 clinical (239) 
PRJEB14952 C76 clinical (239) 
PRJEB14952 C77 clinical (239) 
PRJEB14952 C78 clinical (239) 
PRJEB14952 C79 clinical (239) 
PRJEB14952 C86 clinical (239) 
PRJEB14952 C87 clinical (239) 
PRJEB14952 C88 clinical (239) 
PRJEB14952 C89 clinical (239) 





PRJEB14952 C92 clinical (239) 
PRJEB14952 C94 clinical (239) 
PRJEB14952 C95 clinical (239) 
PRJEB14952 C100 clinical (239) 
PRJEB14952 C101 clinical (239) 
PRJEB14952 C104 clinical (239) 
PRJEB14952 C105 clinical (239) 
PRJEB14952 C107 clinical (239) 
PRJEB14952 C108 clinical (239) 
PRJEB14952 C109 clinical (239) 
PRJEB14952 C110 clinical (239) 
PRJEB14952 C114 clinical (239) 
PRJEB14952 C116 clinical (239) 
PRJEB14952 C119 clinical (239) 
PRJEB14952 C120 clinical (239) 
PRJEB14952 C123 clinical (239) 
PRJEB14952 C124 clinical (239) 
PRJEB14952 C125 clinical (239) 
PRJEB14952 C127 clinical (239) 
PRJEB14952 C129 clinical (239) 
PRJEB14952 C131 clinical (239) 
PRJEB14952 C133 clinical (239) 
PRJEB14952 C134 clinical (239) 
PRJEB14952 C135 clinical (239) 
PRJEB14952 C137 clinical (239) 
PRJEB14952 C139 clinical (239) 
PRJEB14952 C141 clinical (239) 
PRJEB14952 C142 clinical (239) 
PRJEB14952 C143 clinical (239) 
PRJEB14952 C146 clinical (239) 
PRJEB14952 C149 clinical (239) 
PRJEB14952 C150 clinical (239) 
PRJEB14952 C151 clinical (239) 
PRJEB14952 C153 clinical (239) 
PRJEB14952 C155 clinical (239) 
PRJEB14952 C156 clinical (239) 
PRJEB14952 C158 clinical (239) 
PRJEB14952 C159 clinical (239) 
PRJEB14952 C160 clinical (239) 
PRJEB14952 C161 clinical (239) 
PRJEB14952 C164 clinical (239) 
PRJEB14952 C167 clinical (239) 





SAMN07424042 59.2 environmental (60, 407) 
SAMN10478502 62 environmental (60, 407) 
SAMN10478256 18G environmental (60, 407) 
SAMN10478259 19R environmental (60, 407) 
SAMN10478257 19SJO environmental (60, 407) 
SAMN10478258 19SJV environmental (60, 407) 
SAMN10478260 19SV environmental (60, 407) 
SAMN10478262 32SB environmental (60, 407) 
SAMN10478261 32SP environmental (60, 407) 
SAMN10478263 34JS environmental (60, 407) 
SAMN05226611 3C1A environmental (60, 407) 
SAMN10478265 57RV environmental (60, 407) 
SAMN10478264 57SJ environmental (60, 407) 
SAMN10478266 78RV environmental (60, 407) 
SAMN10478427 AUS110 environmental (60, 407) 
SAMN10478429 AUS122 environmental (60, 407) 
SAMN10478430 AUS125 environmental (60, 407) 
SAMN10478431 AUS128 environmental (60, 407) 
SAMN10478432 AUS136 environmental (60, 407) 
SAMN10478433 AUS139 environmental (60, 407) 
SAMN10478435 AUS141 environmental (60, 407) 
SAMN10478436 AUS153 environmental (60, 407) 
SAMN10478437 AUS155 environmental (60, 407) 
SAMN10478438 AUS156 environmental (60, 407) 
SAMN10478439 AUS157 environmental (60, 407) 
SAMN10478440 AUS158 environmental (60, 407) 
SAMN10478441 AUS174 environmental (60, 407) 
SAMN10478442 AUS175 environmental (60, 407) 
SAMN10478443 AUS176 environmental (60, 407) 
SAMN10478444 AUS177 environmental (60, 407) 
SAMN10478445 AUS178 environmental (60, 407) 
SAMN07423914 AUS195 environmental (60, 407) 
SAMN10478413 AUS209 environmental (60, 407) 
SAMN10478414 AUS214 environmental (60, 407) 
SAMN07423922 AUS217 environmental (60, 407) 
SAMN10478415 AUS221 environmental (60, 407) 
SAMN10478417 AUS222 environmental (60, 407) 
SAMN10478419 AUS226 environmental (60, 407) 
SAMN10478420 AUS227 environmental (60, 407) 
SAMN10478418 AUS258 environmental (60, 407) 
SAMN10478425 AUS265 environmental (60, 407) 
SAMN10478423 AUS277 environmental (60, 407) 





SAMN10478434 AUS311 environmental (60, 407) 
SAMN07423938 AUS321 environmental (60, 407) 
SAMN07423941 AUS328 environmental (60, 407) 
SAMN07423939 AUS339 environmental (60, 407) 
SAMN07423931 AUS343 environmental (60, 407) 
SAMN07423947 AUS355 environmental (60, 407) 
SAMN07423918 AUS438 environmental (60, 407) 
SAMN10478454 AUS449 environmental (60, 407) 
SAMN10478421 AUS452 environmental (60, 407) 
SAMN10478446 AUS464 environmental (60, 407) 
SAMN07423917 AUS465 environmental (60, 407) 
SAMN10478447 AUS500 environmental (60, 407) 
SAMN10478448 AUS501 environmental (60, 407) 
SAMN07423921 AUS502 environmental (60, 407) 
SAMN07423960 AUS503 environmental (60, 407) 
SAMN07423942 AUS504 environmental (60, 407) 
SAMN10478449 AUS505 environmental (60, 407) 
SAMN07423970 AUS506 environmental (60, 407) 
SAMN07423983 AUS507 environmental (60, 407) 
SAMN10478450 AUS510 environmental (60, 407) 
SAMN10478451 AUS511 environmental (60, 407) 
SAMN10478452 AUS512 environmental (60, 407) 
SAMN10478422 AUS516 environmental (60, 407) 
SAMN07423937 AUS517 environmental (60, 407) 
SAMN07423913 AUS518 environmental (60, 407) 
SAMN10478426 AUS523 environmental (60, 407) 
SAMN10478416 AUS525 environmental (60, 407) 
SAMN10478453 AUS526 environmental (60, 407) 
SAMN10478424 AUS527 environmental (60, 407) 
SAMN07424026 Co398373 environmental (60, 407) 
SAMN07424086 Cotonu1 environmental (60, 407) 
SAMN07424245 E1-WATER-2 environmental (60, 407) 
SAMN07424189 E2 environmental (60, 407) 
SAMN07424246 E2-DN-2 environmental (60, 407) 
SAMN05226612 E42A(B) environmental (60, 407) 
SAMN07424247 F1-DN-2 environmental (60, 407) 
SAMN05226615 F462 environmental (60, 407) 
SAMN05226613 FA0A environmental (60, 407) 
SAMN07424248 G1-WATER-2A environmental (60, 407) 
SAMN10478529 H2 environmental (60, 407) 
SAMN10478473 Jp100 environmental (60, 407) 
SAMN07424069 Jp1140 environmental (60, 407) 





SAMN10478478 Jp1170 environmental (60, 407) 
SAMN10478479 Jp1200 environmental (60, 407) 
SAMN10478480 Jp1206 environmental (60, 407) 
SAMN10478481 Jp1303 environmental (60, 407) 
SAMN10478474 Jp222 environmental (60, 407) 
SAMN07424067 Jp224 environmental (60, 407) 
SAMN10478475 Jp238 environmental (60, 407) 
SAMN10478476 Jp241 environmental (60, 407) 
SAMN07424065 Jp54 environmental (60, 407) 
SAMN10478472 Jp60 environmental (60, 407) 
SAMN07424066 Jp97 environmental (60, 407) 
SAMN07424201 JYH10 environmental (60, 407) 
SAMN10478507 JYH11 environmental (60, 407) 
SAMN07424202 JYH12 environmental (60, 407) 
SAMN10478508 JYH13 environmental (60, 407) 
SAMN07424203 JYH14 environmental (60, 407) 
SAMN10478509 JYH15 environmental (60, 407) 
SAMN07424204 JYH16 environmental (60, 407) 
SAMN10478510 JYH17 environmental (60, 407) 
SAMN07424205 JYH18 environmental (60, 407) 
SAMN10478511 JYH19 environmental (60, 407) 
SAMN10478512 JYH21 environmental (60, 407) 
SAMN07424206 JYH22 environmental (60, 407) 
SAMN10478513 JYH23 environmental (60, 407) 
SAMN07424207 JYH24 environmental (60, 407) 
SAMN10478514 JYH25 environmental (60, 407) 
SAMN07424208 JYH26 environmental (60, 407) 
SAMN07424209 JYH28 environmental (60, 407) 
SAMN10478515 JYH29 environmental (60, 407) 
SAMN07424199 JYH6 environmental (60, 407) 
SAMN10478505 JYH7 environmental (60, 407) 
SAMN07424200 JYH8 environmental (60, 407) 
SAMN10478506 JYH9 environmental (60, 407) 
SAMN07424087 LMG2107 environmental (60, 407) 
SAMN07424088 LMG5031 environmental (60, 407) 
SAMN07424039 Mex2 environmental (60, 407) 
SAMN10478504 MSH10 environmental (60, 407) 
SAMN10478503 MSH3 environmental (60, 407) 
SAMN10478267 PA-CL501 environmental (60, 407) 
SAMN10478268 PA-CL502 environmental (60, 407) 
SAMN10478269 PA-CL504 environmental (60, 407) 
SAMN10478270 PA-CL505 environmental (60, 407) 





SAMN10478272 PA-CL507 environmental (60, 407) 
SAMN10478273 PA-CL508 environmental (60, 407) 
SAMN10478274 PA-CL509 environmental (60, 407) 
SAMN10478275 PA-CL510 environmental (60, 407) 
SAMN10478276 PA-CL511 environmental (60, 407) 
SAMN10478277 PA-CL512 environmental (60, 407) 
SAMN10478278 PA-CL513 environmental (60, 407) 
SAMN10478279 PA-CL514 environmental (60, 407) 
SAMN10478280 PA-CL515 environmental (60, 407) 
SAMN10478281 PA-CL516 environmental (60, 407) 
SAMN10478282 PA-CL517 environmental (60, 407) 
SAMN10478283 PA-CL518 environmental (60, 407) 
SAMN10478284 PA-CL519 environmental (60, 407) 
SAMN10478285 PA-CL520 environmental (60, 407) 
SAMN10478286 PA-CL521a environmental (60, 407) 
SAMN10478287 PA-CL521b environmental (60, 407) 
SAMN10478288 PA-CL522b environmental (60, 407) 
SAMN10478289 PA-CL524 environmental (60, 407) 
SAMN10478290 PA-CL527 environmental (60, 407) 
SAMN10478291 PA-CL528 environmental (60, 407) 
SAMN10478292 PA-CL529 environmental (60, 407) 
SAMN10478294 PA-CL534a environmental (60, 407) 
SAMN10478295 PA-CL534x environmental (60, 407) 
SAMN10478296 PA-CL542a environmental (60, 407) 
SAMN10478297 PA-CL542b environmental (60, 407) 
SAMN10478298 PA-CL545b environmental (60, 407) 
SAMN10478299 PA-CL547b environmental (60, 407) 
SAMN10478300 PA-CL549 environmental (60, 407) 
SAMN07424094 Pae110 environmental (60, 407) 
SAMN10478537 PT12 environmental (60, 407) 
SAMN07424091 PT31M environmental (60, 407) 
SAMN10478536 PT6 environmental (60, 407) 
SAMN07424021 PUPa3 environmental (60, 407) 
SAMN07424020 Rsan-ver environmental (60, 407) 
SAMN07424040 SWPA15J=NSWPA15a environmental (60, 407) 
SAMN07424062 Tu61 environmental (60, 407) 
SAMN10478482 W15Apr4 environmental (60, 407) 
SAMN10478483 W15Aug23 environmental (60, 407) 
SAMN10478484 W15Dec14 environmental (60, 407) 
SAMN10478485 W15Dec4 environmental (60, 407) 
SAMN10478486 W15Okt31 environmental (60, 407) 
SAMN07424080 W5Aug16 environmental (60, 407) 

















Table 8.2|Differences between Pseudomonas aeruginosa PAO1 and PAO1-Otago used in this study 
Genome 
position 
Mutation Annotation Gene(s) affected Description 
169,284 Δ1 bp intergenic (+121/-77) PA0148/PA0149 adenosine deaminase/ECF subfamily sigma-70 factor 
183,697 T→G C310W (TGT→TGG)  PA0159 transcriptional regulator 
411,130 (C)5→4 intergenic (-196/-94) PA0366/PA0367 coniferyl aldehyde dehydrogenase/transcriptional regulator 
413,850 T→C intergenic (-523/+83) PA0368/PA0370 hypothetical protein/hypothetical protein 
667,029 +C intergenic (+35/-79) PA0604/PA0605 ABC transporter/ABC transporter permease 
721,611 C→T intergenic (+55/-485) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
721,622 C→T intergenic (+66/-474) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
721,663 2 bp→CT intergenic (+107/-432) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
721,667 A→G intergenic (+111/-429) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
721,670 A→G intergenic (+114/-426) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
721,725 C→T intergenic (+169/-371) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
740,419 +C coding (217/1146 nt) PA0683 type II secretion system protein 
816,532 +C intergenic (-520/-550) PA0747/PA0749 aldehyde dehydrogenase/hypothetical protein 
891,100 +C intergenic (-246/+42) PA0812/PA0813 hypothetical protein/hypothetical protein 
1,116,213 +C intergenic (+153/-422) PA1028/PA1030 oxidoreductase/hypothetical protein 
1,215,659 +G intergenic (-585/+461) yfiR/PA1123 hypothetical protein/hypothetical protein 
1,275,768 Δ1 bp coding (31/2490 nt) napA nitrate reductase catalytic subunit 
1,440,625 Δ1 bp coding (1920/1971 nt) PA1327 protease 
1,445,357 +G intergenic (-86/+48) PA1332/PA1333 hypothetical protein/hypothetical protein 

















1,467,484 +G intergenic (-164/+4) PA1352/PA1353 hypothetical protein/hypothetical protein 
1,589,438 G→C G34A (GGC→GCC)  PA1459 chemotaxis-specific methylesterase 
1,835,045 +C coding (653/750 nt) masA enolase-phosphatase 
2,169,350 +G intergenic (-198/-114) exaA/exaB quinoprotein ethanol dehydrogenase/cytochrome C550 
2,186,927 +C intergenic (+11/-138) dhcB/atoB 
dehydrocarnitine CoA transferase subunit B/acetyl-CoA 
acetyltransferase 
2,195,462 (C)5→6 intergenic (-52/+32) PA2006/maiA 
major facilitator superfamily transporter/maleylacetoacetate 
isomerase 
2,239,547 T→G intergenic (-746/+755) PA2045/PA2047 
membrane protein insertion efficiency factor/transcriptional 
regulator 
2,239,555 +G intergenic (-754/+747) PA2045/PA2047 
membrane protein insertion efficiency factor/transcriptional 
regulator 
2,342,111 +T intergenic (-471/-382) PA2127/cupA1 hypothetical protein/fimbrial subunit CupA1 
2,355,771 +G intergenic (+163/-147) PA2138/PA2140 
multifunctional non-homologous end joining protein 
LigD/metallothionein 
2,356,684 Δ1 bp coding (517/549 nt) PA2141 hypothetical protein 
2,532,046 +C intergenic (-206/+13) chiC/PA2301 chitinase/hypothetical protein 
2,669,175 G→C P819A (CCG→GCG)  pvdJ pyoverdine biosynthesis protein PvdJ 
2,753,522 +C intergenic (-860/-1080) PA2450/PA2453 hypothetical protein/hypothetical protein 
2,807,708 Δ8 bp coding (240-247/1044 nt) mexT transcriptional regulator MexT 
2,807,982 T→A F172I (TTC→ATC)  mexT transcriptional regulator MexT 
2,808,193 T→A V242E (GTG→GAG)  mexT transcriptional regulator MexT 
3,016,845 +C intergenic (+246/+389) PA2667/PA2669 hypothetical protein/hypothetical protein 
3,083,196 +G intergenic (+3361/-2946) PA2726/PA2729 radical activating enzyme/hypothetical protein 
3,919,508 +C intergenic (-720/+266) PA3502/PA3504 hypothetical protein/aldehyde dehydrogenase 
4,212,201 A→G H636R (CAC→CGC)  PA3760 


















4,344,266 A→G L190L (CTT→CTC)  narK1 nitrite extrusion protein 1 
4,448,855 2 bp→GC intergenic (-113/+37) PA3969a/amn hypothetical protein/AMP nucleosidase 
4,539,469 +C intergenic (-966/-70) nrdR/PA4060 transcriptional regulator NrdR/hypothetical protein 
4,869,855 T→G E158D (GAA→GAC)  PA4341 transcriptional regulator 
4,888,194 +G intergenic (-688/-654) PA4359/PA4360a ferrous iron transporter A/hypothetical protein 
4,924,552 2 bp→GC coding (531-532/837 nt) PA4394  hypothetical protein 
5,033,101 +C coding (1614/1614 nt) PA4496  ABC transporter 
5,036,891 A→C intergenic (+83/-183) PA4499/PA4500 transcriptional regulator/ABC transporter 
5,071,550 Δ4 bp intergenic (+87/-1142) pilB/pilD 
type 4 fimbrial biogenesis protein PilB/type 4 prepilin 
peptidase PilD 
5,253,694 Δ1,006 bp   [PA4684]–[PA4685] [PA4684], [PA4685] 
5,472,416 +G intergenic (-374/-408) PA4874/osmE hypothetical protein/OsmE family transcriptional regulator 
5,655,230 (GGC)3→4 coding (675/972 nt) PA5024  hypothetical protein 
5,743,461 2 bp→GC coding (1292-1293/1680 nt) hutU  urocanate hydratase 
6,079,222 A→G L393L (CTA→CTG)  dgcB  dimethylglycine catabolism protein DgcB 
6,098,781 G→C G586G (GGG→GGC)  soxA  sarcosine oxidase subunit alpha 



















Table 8.3|Mutations identified in ciprofloxacin resistant experimentally evolved P. aeruginosa 
position mutation annotation gene description 
     
C1 
3,558,951 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,671 A→C H87P (CAC→CCC)  PA3491  electron transport complex subunit C 
5,071,248 300 bp→38 bp   [pilB] [pilB] 
5,115,085 Δ3 bp coding (804-806/1221 nt) obg  GTPase ObgE 
5,155,675 A→C T39P (ACC→CCC)  nfxB  transcriptional regulator NfxB 
5,574,227 G→A S87L (TCG→TTG)  parC  DNA topoisomerase IV subunit A 
     
C2 
2,807,288 Δ6 bp coding (90-95/1020 nt) PA2491 oxidoreductase 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491 electron transport complex subunit C 
5,104,882 Δ11 bp coding (362-372/426 nt) pilE  type 4 fimbrial biogenesis protein PilE 
5,155,682 A→C T39P (ACC→CCC)  nfxB transcriptional regulator NfxB 
5,573,229 G→A S87L (TCG→TTG)  parC DNA topoisomerase IV subunit A 
     
C3 
3,558,958 G→A T83I (ACC→ATC)  gyrA DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491 electron transport complex subunit C 
5,155,682 A→C T39P (ACC→CCC)  nfxB  transcriptional regulator NfxB 
5,573,229 G→A S87L (TCG→TTG)  parC  DNA topoisomerase IV subunit A 
     
C4 
417,560 Δ48 bp coding (36-83/1368 nt) ftsY  signal recognition particle receptor FtsY 
437,137 Δ12 bp coding (570-581/1035 nt) pilT  twitching motility protein PilT 
3,041,851 G→A G535D (GGC→GAC)  pfeA ferric enterobactin receptor 
3,558,958 G→A T83I (ACC→ATC)  gyrA DNA gyrase subunit A 

















4,725,754 Δ9 bp coding (1049-1057/2163 nt) fptA  Fe(III)-pyochelin outer membrane receptor 
5,155,682 A→C T39P (ACC→CCC)  nfxB  transcriptional regulator NfxB 
5,573,229 G→A S87L (TCG→TTG)  parC  DNA topoisomerase IV subunit A 
     
C5 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491 electron transport complex subunit C 
4,265,177 Δ17 bp coding (104-120/759 nt) pilF  type 4 fimbrial biogenesis protein PilF 
5,155,611 (GCTGGC)1→2 coding (44/564 nt) nfxB transcriptional regulator NfxB 
5,575,541 A→C V460G (GTC→GGC)  parE DNA topoisomerase IV subunit B 
5,618,179 Δ13 bp coding (347-359/957 nt) PA5001 hypothetical protein 
     
C6 
114,051 Δ13 bp coding (533-545/1293 nt) PA0093 hypothetical protein 
437,137 Δ12 bp coding (570-581/1035 nt) pilT  twitching motility protein PilT 
1,861,550 Δ12 bp coding (248-259/1299 nt) pscD type III export protein PscD 
3,041,851 G→A G535D (GGC→GAC)  pfeA ferric enterobactin receptor 
3,102,735 +GCT coding (818/1017 nt) pheS phenylalanine--tRNA ligase subunit alpha 
3,558,958 G→A T83I (ACC→ATC)  gyrA DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491 electron transport complex subunit C 
5,155,682 A→C T39P (ACC→CCC)  nfxB  transcriptional regulator NfxB 
5,573,229 G→A S87L (TCG→TTG)  parC  DNA topoisomerase IV subunit A 
     
C7 
2,995,197 Δ3,112 bp   [nuoM]–[PA2650] [nuoM], nuoN, [PA2650] 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491 electron transport complex subunit C 
4,265,177 Δ17 bp coding (104-120/759 nt) pilF  type 4 fimbrial biogenesis protein PilF 
5,155,611 (GCTGGC)1→2 coding (44/564 nt) nfxB transcriptional regulator NfxB 

















5,618,179 Δ13 bp coding (347-359/957 nt) PA5001 hypothetical protein 
     
C8 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491  electron transport complex subunit C 
4,265,177 Δ17 bp coding (104-120/759 nt) pilF  type 4 fimbrial biogenesis protein PilF 
5,155,611 (GCTGGC)1→2 coding (44/564 nt) nfxB  transcriptional regulator NfxB 
5,575,541 A→C V460G (GTC→GGC)  parE  DNA topoisomerase IV subunit B 
     
C9 
437,137 Δ12 bp coding (570-581/1035 nt) pilT  twitching motility protein PilT 
984,779 Δ12 bp coding (229-240/999 nt) aruE  succinylglutamate desuccinylase 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491  electron transport complex subunit C 
4,760,565 G→A T106I (ACC→ATC)  rpsH  30S ribosomal protein S8 
5,155,682 A→C T39P (ACC→CCC)  nfxB  transcriptional regulator NfxB 
5,573,229 G→A S87L (TCG→TTG)  parC  DNA topoisomerase IV subunit A 
     
C10 
471,409 Δ20 bp coding (320-339/444 nt) mexR  multidrug resistance operon repressor MexR 
3,296,744 Δ12 bp coding (371-382/1140 nt) PA2940  acyl-CoA thiolase 
3,557,371 G→A S612L (TCG→TTG)  gyrA  DNA gyrase subunit A 
3,558,965 C→A G81C (GGC→TGC)  gyrA  DNA gyrase subunit A 
6,120,241 Δ9 bp coding (810-818/882 nt) PA5438  transcriptional regulator 
     
C11 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491  electron transport complex subunit C 
5,156,131 A→C *188C (TGA→TGC)  nfxB  transcriptional regulator NfxB 

















5,678,924 (CGTCC)1→2 coding (795/1065 nt) pilM  type 4 fimbrial biogenesis protein PilM 
     
C12 
792,317 C→A P316P (CCC→CCA)  PA0724  phage coat protein A 
792,326 C→T P319P (CCC→CCT)  PA0724  phage coat protein A 
3,558,947 C→T D87N (GAC→AAC)  gyrA  DNA gyrase subunit A 
3,908,678 A→C H87P (CAC→CCC)  PA3491  electron transport complex subunit C 
5,156,131 A→C *188C (TGA→TGC)  nfxB  transcriptional regulator NfxB 
5,331,818 (C)6→7 coding (685/756 nt) tpiA  triosephosphate isomerase 
     
C13 
792,124 G→A G252D (GGC→GAC)  PA0724  phage coat protein A 
3,101,612 Δ6 bp coding (885-890/2379 nt) pheT  phenylalanine--tRNA ligase subunit beta 
3,558,958 G→A T83I (ACC→ATC)  gyrA  DNA gyrase subunit A 
5,094,347 Δ14 bp coding (963-976/1593 nt) pilS  two-component sensor PilS 
5,155,674 G→A S36N (AGC→AAC)  nfxB  transcriptional regulator NfxB 
6,023,221 Δ10 bp coding (310-319/756 nt) glcC  




















Table 8.4|Mutations identified in meropenem resistant experimentally evolved P. aeruginosa  
position mutation annotation gene description 
     
M1 
471,366 G→A Q128* (CAG→TAG)  mexR multidrug resistance operon repressor MexR 
1,044,110 A→G S403P (TCC→CCC)  oprD porin D 
2,176,372 Δ266,340 bp   [pqqH]–PA2220 Δ231 genes 
3,106,354 T→C K136E (AAG→GAG)  thrS threonine--tRNA ligase 
4,220,964 G→A W372* (TGG→TGA)  PA3764 membrane-bound lytic murein transglycosylase F 
4,952,745 C→A V537L (GTG→TTG)  ftsI  penicillin-binding protein 3 
     
M2 
1,044,791 C→A E176* (GAG→TAG)  oprD  porin D 
1,951,368 Δ6 bp coding (359-364/1287 nt) parS  two-component sensor ParS 
4,167,109 C→G S195W (TCG→TGG)  nalC  transcriptional regulator 
6,005,058 G→T R52L (CGC→CTC)  rpoZ  DNA-directed RNA polymerase subunit omega 
6,005,575 Δ12 bp coding (340-351/2106 nt) spoT  guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase 
     
M3 
1,044,376 C→T G314D (GGC→GAC)  oprD  porin D 
1,945,093 C→T A114V (GCC→GTC)  cysS  cysteine--tRNA ligase 
4,006,549 C→A T11N (ACC→AAC)  nalD  transcriptional regulator 
4,166,679 +C coding (154/642 nt) nalC  transcriptional regulator 
     
M4 
1,044,253 +T coding (1064/1332 nt) oprD  porin D 
2,213,752 Δ225,261 bp   [PA2022]–[PA2217] Δ196 genes 
3,896,235 T→A L302Q (CTG→CAG)  metG  methionine--tRNA ligase 
4,166,679 +C coding (154/642 nt) nalC  transcriptional regulator 

















5,331,818 (C)6→5 coding (685/756 nt) tpiA  triosephosphate isomerase 
     
M5 
718,522 Δ10 bp coding (195-204/1092 nt) PA0666  anhydro-N-acetylmuramic acid kinase 
1,044,368 C→G G317R (GGC→CGC)  oprD  porin D 
4,166,679 +C coding (154/642 nt) nalC  transcriptional regulator 
5,690,178 G→A A404T (GCC→ACC)  argS  arginine--tRNA ligase 
     
M6 
794,707 C→G L69L (CTC→CTG)  PA0727  hypothetical protein 
1,279,143 T→G V260G (GTC→GGC)  phoQ  two-component sensor PhoQ 
1,736,425 Δ1,801 bp   [PA1595]–[htpG] [PA1595], [htpG] 
4,006,993 C→A P159Q (CCG→CAG)  nalD  transcriptional regulator 
4,227,193 T→A Q18L (CAG→CTG)  guaA  GMP synthase 
5,480,160 +T coding (89/1392 nt) PA4886  two-component sensor 
     
M7 
1,044,565 G→T S251* (TCG→TAG)  oprD  porin D 
4,166,571 +T coding (46/642 nt) nalC  transcriptional regulator 
4,767,743 (C)5→4 intergenic (-80/+77) rpsJ/tufA 30S ribosomal protein S10/elongation factor Tu 
5,643,016 G→A G71D (GGT→GAT)  msrA peptide methionine sulfoxide reductase 
5,673,740 C→T D134N (GAC→AAC)  aroB 3-dehydroquinate synthase 
     
M8 
13,334 G→C D34E (GAC→GAG)  glyQ  glycine--tRNA ligase subunit alpha 
1,045,300 C→T W6* (TGG→TAG)  oprD  porin D 
1,976,265 Δ479,450 bp   [ldcA]–[pslB] Δ415 genes 
5,064,960 Δ1 bp coding (392/567 nt) ampD  N-acetyl-anhydromuranmyl-L-alanine amidase 


















1,044,904 Δ1 bp coding (413/1332 nt) oprD  porin D 
2,214,413 Δ1,986 bp   [PA2022]–[PA2024] [PA2022], galU, [PA2024] 
4,166,396 T→C intergenic (-75/-130) PA3720/nalC hypothetical protein/transcriptional regulator 
     
M10 
1,044,650 A→G S223P (TCC→CCC)  oprD porin D 
1,980,978 Δ462,920 bp   [PA1821]–[PA2221] Δ401 genes 
3,529,234 (C)9→10 coding (221/1020 nt) wbpL glycosyltransferase WbpL 
4,006,989 A→C T158P (ACC→CCC)  nalD transcriptional regulator 
     
M11 
471,930 C→T intergenic (-183/-92) mexR/mexA 
multidrug resistance operon repressor MexR/multidrug 
resistance protein MexA 
2,150,774 Δ276,726 bp   [PA1968]–[PA2208] Δ241 genes 
3,164,199 G→T E271* (GAA→TAA)  copS two-component sensor CopS 
4,952,942 A→C V471G (GTG→GGG)  ftsI penicillin-binding protein 3 
     
M12 
471,339 G→A Q137* (CAG→TAG)  mexR  multidrug resistance operon repressor MexR 
1,044,170 Δ1 bp coding (1147/1332 nt) oprD  porin D 
1,044,171 G→T Y382* (TAC→TAA)  oprD  porin D 
1,277,787 G→C A33P (GCC→CCC)  phoP  two-component response regulator PhoP 
1,279,683 Δ536 bp   [phoQ]–[PA1181] [phoQ], [PA1181] 
4,952,942 A→C V471G (GTG→GGG)  ftsI  penicillin-binding protein 3 
5,673,847 A→T I98N (ATC→AAC)  aroB  3-dehydroquinate synthase 
     
M13 

















3,790,118 +TG intergenic (-14/+39) PA3383/phnC 
phosphonate ABC transporter substrate-binding 
protein/phosphonate ABC transporter ATP-binding 
protein 
4,166,571 +T coding (46/642 nt) nalC transcriptional regulator 
4,767,743 (C)5→4 intergenic (-80/+77) rpsJ/tufA 30S ribosomal protein S10/elongation factor Tu 
5,643,016 G→A G71D (GGT→GAT)  msrA peptide methionine sulfoxide reductase 



















Table 8.5|Mutations identified in tobramycin resistant experimentally evolved P. aeruginosa  
position mutation annotation gene description 
     
T1 
4,770,866 T→C E100G (GAG→GGG)  fusA1  elongation factor G 
5,706,761 Δ12 bp coding (521-532/804 nt) tatC  transporter TatC 
     
T2 
1,690,274 C→T W82* (TGG→TAG)  ccoP1  cytochrome C oxidase cbb3-type subunit CcoP 
1,911,273 (ATGATC)2→3 coding (945/1527 nt) PA1767  hypothetical protein 
2,988,555 Δ191 bp coding (830-1020/2718 nt) nuoG  NADH-quinone oxidoreductase subunit G 
4,289,998 G→A E350K (GAA→AAA)  pepA  leucyl aminopeptidase 
4,770,866 T→C E100G (GAG→GGG)  fusA1  elongation factor G 
5,617,932 G→T S202R (AGC→AGA)  PA5001  hypothetical protein 
          
T3 
3,529,234 (C)9→8 coding (221/1020 nt) wbpL glycosyltransferase WbpL 
4,166,679 +C coding (154/642 nt) nalC transcriptional regulator 
4,754,495 Δ1 bp coding (939/1002 nt) rpoA DNA-directed RNA polymerase subunit alpha 
4,769,127 G→A R680C (CGC→TGC)  fusA1 elongation factor G 
1691258 Δ3432  [ccoO1]–[ccoO2] [ccoO1], ccoN1, ccoP2, ccoQ2, [ccoO2] 
     
T4 
1,911,268 (ATGATC)2→1 coding (945-950/1527 nt) PA1767  hypothetical protein 
3,529,234 (C)9→8 coding (221/1020 nt) wbpL  glycosyltransferase WbpL 
4,166,679 +C coding (154/642 nt) nalC  transcriptional regulator 
4,769,127 G→A R680C (CGC→TGC)  fusA1  elongation factor G 

















          
T5 
432,478 C→T R449Q (CGG→CAG)  PA0391  hypothetical protein 
1,278,880 Δ1 bp coding (516/1347 nt) phoQ  two-component sensor PhoQ 
2,210,457 C→T G287S (GGC→AGC)  PA2018  multidrug efflux protein MexY 
3,529,234 (C)9→8 coding (221/1020 nt) wbpL  glycosyltransferase WbpL 
4,769,132 T→A Q678L (CAG→CTG)  fusA1  elongation factor G 
5,850,423 G→A P381S (CCC→TCC)  amgS  protein AmgS 
6,218,881 Δ12 bp   [PA5528] [PA5528] 
1,690,964 Δ3449   [ccoO1]–[ccoO2] [ccoO1], ccoN1, ccoP2, ccoQ2, [ccoO2] 
     
T6 
1,685,948 (GCCGCGGTG)1→2 coding (1434/2436 nt) PA1549  cation-transporting P-type ATPase 
4,769,127 G→A R680C (CGC→TGC)  fusA1  elongation factor G 
4,769,852 A→T L438Q (CTG→CAG)  fusA1  elongation factor G 
     
T7 
3,525,453 Δ1 bp coding (1233/1998 nt) wbpM  nucleotide sugar epimerase/dehydratase WbpM 
4,769,154 T→C T671A (ACC→GCC)  fusA1  elongation factor G 
5,851,202 A→C V121G (GTG→GGG)  amgS  protein AmgS 
     
T8 
2,210,457 C→T G287S (GGC→AGC)  PA2018  multidrug efflux protein MexY 
3,529,234 (C)9→8 coding (221/1020 nt) wbpL  glycosyltransferase WbpL 
4,769,132 T→A Q678L (CAG→CTG)  fusA1  elongation factor G 
5,850,423 G→A P381S (CCC→TCC)  amgS  protein AmgS 
6,219,701 Δ4 bp coding (41-44/855 nt) PA5528  hypothetical protein 

















     
T9 
696,784 C→T S568S (AGC→AGT)  PA0641  bacteriophage protein 
721,717 A→G intergenic (+162/-378) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
721,739 C→T intergenic (+184/-356) tyrZ/PA0668.1 tyrosine--tRNA ligase/16S ribosomal RNA 
4,769,238 C→A G643C (GGT→TGT)  fusA1 elongation factor G 
4,771,103 G→A A21V (GCG→GTG)  fusA1 elongation factor G 
1,690,604 Δ3394  [ccoQ1]–[ccoQ2] [ccoQ1], ccoO1, ccoN1, ccoP2, [ccoQ2] 
     
T10 
2,210,457 C→T G287S (GGC→AGC)  PA2018 multidrug efflux protein MexY 
3,529,234 (C)9→8 coding (221/1020 nt) wbpL  glycosyltransferase WbpL 
4,769,132 T→A Q678L (CAG→CTG)  fusA1  elongation factor G 
5,700,136 G→T T186N (ACC→AAC)  phaF  polyhydroxyalkanoate synthesis protein PhaF 
5,850,423 G→A P381S (CCC→TCC)  amgS  protein AmgS 
6,218,111 Δ5,249 bp   PA5527–[PA5530] PA5527, PA5528, PA5529, [PA5530] 
1,690,964 Δ3460  [ccoO1]–[ccoO2] [ccoO1], ccoN1, ccoP2, ccoQ2, [ccoO2] 
     
T11 
2,211,080 T→G K79T (AAG→ACG)  PA2018  multidrug efflux protein MexY 
3,529,234 (C)9→8 coding (221/1020 nt) wbpL  glycosyltransferase WbpL 
4,760,200 C→G G93A (GGT→GCT)  rplF  50S ribosomal protein L6 
4,769,127 G→A R680C (CGC→TGC)  fusA1  elongation factor G 
4,962,669 Δ11 bp coding (387-397/783 nt) PA4429  cytochrome C1 
     
T12 
1,911,268 (ATGATC)2→1 coding (945-950/1527 nt) PA1767  hypothetical protein 

















4,760,200 C→G G93A (GGT→GCT)  rplF  50S ribosomal protein L6 
4,769,127 G→A R680C (CGC→TGC)  fusA1  elongation factor G 
4,962,669 Δ11 bp coding (387-397/783 nt) PA4429  cytochrome C1 
5,229,906 Δ24 bp coding (59-82/522 nt) pagL  lipid A 3-O-deacylase 
     
T13 
1,692,686 (C)6→5 coding (74/1428 nt) ccoN1  cbb3-type cytochrome C oxidase subunit I 
1,911,268 (ATGATC)2→1 coding (945-950/1527 nt) PA1767  hypothetical protein 




3,104,140 +T coding (85/195 nt) rpmI  50S ribosomal protein L35 
4,755,817 C→G G87A (GGT→GCT)  rpsD  30S ribosomal protein S4 
4,769,801 T→C Q455R (CAG→CGG)  fusA1  elongation factor G 
5,618,333 G→A Q69* (CAG→TAG)  PA5001  hypothetical protein 
 
 
 
 
 
